US20030130199A1 - Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents - Google Patents
Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents Download PDFInfo
- Publication number
- US20030130199A1 US20030130199A1 US10/172,809 US17280902A US2003130199A1 US 20030130199 A1 US20030130199 A1 US 20030130199A1 US 17280902 A US17280902 A US 17280902A US 2003130199 A1 US2003130199 A1 US 2003130199A1
- Authority
- US
- United States
- Prior art keywords
- residue
- acid
- alkyl
- dpiv
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 title description 4
- 239000002246 antineoplastic agent Substances 0.000 title description 4
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 130
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 88
- 108090000790 Enzymes Proteins 0.000 claims abstract description 70
- 102000004190 Enzymes Human genes 0.000 claims abstract description 69
- 239000003112 inhibitor Substances 0.000 claims abstract description 53
- 201000011510 cancer Diseases 0.000 claims abstract description 48
- 150000003839 salts Chemical group 0.000 claims abstract description 44
- 238000011282 treatment Methods 0.000 claims abstract description 38
- 239000002253 acid Substances 0.000 claims abstract description 30
- 206010027476 Metastases Diseases 0.000 claims abstract description 24
- 230000009401 metastasis Effects 0.000 claims abstract description 23
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims description 145
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 137
- 230000000694 effects Effects 0.000 claims description 101
- 238000000034 method Methods 0.000 claims description 77
- 229940024606 amino acid Drugs 0.000 claims description 53
- 235000001014 amino acid Nutrition 0.000 claims description 51
- -1 CONHOH Inorganic materials 0.000 claims description 47
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 108090000765 processed proteins & peptides Chemical class 0.000 claims description 40
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 38
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 32
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 31
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 26
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 108010016626 Dipeptides Proteins 0.000 claims description 20
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 235000018102 proteins Nutrition 0.000 claims description 19
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 18
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 claims description 17
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 claims description 17
- FAAZAHIRCXGFFM-ZETCQYMHSA-N (4s)-4-amino-5-oxo-5-pyrrolidin-1-ylpentanamide Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCCC1 FAAZAHIRCXGFFM-ZETCQYMHSA-N 0.000 claims description 16
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 claims description 16
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 claims description 16
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 15
- 150000008574 D-amino acids Chemical class 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 11
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 11
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 239000003937 drug carrier Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 108010066823 proline dipeptidase Proteins 0.000 claims description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 9
- 235000008206 alpha-amino acids Nutrition 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 9
- 150000008064 anhydrides Chemical class 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 125000000524 functional group Chemical group 0.000 claims description 9
- 102000035195 Peptidases Human genes 0.000 claims description 8
- 108091005804 Peptidases Proteins 0.000 claims description 8
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 claims description 8
- 150000001412 amines Chemical class 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 claims description 7
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 claims description 7
- 102000003958 Glutamate Carboxypeptidase II Human genes 0.000 claims description 7
- 108090000369 Glutamate Carboxypeptidase II Proteins 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 7
- 108010072257 fibroblast activation protein alpha Proteins 0.000 claims description 7
- 229920006395 saturated elastomer Polymers 0.000 claims description 7
- 102100040449 Inactive dipeptidyl peptidase 10 Human genes 0.000 claims description 6
- 125000004060 L-alloisoleucine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@@](C([H])([H])[H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 6
- 102000015636 Oligopeptides Human genes 0.000 claims description 6
- 108010038807 Oligopeptides Proteins 0.000 claims description 6
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 6
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 150000002148 esters Chemical class 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 235000004400 serine Nutrition 0.000 claims description 6
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 claims description 5
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 claims description 5
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 5
- 235000003704 aspartic acid Nutrition 0.000 claims description 5
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 5
- 238000006555 catalytic reaction Methods 0.000 claims description 5
- 235000013922 glutamic acid Nutrition 0.000 claims description 5
- 239000004220 glutamic acid Substances 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 102100027936 Attractin Human genes 0.000 claims description 4
- 101100278476 Homo sapiens DPP10 gene Proteins 0.000 claims description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- 150000001491 aromatic compounds Chemical class 0.000 claims description 4
- 125000005418 aryl aryl group Chemical group 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000002837 carbocyclic group Chemical group 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052740 iodine Inorganic materials 0.000 claims description 4
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 4
- QJRYYOWARFCJQZ-UHFFFAOYSA-N pyrrolidine-1-carbonitrile Chemical compound N#CN1CCCC1 QJRYYOWARFCJQZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004475 Arginine Substances 0.000 claims description 3
- 101710134735 Attractin Proteins 0.000 claims description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 claims description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 3
- 239000004473 Threonine Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 235000009697 arginine Nutrition 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 108090000212 dipeptidyl peptidase II Proteins 0.000 claims description 3
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 3
- 229960002591 hydroxyproline Drugs 0.000 claims description 3
- 235000018977 lysine Nutrition 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 235000019833 protease Nutrition 0.000 claims description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
- 235000008521 threonine Nutrition 0.000 claims description 3
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 3
- 235000002374 tyrosine Nutrition 0.000 claims description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 3
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- 229910006069 SO3H Inorganic materials 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- 125000004104 aryloxy group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 2
- 125000005243 carbonyl alkyl group Chemical group 0.000 claims description 2
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 2
- 229920001519 homopolymer Polymers 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 2
- 229930182852 proteinogenic amino acid Natural products 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 150000003536 tetrazoles Chemical class 0.000 claims description 2
- 125000004001 thioalkyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
- NPSLKZBLPSTQGO-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;1,3-thiazolidine Chemical compound C1CSCN1.OC(=O)[C@@H](N)CCC(O)=O NPSLKZBLPSTQGO-DFWYDOINSA-N 0.000 claims 1
- ULFVCDOOHOEPBW-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;pyrrolidine Chemical compound C1CCNC1.OC(=O)[C@@H](N)CCC(O)=O ULFVCDOOHOEPBW-DFWYDOINSA-N 0.000 claims 1
- GAJSPNHIKHRBGQ-NTFOPCPOSA-N (4s)-4-amino-5-oxo-5-(1,3-thiazolidin-2-yl)pentanamide Chemical compound NC(=O)CC[C@H](N)C(=O)C1NCCS1 GAJSPNHIKHRBGQ-NTFOPCPOSA-N 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 210000004072 lung Anatomy 0.000 description 54
- 239000000203 mixture Substances 0.000 description 51
- 210000004881 tumor cell Anatomy 0.000 description 50
- 241000700159 Rattus Species 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 43
- 239000000243 solution Substances 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 40
- 235000002639 sodium chloride Nutrition 0.000 description 37
- 239000007924 injection Substances 0.000 description 36
- 238000002347 injection Methods 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 30
- NJFKAKRPIBPWCO-ZICNZCGDSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-2-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)C1NCCS1 NJFKAKRPIBPWCO-ZICNZCGDSA-N 0.000 description 29
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 22
- 230000005764 inhibitory process Effects 0.000 description 22
- 238000003786 synthesis reaction Methods 0.000 description 22
- 238000001727 in vivo Methods 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 19
- 239000002904 solvent Substances 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- 230000001684 chronic effect Effects 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 16
- 238000001802 infusion Methods 0.000 description 16
- 239000011780 sodium chloride Substances 0.000 description 16
- AOFTVKLTJLMFLW-SMILAEQMSA-N 2-[(2s,3s)-2-amino-3-methylpentanoyl]pyrrolidine-1-carbonitrile Chemical compound CC[C@H](C)[C@H](N)C(=O)C1CCCN1C#N AOFTVKLTJLMFLW-SMILAEQMSA-N 0.000 description 14
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 14
- 230000021164 cell adhesion Effects 0.000 description 14
- 230000007935 neutral effect Effects 0.000 description 14
- 0 *BC[2H]C Chemical compound *BC[2H]C 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 239000003826 tablet Substances 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000011081 inoculation Methods 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000000540 analysis of variance Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000011002 quantification Methods 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 239000003480 eluent Substances 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 230000004048 modification Effects 0.000 description 9
- 238000012986 modification Methods 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 239000000651 prodrug Substances 0.000 description 9
- 229940002612 prodrug Drugs 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 101001095266 Homo sapiens Prolyl endopeptidase Proteins 0.000 description 8
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 8
- 241000534944 Thia Species 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 208000020816 lung neoplasm Diseases 0.000 description 8
- 208000037841 lung tumor Diseases 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 229950003188 isovaleryl diethylamide Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000003204 osmotic effect Effects 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KSPIYJQBLVDRRI-UHFFFAOYSA-N N-methylisoleucine Chemical compound CCC(C)C(NC)C(O)=O KSPIYJQBLVDRRI-UHFFFAOYSA-N 0.000 description 6
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 229960000583 acetic acid Drugs 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000011065 in-situ storage Methods 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 235000013930 proline Nutrition 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000003462 vein Anatomy 0.000 description 6
- NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 5
- 108090000267 Cathepsin C Proteins 0.000 description 5
- 102000003902 Cathepsin C Human genes 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- NHXZRXLFOBFMDM-AVGNSLFASA-N Val-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C NHXZRXLFOBFMDM-AVGNSLFASA-N 0.000 description 5
- 230000033115 angiogenesis Effects 0.000 description 5
- 239000012736 aqueous medium Substances 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 229960004132 diethyl ether Drugs 0.000 description 5
- 108010054813 diprotin B Proteins 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 238000010191 image analysis Methods 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 238000013105 post hoc analysis Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 238000011533 pre-incubation Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- JNTMAZFVYNDPLB-PEDHHIEDSA-N (2S,3S)-2-[[[(2S)-1-[(2S,3S)-2-amino-3-methyl-1-oxopentyl]-2-pyrrolidinyl]-oxomethyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O JNTMAZFVYNDPLB-PEDHHIEDSA-N 0.000 description 4
- ARNUPLMOASAEAN-ASLNEKEESA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-2-yl)pentan-1-one Chemical class CC[C@H](C)[C@H](N)C(=O)C1NCCS1 ARNUPLMOASAEAN-ASLNEKEESA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 239000011547 Bouin solution Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- 102000046014 Peptide Transporter 1 Human genes 0.000 description 4
- 108091006594 SLC15A1 Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000012317 TBTU Substances 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000007795 chemical reaction product Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 108010054812 diprotin A Proteins 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000001394 metastastic effect Effects 0.000 description 4
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000375 suspending agent Substances 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- NCOCKEVUJUIWRX-NSHDSACASA-N (2s)-1-(2-aminoacetyl)-n-(4-nitrophenyl)pyrrolidine-2-carboxamide Chemical compound NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 NCOCKEVUJUIWRX-NSHDSACASA-N 0.000 description 3
- BLOQNYJEEVPVOT-YMNIQAILSA-N (4s)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-(1,3-thiazolidin-2-yl)pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC(O)=O)C(=O)C1NCCS1 BLOQNYJEEVPVOT-YMNIQAILSA-N 0.000 description 3
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 3
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
- TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 108010012236 Chemokines Proteins 0.000 description 3
- 102000019034 Chemokines Human genes 0.000 description 3
- 108010074604 Epoetin Alfa Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MLSUZXHSNRBDCI-CYDGBPFRSA-N Ile-Pro-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)O)N MLSUZXHSNRBDCI-CYDGBPFRSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical compound C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 3
- QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Natural products CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- IDGQXGPQOGUGIX-VIFPVBQESA-N O-BENZYL-l-SERINE Chemical compound OC(=O)[C@@H](N)COCC1=CC=CC=C1 IDGQXGPQOGUGIX-VIFPVBQESA-N 0.000 description 3
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoserine Chemical compound OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 3
- FZBGMXYQPACKNC-HJWJTTGWSA-N Phe-Pro-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FZBGMXYQPACKNC-HJWJTTGWSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 101000870232 Tenebrio molitor Diuretic hormone 1 Proteins 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- QSPOLEBZTMESFY-SRVKXCTJSA-N Val-Pro-Val Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O QSPOLEBZTMESFY-SRVKXCTJSA-N 0.000 description 3
- 239000007825 activation reagent Substances 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000004712 cancer cell adhesion Effects 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 210000001715 carotid artery Anatomy 0.000 description 3
- 238000003352 cell adhesion assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000000132 electrospray ionisation Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 108010082406 peptide permease Proteins 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 208000017497 prostate disease Diseases 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 229960001407 sodium bicarbonate Drugs 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 3
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 238000010792 warming Methods 0.000 description 3
- VVNYDCGZZSTUBC-LURJTMIESA-N (2s)-5-amino-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC(N)=O VVNYDCGZZSTUBC-LURJTMIESA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- MPGQQQKGAXDBDN-UHFFFAOYSA-N 1,3-thiazolidin-3-ium;chloride Chemical compound Cl.C1CSCN1 MPGQQQKGAXDBDN-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 2
- BPVHBBXCESDRKW-UHFFFAOYSA-N 5(6)-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(C(=O)O)=CC=C21.C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BPVHBBXCESDRKW-UHFFFAOYSA-N 0.000 description 2
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- BMILLJORICKAPA-TXOOBNKBSA-N CC(=O)/C=C(\C)N(C)C.CN(C)C.CN=C(C)C Chemical compound CC(=O)/C=C(\C)N(C)C.CN(C)C.CN=C(C)C BMILLJORICKAPA-TXOOBNKBSA-N 0.000 description 2
- 108010005843 Cysteine Proteases Proteins 0.000 description 2
- 102000005927 Cysteine Proteases Human genes 0.000 description 2
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101100010319 Homo sapiens DPP9 gene Proteins 0.000 description 2
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 2
- 101000967820 Homo sapiens Inactive dipeptidyl peptidase 10 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000007987 MES buffer Substances 0.000 description 2
- 241000579835 Merops Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- VTMGKRABARCZAX-OSUNSFLBSA-N Thr-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O VTMGKRABARCZAX-OSUNSFLBSA-N 0.000 description 2
- 239000003875 Wang resin Substances 0.000 description 2
- AYDUWHHXQJWWGJ-BCVNIXSYSA-N [2H]C1=C(C)C2=C(N=C(C)B2)C(F)=C1C.[H]C1=C(C)BC(C)=N1 Chemical compound [2H]C1=C(C)C2=C(N=C(C)B2)C(F)=C1C.[H]C1=C(C)BC(C)=N1 AYDUWHHXQJWWGJ-BCVNIXSYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000002001 anti-metastasis Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000007900 aqueous suspension Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000002224 dissection Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 235000004554 glutamine Nutrition 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000009215 host defense mechanism Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 239000000677 immunologic agent Substances 0.000 description 2
- 229940124541 immunological agent Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 235000005772 leucine Nutrition 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 235000006109 methionine Nutrition 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229940073584 methylene chloride Drugs 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 239000002691 unilamellar liposome Substances 0.000 description 2
- 235000014393 valine Nutrition 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- QOMLWUOJCBLHPI-UHFFFAOYSA-N (1-cyclopentyl-3-methyl-1-oxopentan-2-yl)azanium;chloride Chemical compound [Cl-].CCC(C)C([NH3+])C(=O)C1CCCC1 QOMLWUOJCBLHPI-UHFFFAOYSA-N 0.000 description 1
- VBBFIBMVFSUUBP-MERQFXBCSA-N (2S)-1-(2-aminoacetyl)-N-(4-nitrophenyl)pyrrolidine-2-carboxamide hydrochloride Chemical compound Cl.NCC(=O)N1CCC[C@H]1C(=O)NC1=CC=C([N+]([O-])=O)C=C1 VBBFIBMVFSUUBP-MERQFXBCSA-N 0.000 description 1
- CMIBUZBMZCBCAT-HZPDHXFCSA-N (2r,3r)-2,3-bis[(4-methylbenzoyl)oxy]butanedioic acid Chemical compound C1=CC(C)=CC=C1C(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(=O)C1=CC=C(C)C=C1 CMIBUZBMZCBCAT-HZPDHXFCSA-N 0.000 description 1
- ZPGDWQNBZYOZTI-SFHVURJKSA-N (2s)-1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-SFHVURJKSA-N 0.000 description 1
- UUWFBAFUDUAMEM-GJZGRUSLSA-N (2s)-1-[(2s)-1-(2-aminoacetyl)pyrrolidine-2-carbonyl]-n-(4-nitrophenyl)pyrrolidine-2-carboxamide Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NC=2C=CC(=CC=2)[N+]([O-])=O)CCC1 UUWFBAFUDUAMEM-GJZGRUSLSA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- MRTPISKDZDHEQI-YFKPBYRVSA-N (2s)-2-(tert-butylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC(C)(C)C MRTPISKDZDHEQI-YFKPBYRVSA-N 0.000 description 1
- SZXBQTSZISFIAO-ZETCQYMHSA-N (2s)-3-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)OC(C)(C)C SZXBQTSZISFIAO-ZETCQYMHSA-N 0.000 description 1
- JIMLDJNLXLMGLX-JTQLQIEISA-N (2s)-5-amino-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 JIMLDJNLXLMGLX-JTQLQIEISA-N 0.000 description 1
- OHYMUFVCRVPMEY-ZETCQYMHSA-N (2s)-5-methoxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxopentanoic acid Chemical compound COC(=O)CC[C@@H](C(O)=O)NC(=O)OC(C)(C)C OHYMUFVCRVPMEY-ZETCQYMHSA-N 0.000 description 1
- WQIRZULZPQRECJ-GSTITVNRSA-N (4s)-4-amino-5-oxo-5-(1,3-thiazolidin-2-yl)pentanamide;hydrochloride Chemical compound Cl.NC(=O)CC[C@H](N)C(=O)C1NCCS1 WQIRZULZPQRECJ-GSTITVNRSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- JFMNKDRNEZZRBW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxamide Chemical class C1=CC=C2CNC(C(=O)N)CC2=C1 JFMNKDRNEZZRBW-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- GODZNYBQGNSJJN-UHFFFAOYSA-N 1-aminoethane-1,2-diol Chemical compound NC(O)CO GODZNYBQGNSJJN-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- HLBOAQSKBNNHMW-UHFFFAOYSA-N 3-(3-methoxyphenyl)pyridine Chemical compound COC1=CC=CC(C=2C=NC=CC=2)=C1 HLBOAQSKBNNHMW-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- SEJDHVVTMRLBCC-UHFFFAOYSA-O CCC(C)C(CO)NC(=O)OC(C)(C)C.CCC(C)C(NC(=O)OC(C)(C)C)C(=O)C1CCCC1.CCC(C)C(NC(=O)OC(C)(C)C)C(O)C1CCCC1.CCC(C)C([NH3+])C(=O)C1CCCC1.[Cl-].[H]C(=O)C(NC(=O)OC(C)(C)C)C(C)CC Chemical compound CCC(C)C(CO)NC(=O)OC(C)(C)C.CCC(C)C(NC(=O)OC(C)(C)C)C(=O)C1CCCC1.CCC(C)C(NC(=O)OC(C)(C)C)C(O)C1CCCC1.CCC(C)C([NH3+])C(=O)C1CCCC1.[Cl-].[H]C(=O)C(NC(=O)OC(C)(C)C)C(C)CC SEJDHVVTMRLBCC-UHFFFAOYSA-O 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102100025566 Chymotrypsin-like protease CTRL-1 Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- JDMUPRLRUUMCTL-VIFPVBQESA-N D-pantetheine 4'-phosphate Chemical compound OP(=O)(O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS JDMUPRLRUUMCTL-VIFPVBQESA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 229910004373 HOAc Inorganic materials 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000697936 Homo sapiens Attractin Proteins 0.000 description 1
- 101000856199 Homo sapiens Chymotrypsin-like protease CTRL-1 Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 244000137850 Marrubium vulgare Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVRNDRQMDRJTHS-BKJPEWSUSA-N N-acetyl-D-hexosamine Chemical class CC(=O)NC1C(O)O[C@H](CO)C(O)C1O OVRNDRQMDRJTHS-BKJPEWSUSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- SUHQNCLNRUAGOO-UHFFFAOYSA-N N-glycoloyl-neuraminic acid Natural products OCC(O)C(O)C(O)C(NC(=O)CO)C(O)CC(=O)C(O)=O SUHQNCLNRUAGOO-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-UHFFFAOYSA-N N-glycolyl-beta-neuraminic acid Natural products OCC(O)C(O)C1OC(O)(C(O)=O)CC(O)C1NC(=O)CO FDJKUWYYUZCUJX-UHFFFAOYSA-N 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- AMFCMZMIVCHFEL-UHFFFAOYSA-N NC(=O)CCC(N)C(=O)N1CCCC1.NC(=O)CCC(N)C(=O)N1CCSC1 Chemical compound NC(=O)CCC(N)C(=O)N1CCCC1.NC(=O)CCC(N)C(=O)N1CCSC1 AMFCMZMIVCHFEL-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108090000189 Neuropeptides Proteins 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- OEMQISJBGYQOPW-WCCKRBBISA-N P(O)(O)=O.N1[C@H](C(=O)O)CCC1 Chemical class P(O)(O)=O.N1[C@H](C(=O)O)CCC1 OEMQISJBGYQOPW-WCCKRBBISA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- UREQLMJCKFLLHM-NAKRPEOUSA-N Pro-Ile-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O UREQLMJCKFLLHM-NAKRPEOUSA-N 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- 101710129873 Prolyl endopeptidase FAP Proteins 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- VCGOTJGGBXEBFO-FDARSICLSA-N Trp-Pro-Ile Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VCGOTJGGBXEBFO-FDARSICLSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- USLVEJAHTBLSIL-CYDGBPFRSA-N Val-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C USLVEJAHTBLSIL-CYDGBPFRSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 101710171640 Xaa-Pro dipeptidase Proteins 0.000 description 1
- 108030005221 Xaa-Pro dipeptidases Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 125000005577 anthracene group Chemical group 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000001508 asparagines Chemical class 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229940090047 auto-injector Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000008274 breast adenocarcinoma Diseases 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical class CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002901 elastaselike Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960003388 epoetin alfa Drugs 0.000 description 1
- 229940089118 epogen Drugs 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 239000002038 ethyl acetate fraction Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000012054 flavored emulsion Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000020375 flavoured syrup Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000022244 formylation Effects 0.000 description 1
- 238000006170 formylation reaction Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007897 gelcap Substances 0.000 description 1
- 230000006130 geranylgeranylation Effects 0.000 description 1
- 230000035430 glutathionylation Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Chemical compound NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 150000008273 hexosamines Chemical class 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- IZAPPFQMAUWRCO-IUCAKERBSA-N methyl (2s)-1-[(2s)-2-amino-3-methylbutanoyl]pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)C(C)C IZAPPFQMAUWRCO-IUCAKERBSA-N 0.000 description 1
- BLWYXBNNBYXPPL-YFKPBYRVSA-N methyl (2s)-pyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1 BLWYXBNNBYXPPL-YFKPBYRVSA-N 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 210000003550 mucous cell Anatomy 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- TYRGLVWXHJRKMT-QMMMGPOBSA-N n-benzyloxycarbonyl-l-serine-betalactone Chemical compound OC(=O)[C@H](C)NC(=O)OCC1=CC=CC=C1 TYRGLVWXHJRKMT-QMMMGPOBSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- MXHCPCSDRGLRER-UHFFFAOYSA-N pentaglycine Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(O)=O MXHCPCSDRGLRER-UHFFFAOYSA-N 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000027232 peripheral nervous system disease Diseases 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 229940029359 procrit Drugs 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 1
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940069575 rompun Drugs 0.000 description 1
- 229940021384 salt irrigating solution Drugs 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000010972 statistical evaluation Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 210000000538 tail Anatomy 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- INSIDPOXJWFGJV-UHFFFAOYSA-N tert-butyl n-(1-cyclopentyl-3-methyl-1-oxopentan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C(C)CC)C(=O)C1CCCC1 INSIDPOXJWFGJV-UHFFFAOYSA-N 0.000 description 1
- YJAAJMSZVZJPOQ-DTWKUNHWSA-N tert-butyl n-[(2s,3s)-3-methyl-1-oxopentan-2-yl]carbamate Chemical compound CC[C@H](C)[C@@H](C=O)NC(=O)OC(C)(C)C YJAAJMSZVZJPOQ-DTWKUNHWSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000034005 thiol-disulfide exchange Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 238000005583 trifluoroacetylation reaction Methods 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- QYEFBJRXKKSABU-UHFFFAOYSA-N xylazine hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1NC1=NCCCS1 QYEFBJRXKKSABU-UHFFFAOYSA-N 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
Definitions
- the present invention relates to inhibitors of dipeptidyl peptidase IV and dipeptidyl peptidase IV-like enzyme activity and, more particularly, pharmaceutical compositions containing said compounds, and the use of said compounds for the treatment of cancer and tumors.
- the present invention especially provides a method for the inhibition of metastasis and tumor colonization.
- Dipeptidyl peptidase IV is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position.
- DPIV Dipeptidyl peptidase IV
- DPIV is responsible for inactivating glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide also known as gastric-inhibitory peptide (GIP). Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, in WO 97/40832 and U.S. Pat. No. 6,303,661 inhibition of DPIV and DPIV-like enzyme activity was shown to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (NIDDM).
- NIDDM non-insulin-dependent diabetes mellitus
- the present invention provides a new use of DPIV-inhibitors for the treatment of conditions mediated by inhibition of DPIV and DPIV-like enzymes, in particular the treatment of cancer and tumors and the inhibition of metastasis and tumor colonization, and pharmaceutical compositions e.g. useful in inhibiting DPIV and DPIV-like enzymes and a method of inhibiting said enzyme activity.
- This invention relates to a method of treatment, in particular to a method for the treatment of cancer, tumors, metastasis and tumor colonization and to compositions for use in such method.
- Dipeptidyl peptidase IV (DPIV) is a post-proline (to a lesser extent post-alanine, post-serine or post-glycine) cleaving serine protease found in various tissues of the body including kidney, liver, and intestine.
- DPIV-Inhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus (International Patent Application, Publication Number WO 99/61431, Pederson R A et al, Diabetes. 1998 August; 47(8):1253-8 and Pauly RP et al, Metabolism 1999 March; 48(3):385-9).
- DPIV-Inhibitors comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-threo-isoleucyl thiazolidine, L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolidine, and salts thereof.
- low molecular weight dipeptidyl peptidase IV inhibitors are agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2-cyanopyroles and -pyrrolidines, N-(N′-substituted glycyl)2-cyanopyrrolidines, N-(substituted glycyl)-thiazolidines, N-(substituted glycyl)-4-cyanothiazolidines, amino-acyl-borono-prolyl-inhibitors, cyclopropyl-fused pyrrolidines and heterocyclic compounds.
- agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2-cyanopyroles and -pyrrolidines, N-(N′-substituted glycyl)2-cyanopyrrolidines, N-(substituted glyc
- Inhibitors of dipeptidyl peptidase IV are described in U.S. Pat. Nos. 6,380,398, 6,011,155; 6,107,317; 6,110,949; 6,124,305; 6,172,081; WO 95/15309, WO 99/61431, WO 99/67278, WO 99/67279, DE 198 34 591, WO 97/40832, DE 196 16 486 C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501, WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271, the teachings of which are herein incorporated by reference in their entirety.
- DPIV-like enzymes relate to structurally and/or functionally DPIV/CD26-related enzyme proteins (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001, 36506: 1-10).
- this small group of enzymes has evolved during evolution to release H-Xaa-Pro-Dipeptides and H-Xaa-Ala-Dipeptides from N-terminus of oligo- or polypeptides. They show the common feature, that they accomotate in the Pro-position also Al, Ser, Thr and other amino acids with small hydrophobic side-chains as, Gly or Val.
- the hydrolytic efficacy is ranked Pro>Ala Ser, Thr Gly, Val. Same proteins have been only available in such small quantities, that only the post-Pro or post-Ala cleavage could be established. While the proteins: DPIV, DP II, FAP ⁇ (Seprase), DP 6, DP 8 and DP 9 are structurally related and show a high sequence homology, attractin is an extraordinary functional DPIV-like enzyme, characterized by a similar activity and inhibitory pattern.
- DPIV-Like enzymes are disclosed in WO 01/19866, WO 02/04610, WO 02/34900 and WO02/31134.
- WO 01/19866 discloses novel human dipeptidyl aminopeptidase (DPP8) with structural and functional similarities to DPIV and fibroblast activation protein (FAP).
- DPP8 novel human dipeptidyl aminopeptidase
- FAP fibroblast activation protein
- WO 02/04610 provides reagents, which regulate human dipeptidyl peptidase IV-like enzyme and reagents which bind to human dipeptidyl peptidase IV-like enzyme gene product. These reagents can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, tumors and peripheral and central nervous system disorders including pain and neurodegenerative disorders.
- the dipeptidyl peptidase IV-like enzyme of WO 02/04610 is well known in the art. In the Gene Bank data base, this enzyme is registered as KIAA1492 (registration in February 2001, submitted on Apr. 04, 2000, AB040925). In the Merops data base, the dipeptidyl peptidase IV-like enzyme of WO 02/04610 is registered as non-protease homologue, because the active site serine motive is GKGYGG in contrast to DPIV, which has a active site serine motive consisting of GWSYGG. The Merops homologue of the dipeptidyl peptidase IV-like enzyme disclosed in WO 02/04610 and the active site motive thereof was confirmed by the human genome project.
- WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology with the amino acid sequences of DPIV and DPP8.
- DPP9 dipeptidyl peptidase 9
- WO 02/31134 discloses three DPIV-like enzymes, DPRP1, DPRP2 and DPRP3. Sequence analysis revealed, that DPRP1 is identical to DPP8, as disclosed in WO 01/19866, that DPRP2 is identical to DPP9 and that DPRP3 is identical to KIAA1492 as disclosed in WO 02/04610.
- Dipeptidyl peptidase IV (DPIV; EC 3.4.14.5; CD26) CD26 is a M r 110,000 surface glycoprotein with an array of diverse functional properties that is expressed on a number of tissues, including epithelial cells and leukocyte subsets (Mentlein, 1999). Furthermore, it is a membrane-associated ectopeptidase that possesses DPIV-like activity in its extracellular domain and is able to cleave N-terminal dipeptides from polypeptides with either L-proline or L-alanine in the penultimate position. In general, DPIV is recognized as an ectopeptidase with a triple functional role.
- DPIV is involved in catalyzing the release of Xaa-Pro dipeptides from circulating hormones and chemokines (De Meester et al, 1999; Mentlein, 1999), in T cell dependent immune responses (Kähne et al, 1999; Korom et al, 1997), and in cell adhesion including metastasis (Mentlein, 1999).
- DPIV has been identified as the ADA binding protein, thereby regulating ADA surface expression, with the DPIV/ADA complex perhaps playing a key role in the catalytic removal of local adenosine to regulate immune system function.
- DPIV may have a potential role in the development of certain neoplasms (Mattern et al., 1993; Carbone et al., 1995).
- CDKs a group of related enzymes known as the CDKs, which are positively regulated by their physical association with regulatory subunits called cyclins. It has been demonstrated that binding of soluble anti-CD26 antibodies inhibits the growth of anaplastic large cell T-cell lymphoma cell lines, both in in vitro and in vivo experiments (Ho et al., 2001).
- Cancer is a group of over 150 diseases characterized by the uncontrolled growth of abnormal cells in the body.
- Normal cells can become abnormal when they are exposed to carcinogens such as radiation or particular drugs or chemicals. They can also turn malignant (cancerous) when they are attacked by certain viruses or when some not-yet-fully-understood internal signal occurs. Once cells become malignant, they multiply more rapidly than usual. Then they often form masses called tumors that invade nearby tissue and interfere with normal bodily functions. Cancer cells also have a tendency to spread to other parts of the body, where they may form a secondary tumor.
- WO 95/29691 discloses proline phosphonate derivatives as inhibitors of serine proteases with chymotrypsin-like, trypsin-like, elastase-like and dipeptidyl peptidase IV specificity and their roles as anti-inflammatory agents, anticoagulants, anti-tumor agents and anti-AIDS agents.
- WO 98/53812 and WO 97/48409 disclose novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated ⁇ -Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using these compounds for the inhibition of prostate cancer cell growth.
- NAALADase N-Acetylated ⁇ -Linked Acidic Dipeptidase
- WO 01/92273 discloses new benzenedicarboxylic acid derivative compounds, pharmaceutical compositions, diagnostic methods and diagnostic kits that include those compounds and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, affecting neuronal activity, affecting TGF- ⁇ activity, inhibiting angiogenesis and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancer and glaucoma.
- WO 01/34596 discloses pyrrolecarbonylimino derivatives, pharmaceutical compounds and methods of using those compounds to inhibit NAALADase enzyme activity, thereby affecting neuronal activities, inhibiting angiogenesis and treating glutamate abnormalities, compulsive disorders, prostate diseases and cancer.
- WO 00/71135 discloses a method for treating subjects with abnormal cell proliferation. The method involves administering to subjects in need of such treatment an effective amount of boro-proline compounds, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of a boro-proline derivative is also provided.
- the invention of WO 00/71135 is based, in part, on the observation, that the boro-proline derivatives are able to inhibit the enzymatic activity of fibroblast activation protein-alpha (FAP- ⁇ ).
- FAP- ⁇ fibroblast activation protein-alpha
- WO 00/71571 relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein-alpha (FAP- ⁇ ), said prodrug having a cleavage site which is recognised by FAP- ⁇ , and said drug being cytotoxic or cytostatic under physiological conditions.
- FAP- ⁇ human fibroblast activation protein-alpha
- These prodrugs are converted into a drug at the site of the tumor.
- WO 00/10549 discloses compounds and a method for regulation of substrate activity in vivo useful for the treatment of medical disorders such as arteriosclerosis, allergies, inflammation, angiogenesis, cardiogenesis, neoplasm, tumor, cancer, a hepatic disease, an intestinal disease, organ vascularization, and microbial and viral infections.
- the compounds consist of a targeting moiety that binds to DPIV, and a reactive group, that reacts at a reactive center of DPIV. Said compounds are used to prevent chemokine alteration by inhibiting DPIV activity.
- WO 00/36420 discloses a method for identifying nucleotide sequences that are differentially expressed in tumor cells, preferably primary breast tumor cells, comprising exposing a tumor cell containing tissue sample to an agent specific for fibroblast activation protein (FAP) separating cells recognised by said agent from the remaining cells in the sample and harvesting said remaining cells.
- FAP fibroblast activation protein
- WO 99/47152 discloses a method of suppressing the malignant phenotype or inducing apoptosis of cancer cells in a subject, comprising introducing into the cancer cell an amount of a nucleic acid encoding a dipeptidyl peptidase IV protein or fibroblast activating protein- ⁇ , thereby suppressing the malignant phenotype of the cancer.
- WO 99/47152 also discloses a method of inducing expression of dipeptidyl peptidase IV or fibroblast activating protein- ⁇ in cancer cells of a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an agent capable of activating transcription of the dipeptidyl peptidase IV gene or fibroblast activating protein- ⁇ gene and a pharmaceutical acceptable carrier or diluent.
- WO 01/74299 discloses antibodies that specifically bind to a membrane protease complex, the complex consisting of two homodimers of seprase and dipeptidyl peptidase IV (DPIV), obtained from mammalian, preferably human cell membranes.
- DPIV dipeptidyl peptidase IV
- the antibodies specifically bind to the DPIV protease of the seprase-DPIV complex.
- This membrane protease complex resides on cell surface invadopodia at the leading edge of angiogenic endothelia, migratory fibroblasts, and invading cancer cells.
- WO 02/20825 relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. WO 02/20825 further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the indentification of agents having anti-metastatic potential. Also disclosed are methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipeptidyl peptidase IV (DPIV)] expressed on the surface of metastasizing cancer cells, by using antibodies against SIMP.
- SIMP serine integral membrane proteases
- DPIV dipeptidyl peptidase IV
- Immunotherapy is composed of the usage or the modification of intrinsic bodily mechanisms—in most cases immune mechanisms—to fight cancer.
- Chemotherapy kills cancer cells through the use of drugs or hormones. Taken either orally or through injection, chemotherapeutic agents are used to treat a wide variety of cancer. They may be given alone or in combination with surgery or radiation or both. Chemotherapy is an established way to destroy hard-to-detect cancer cells that have spread and are circulating in the body. Anemia (low number of red blood cells) is a frequent side effect of chemotherapy and may cause symptoms such as extreme tiredness, dizziness, or shortness of breath.
- Epoetin alfa Procrit®, Epogen®
- Epogen® recombinant erythropoietin that stimulates red blood cell production—is a prescription drug available for the treatment of chemotherapy-related anemia.
- Immunotherapy uses the body's own immune system or other parts of the organism to destroy cancer cells. This form of treatment is still being intensively studied in clinical trials; it is not yet widely available to most cancer patients.
- the various immunological agents used include substances produced by the body (such as the interferons, the interleukins and tumor necrosis factor) and laboratory-produced substances (such as monoclonal antibodies and vaccines). Immunological agents work in different ways and can be used independently or in combination with other forms of treatment.
- Angiogenesis inhibitors are drugs that block the development of new blood vessels. Solid tumors cannot grow without inducing the formation of new blood vessels. Blocking the development of new blood vessels cuts off the tumor's supply of oxygen and nutrients.
- angiogenesis inhibitors are currently being tested in human trials. In cancerous tissue, tumors cannot grow or spread (metastasize) without the development of new blood vessels. Blood vessels supply tissues with oxygen and nutrients necessary for survival and growth.
- the present invention provides new uses of DPIV-inhibitors of formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms for treating cancer and tumors.
- the compounds of the present invention are useful for the prevention and inhibition of metastasis and tumor colonization.
- isoleucyl thiazolidine fumarate and isoleucyl cyano pyrrolidine TFA protect from metastasis either via interaction with cell adhesion processes, via a modification of the cellular host defense mechanisms, via modulation of angiogenesis, via direct effects on cancer cells, or via increased levels of DPIV substrates, which indirectly mediate protective-like effects.
- FIG. 1 Effect of single injection of isoleucyl thiazolidine fumarate on lung metastasis in F344 rats.
- Vital dye Carboxyfluorescein; CFSE
- CFSE Carboxyfluorescein labeled MADB106 tumor cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation.
- FIG. 2 Effect of single injection of isoleucyl thiazolidine fumarate on tumor cell adhesion 30 min after injection in F344 substrains mutant for DPIV.
- CFSE labeled MADB106 tumor cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation. Note the promoting effect in mutant F344GER and F344JAP rats in contrast to the lack of effects in wild-type F344 rats.
- Data represent means ⁇ SEM; *p ⁇ 0.05 reflecting significant differences vs. wild-type F344USA animals determined by ANOVA and Fisher PLSD.
- FIG. 3 Effect of single injection of isoleucyl cyanopyrrolidine TFA on tumor cell adhesion 30 min after injection in F344USA rats.
- CFSE labeled MADB106 cancer cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation.
- CFSE positive tumor cells in lungs were quantified by means of immunohistology and image analysis. Data represent means ⁇ SEM; significant differences vs. saline treated controls were not found.
- FIG. 4 Effect of single injection of valyl pyrrolidine fumarate on tumor cell adhesion 30 min after injection in F344USA rats.
- CFSE labeled of MADB106 adenocarcinoma cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation.
- CFSE positive tumor cells in lungs were quantified by means of immunohistology and image analysis. Data represent means ⁇ SEM; significant differences vs. saline treated controls were not found.
- FIG. 5 Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate on body weight change in grams in F344 rats with lung metastasis. A dose dependent reduction of the loss of body weight after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated.
- One factor ANOVA revealed a significant effect on body weight, which became significant in the post-hoc analysis at the 0.4 mg and 4 mg dosages. Data represent means ⁇ SEM; *p ⁇ 0.05 reflecting significant differences vs. saline treated SHAM controls determined by Fisher PLSD.
- FIG. 6 Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate on the number of lung tumor colonies in F344 rats. A dose dependent reduction of lung colony numbers after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated. One factor ANOVA revealed a significant effect, which became significant in the post-hoc analysis at the 4 mg dosage. Data represent means ⁇ SEM; *p ⁇ 0.05 reflecting significant differences vs. saline treated SHAM controls determined by Fisher PLSD.
- FIG. 7 Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA, and valyl pyrrolidine fumarate on the number of lung tumor colonies in F344 rats.
- Data represent means ⁇ SEM; *p ⁇ 0.05 reflecting significant differences vs. saline treated SHAM controls determined by ANOVA and Fisher PLSD.
- the present invention relates to the area of dipeptidyl peptidase IV (DPIV) inhibition and, more particularly, to a new use of inhibitors of DPIV and DPIV-like enzyme activity for the treatment of cancer and tumors, in particular for the prevention and inhibition of metastasis and tumor colonization, and pharmaceutical compositions containing said compounds.
- DPIV dipeptidyl peptidase IV
- the present invention provides an orally available therapy with low molecular weight inhibitors of dipeptidyl peptidase IV.
- the instant invention represents a novel approach for the treatment of cancer and metastatic disease. It is user friendly, commercially useful and suitable for use in a therapeutic regime, especially concerning human diseases.
- Spontaneous mutations of the DPIV gene observed in substrains of F344 rats provide a model for studying the role of DPIV in tumor adhesion and colonization.
- the mutations in F344 rats result in a lack of DPIV enzymatic activity and are found in substrains from Germany (GER) and Japan (JAP) (Thompson et al, 1991; Tsuji et al, 1992), while rats from USA breeders show significant enzyme activity.
- the goal of the present invention is the development of dipeptidyl peptidase IV inhibitors and/or ligands, which display a high bioavailability.
- the present invention provides DPIV inhibitors, which have an exactly predictable activity time in the target tissue.
- Examples for target specific, orally available low molecular weight agents are prodrugs of stable and unstable dipeptidyl peptidase IV inhibitors which comprise general formula A-B-C, whereby A represents an amino acid, B represents the chemical bond between A and C or an amino acid, and C represents an unstable or a stable inhibitor of dipeptidyl peptidase IV respectively. They are described in WO 99/67278, WO 99/67279 the teachings of which are herein incorporated by reference in their entirety.
- the present invention relates to a novel method, in which the reduction of activity in the enzyme dipeptidyl peptidase (DPIV or CD 26), or of DPIV-Like enzyme activity, or where binding of a DPIV specific ligand exerts tumor suppressive or immunostimulating effects in the organisms of mammals induced by effectors of the enzyme leads as a causal consequence to a reduced growth or adhesion of cancer cells.
- DPIV dipeptidyl peptidase
- CD 26 dipeptidyl peptidase
- DPIV-Like enzyme activity or where binding of a DPIV specific ligand exerts tumor suppressive or immunostimulating effects in the organisms of mammals induced by effectors of the enzyme leads as a causal consequence to a reduced growth or adhesion of cancer cells.
- Such treatment will result in a reduction or delay of cancer cell adhesion (metastasis) or the growth of tumor.
- mammals bearing cancer will benefit from the treatment with inhibitors of DPIV a DPIV-like
- the method of the present invention for treating cancer in an animal, including humans, in need thereof comprises anti-cancer effects by binding or by inhibiting DPIV, or related enzyme activities, using an inhibitor or ligand of these enzymes.
- Oral administration of a DPIV inhibitor may be preferable in most circumstances.
- the present invention relates to dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof, referred to hereinafter as dipeptide compounds.
- dipeptide compounds in which the amino acid is selected from a natural amino acid, such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid.
- a natural amino acid such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid.
- the dipeptide compounds according to the invention exhibit at a concentration (of dipeptide compounds) of 10 ⁇ M, especially under the conditions indicated in Table 1, a reduction in the activity of dipeptidyl peptidase IV or DPIV-analogous enzyme activities of at least 10%, especially of at least 40%. Frequently a reduction in activity of at least 60% or at least 70% is also required. Preferred effectors may also exhibit a reduction in activity of a maximum of 20% or 30%.
- Preferred compounds are L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine and salts thereof, especially the fumaric salts, and L-allo-isoleucyl pyrrolidine and salts thereof.
- Especially preferred compounds are glutaminyl pyrrolidine and glutaminyl thiazolidine of formulas 1 and 2:
- the salts of the dipeptide compounds can be present in a molar ration of dipeptide (-analogous) component to salt component of 1:1 or 2:1.
- a salt is, for example, (lle-Thia) 2 fumaric acid.
- the present invention provides peptide compounds of formula 3 useful for competitive modulation of dipeptidyl peptidase IV catalysis:
- A, B, C, D and E are any amino acid residues including proteinogenic amino acids, non-proteinogenic amino acids, L-amino acids and D-amino acids and wherein E and/or D may be absent or B and/or A may be absent with additional conditions as hereinafter detailed:
- A is any amino acid residue except D-amino acid residues
- B is any proteinogenic amino acid residue, but
- B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid
- C is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid and E may be unused to generate tetrapeptides of the formula A-B-C-D, or D and E may be unused to generate tripeptides of the formula A-B-C provided, but
- B is not an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid
- C is any ⁇ -amino acid except D-amino acids
- D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid
- E is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, but
- D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid
- C is any ⁇ -amino acid except D-amino acids and Pro
- A may be unused to generate tetrapeptides of the formula B-C-D-E, or A and B may be unused to generate tripeptides of the formula C-D-E provided however,
- D is not selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then E is any amino acid residue including D-amino acids.
- Amino acid residues used for the preparation of the compounds of formula (3) can be generally subclassified into four major subclasses as follows.
- Acidic The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.
- Neutral/nonpolar The residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. These residues are also designated “hydrophobic” herein.
- Neutral/polar The residues are not charged at physiological pH, but the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.
- Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large.
- the residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.
- Acidic Aspartic acid and Glutamic acid
- Neutral/nonpolar/large/aromatic Phenylalanine, and Tryptophan.
- Certain commonly encountered amino acids include, for example, beta-alanine (beta-ala), or other omega-amino acids, such as 3-amino propionic, 4-amino butyric and so forth, alpha-aminoisobutyric acid (Aib), sarcosine (Sar), ornithine (Orn), citrulline (Cit), homoarginine (Har), t-butylalanine (t-butyl-Ala), t-butylglycine (t-butyl-Gly), N-methylisoleucine (N-Melle), phenylglycine (Phg), cyclohexylalanine (Cha), norleucine (Nle), cysteic acid (Cya) and methionine sulfoxide (MSO). These also fall conveniently into particular categories.
- beta-alanine beta-ala
- omega-amino acids such as 3-amino propionic, 4-amino butyric and so
- t-butyl-Ala, t-butyl-Gly, N-Melle, Nle and Cha are neutral/nonpolar/large/nonaromatic;
- Har and Orn are basic/noncyclic
- Cya is acidic
- Cit, Acetyl-Lys, and MSO are neutral/polar/large/nonaromatic;
- Phg is neutral/nonpolar/large/aromatic.
- omega-amino acids are classified according to size as neutral/nonpolar/small (beta-Ala, i.e., 3-aminopropionic, 4-aminobutyric) or large (all others).
- Proteinogenic amino acids are defined as natural protein-derived ⁇ -amino acids. Non-proteinogenic amino acids are defined as all other amino acids, which are not building blocks of common natural proteins.
- the resulting peptides may be synthesized as the free C-terminal acid or as the C-terminal amide form.
- the free acid peptides or the amides may be varied by side chain modifications.
- Such side chain modifications include for instance, but not restricted to, homoserine formation, pyroglutamic acid formation, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t-butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, bencyloxymethylation, 4-nitrophenylation, bencyloxycarbonylation, 2-nitrobencoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2-chlorobenzyloxycarbonylation, 2,4,5-trichlorophenylation, 2-bromobenzyloxycarbonylation, 9-fluoren
- amino acid residues comprising A, B, C, D, and E substituents are attached to the adjacent moiety according to standard nomenclature so that the amino-terminus (N-terminus) of the amino acids is drawn on the left and the carboxyl-terminus of the amino acid is drawn to the right.
- peptide substrates of the proline-specific serine protease dipeptidyl peptidase IV in vitro are the tripeptides Diprotin A (lle-Pro-lle), Diprotin B (Val-Pro-Leu) and Diprotin C (Val-Pro-lle).
- Applicants have unexpectedly discovered that the compounds disclosed here act as substrates of dipeptidyl peptidase IV in vivo in a mammal and, in pharmacological doses, inhibit the physiological turnover of endogenous substrates by competitive catalysis.
- Particularly preferred compounds of the present invention that could be useful as modulators of dipeptidyl peptidase IV and DPIV—like enzymes include those compounds which show K i -values for DPIV-binding, effectively in DPIV-inhibition in vivo after i.v. and/or p.o. administration to Wistar rats
- A is selected from:
- X 1 is H or a acyl or oxycarbonyl group incl. all amino acids and peptide residues,
- X 3 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue,
- X 4 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue,
- X 5 is H or an alkyl, alkoxy or phenyl residue
- X 6 is H or a alkyl residue.
- X is selected from: H, OR 2 , SR 2 , NR 2 R 3 , N + R 2 R 3 R 4 , wherein:
- R 2 stands for acyl residues, which are substituted with alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are substituted with alkyl, cycloalkyl, aryl and heteroaryl residues,
- R 3 stands for alkyl and acyl functions, wherein R 2 and R 3 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
- R 4 stands for alkyl residues, wherein R 2 and R 4 or R 3 and R 4 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures.
- X is selected from:
- B stands for: O, S, NR 5 , wherein R 5 is H, a alkyl or acyl, C, D, E, F, G, H are independently selected from alkyl and substituted alkyl residues, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
- Z is selected from H, or a branched or single chain alkyl residue from C 1 -C 9 or a branched or single chain alkenyl residue from C 2 -C 9 , a cycloalkyl residue from C 3 -C 8 , a cycloalkenyl residue from C 5 -C 7 , a aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
- the present invention provides compounds of formulas 5, 6, 7,8, 9, 10 and 11, including all stereoisomers and pharmaceutical acceptable salts thereof,
- R 1 is H, a branched or linear C 1 -C 9 alkyl residue, a branched or linear C 2 -C 9 alkyl residue, a C 3 -C 8 cycloalkyl-, C 5 -C 7 cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof,
- R 3 and R 4 are selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen.
- A is H or an isoster of an carbonic acid, like a functional group selected from CN, SO 3 H, CONHOH, PO 3 R 5 R 6 , tetrazole, amide, ester, anhydride, thiazole and imidazole,
- B is selected from:
- R 10 is H, a acyl, oxycarbonyl or a amino acid residue
- W is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue,
- W 1 is H, a alkyl, alkoxy or phenyl residue
- Z is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue,
- Z 1 is H or a alkyl residue
- D is a cyclic C 4 -C 7 alkyl, C 4 -C 7 alkenyl residue or a alkyl substituted derivative thereof or a cyclic 4-7-membered heteroalkyl or 4-7-membered heteroalkenyl residue,
- X 2 is O, NR 6 , N + (R 7 ) 2 , or S,
- X 3 to X 12 are selected from CH 2 , CR 8 R 9 , NR 6 , N + (R 7 ) 2 , O, S, SO and SO 2 , including all saturated and unsaturated structures,
- R 6 , R 7 , R 8 , R 9 are selected from H, a branched or linear C 1 -C 9 alkyl residue, a branched or lienar C 2 -C 9 alkenyl residue, a C 3 -C 8 cycloalkyl residue, a C 5 -C 7 cycloalkenyl residue, an aryl or heteroaryl residue,
- DPIV-inhibitors such as, for example, Glu(Gly)-Thia or Lys(Z-NO 2 )-Thia [REINHOLD, D., et al., 1998] are transported completely.
- the problem to be solved consisted in preparing compounds that can be used for targeted influencing of locally limited pathophysiological and physiological processes.
- the problem of the invention especially consists in obtaining locally limited inhibition of DPIV or DPIV-analogous activity for the purpose of targeted intervention in the regulation of the activity of locally active substrates.
- A is an amino acid having at least one functional group in the side chain
- B is a chemical compound covalently bound to at least one functional group of the side chain of A, namely
- oligopeptides having a chain length of up to 20 amino acids except for homopolymers of glycine consisting of up to 6 glycine monomers, or
- C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A.
- compositions comprising at least one compound of the general formula (12)
- A is an amino acid, preferably an ⁇ -amino acid, especially a natural ⁇ -amino acid having at least one functional group in the side chain, preferably threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine,
- B is a chemical compound covalently bound to at least one functional group in the side chain of A, namely oligopeptides having a chain length of up to 20 amino acids, polyethylene glycols having molar masses of up to 20 000 g/mol, optionally substituted organic amines, amides, alcohols, acids or aromatic compounds having from 8 to 50 C atoms,
- C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A,
- alkyl can denote a C 1-50 alkyl group, preferably a C 6-30 alkyl group, especially a C 8-12 alkyl group; for example, an alkyl group may be a methyl, ethyl, propyl, isopropyl or butyl group.
- alk for example in the expression “alkoxy”, and the expression “alkan”, for example in the expression “alkanoyl”, are defined as for “alkyl”; aromatic compounds are preferably substituted or optionally unsubstituted phenyl, benzyl, naphthyl, biphenyl or anthracene groups, which preferably have at least 8 C atoms;
- alkenyl can denote a C 2-10 alkenyl group, preferably a C 2-6 alkenyl group, which has the double bond(s) at any desired location and may be substituted or unsubstituted;
- alkynyl can denote a C 2-10 alkynyl group, preferably a C 2-6 alkynyl group, which has the triple bond(s) at any desired location and may be substituted or unsubstituted;
- substituted or substituent can denote any desired substitution by one or more, preferably one or two, alkyl
- the compounds of formula (12) can still bind to the active centre of the enzyme dipeptidyl peptidase IV and analogous enzymes but are no longer actively transported by the peptide transporter PepT1.
- the resulting reduced or greatly restricted transportability of the compounds according to the invention leads, in ideal manner, to local or site directed inhibition of DPIV and DPIV-like enzyme activity.
- the compounds of formula (12) or compounds used in accordance with the invention can be present or used, respectively, in the form of racemates or in the form of enantiomerically pure compounds, preferably in the L-threo or L-allo form with respect to part A of formula (12).
- the compounds of formula (12) inhibit DPIV or DPIV-like enzyme activity in the body of a mammal in a site specific manner. It is accordingly possible to influence local physiological and pathophysiological conditions (inflammation, psoriasis, arthritis, autoimmune diseases, allergies) effectively and with dramatically reduced side-effects.
- Preferred compounds of formula (12) are compounds, wherein the oligopeptides have chain lengths of from 3 to 15, especially from 4 to 10, amino acids, and/or the polyethylene glycols have molar masses of at least 250 g/mol, preferably of at least 1500 g/mol and up to 15 000 g/mol, and/or the optionally substituted organic amines, amides, alcohols, acids or aromatic compounds have at least 12 C atoms and preferably up to 30 C atoms.
- the compounds of the present invention can be converted into acid addition salts, especially pharmaceutically acceptable acid addition salts.
- the pharmaceutically acceptable salt generally takes a form in which an amino acids basic side chain is protonated with an inorganic or organic acid.
- Representative organic or inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. All pharmaceutically acceptable acid addition salt forms of the compounds of formulas (1) to (12) are intended to be embraced by the scope of this
- the present invention further includes within its scope prodrugs of the compounds of this invention.
- prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound.
- the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject.
- Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 198 28 113 and DE 198 28 114, which are fully incorporated herein by reference.
- the compounds according to this invention may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
- the compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms are useful in inhibiting DPIV and DPIV-like enzyme activity.
- the ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV and DPIV-like enzyme activity may be demonstrated employing the DPIV activity assay for determination of the K i -values and the IC 50 -values in vitro, as described in examples 7 and 8.
- DPIV is present in a wide variety of mammalian organs and tissues e.g. the intestinal brush-border (Gutschmidt S. et al., “In situ” —measurements of protein contents in the brush border region along rat jejunal villi and their correlations with four enzyme activities. Histochemistry 1981, 72 (3), 467-79), exocrine epithelia, hepatocytes, renal tubuli, endothelia, myofibroblasts (Feller A. C. et al., A monoclonal antibody detecting dipeptidylpeptidase IV in human tissue. Virchows Arch. A. Pathol. Anat. Histopathol.
- DPIV was originally believed to be the only membrane-bound enzyme specific for proline as the penultimate residue at the amino-terminus of the polypeptide chain.
- DPIV-like enzymes which are identified so far, are e.g.
- fibroblast activation protein ⁇ dipeptidyl peptidase IV ⁇ , dipeptidyl aminopeptidase-like protein, N-acetylated ⁇ -linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin and dipeptidyl peptidase IV related protein (DPP 8), and are described in the review article by Sedo & Malik (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001, 36506: 1-10).
- DPIV like enzymes are disclosed in WO 01/19866, WO 02/04610 and WO 02/34900.
- WO 01/19866 discloses novel human dipeptidyl aminopeptidase (DPP8) with structural and functional similarities to DPIV and fibroblast activation protein (FAP).
- DPP8 novel human dipeptidyl aminopeptidase
- FAP fibroblast activation protein
- the dipeptidyl peptidase IV-like enzyme of WO 02/04610 is well known in the art. In the Gene Bank data base, this enzyme is registered as KIAA1492.
- all molecular forms, homologues and epitopes of proteins comprising DPIV-like enzyme activity from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
- the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms have only low, if no inhibitory activity against non-DPIV and non-DPIV-like proline specific enzymes.
- glutaminyl thiazolidine and glutaminyl pyrrolidine exemplarily, no inhibition of dipeptidyl peptidase I and prolyl oligopeptidase was found.
- prolidase both compounds explained a marked lower efficacy compared to DPIV.
- the present invention provides a method of treating a condition mediated by modulation of the DPIV or DPIV-like enzyme activity in a subject in need thereof which comprises administering any of the compounds of the present invention or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition. Additionally, the present invention includes the use of the compounds of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for the preparation of a medicament for the treatment of a condition mediated by modulation of the DPIV activity in a subject.
- the compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral.
- the present invention provides formulations for the compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms, in pharmaceutical compositions.
- subject refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
- terapéuticaally effective amount means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- composition is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
- compositions of this invention one or more compounds of formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- a pharmaceutical carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular.
- any of the usual pharmaceutical media may be employed.
- suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like;
- suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques.
- the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included.
- Injectable suspensions may also prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed.
- the pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above.
- the pharmaceutical compositions herein will contain, per unit a dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.03 mg to 100 mg/kg (preferably 0.1-30 mg/kg) and may be given at a dosage of from about 0.1-300 mg/kg per day (preferably 1-50 mg/kg per day).
- the dosages may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed.
- the use of either daily administration or post-periodic dosing may be employed.
- the dosage will be regulated by the physician based on the characteristics of the patient, his/her condition and the therapeutic effect desired.
- compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation.
- the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection.
- the principal active ingredient is ideally mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof.
- a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water
- a pharmaceutical carrier e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium
- the tablets or pills of the novel composition can be advantageously coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action.
- the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.
- the two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release.
- enteric layers or coatings such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- This liquid forms in which the novel compositions of the present invention may be advantageously incorporated for administration orally or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
- Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers
- these isomers may be separated by conventional techniques such as preparative chromatography.
- the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
- the compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as ( ⁇ )-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base.
- the compounds may also resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- any of the processes for preparation of the compounds of the present invention it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry , ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis , John Wiley & Sons, 1991, fully incorporated herein by reference.
- the protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- the method of treating conditions modulated by dipeptidyl peptidase IV and DPIV—like enzymes described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier.
- the pharmaceutical composition may contain between about 0.01 mg and 1000 mg, preferably about 5 to 500 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected.
- Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings.
- compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions.
- forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
- compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
- compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art.
- the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen and dosage strength will need to be accordingly modified to obtain the desired therapeutic effects.
- the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
- suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and other compounds known within the art.
- liquid forms are suitable in flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
- suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like.
- sterile suspensions and solutions are desired.
- Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
- the compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines using processes well described in the art.
- Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers.
- soluble polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue.
- compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
- the daily dosage of the products may be varied over a wide range from 0.01 to 1.000 mg per adult human per day.
- the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated.
- An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day.
- the range is from about 1 to about 50 mg/kg of body weight per day.
- the compounds may be administered on a regimen of 1 to 4 times per day.
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, bioavailability due to the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, should generally be considered in adjusting dosages.
- N-Benzyl-oxycarbonylglutamine (2.02 g, 7.21 mmol) was dissolved in 35 ml THF and brought to ⁇ 15° C.
- CAIBE isobutylchloroformiate
- 4-methylmorpholine 0.795 ml, 7.21 mmol
- N-t-Butyl-oxycarbonylglutamine (2.0 g, 8.12 mmol) was dissolved in, 5 ml THF and brought to ⁇ 15° C.
- CAIBE isobutylchloroformiate
- 4-methylmorpholine (0.895 ml, 8.12 mmol) where added and the solution was stirred for 15 min.
- the formation of the mixed anhydride was checked by TLC (eluent: CHCl3/MeOH: 9/1). After warming to ⁇ 10° C. another equivalent 4-methylmorpholine (0.895 ml, 8.12 mmol) and thiazolidinehydrochloride (1.02 g, 8.12 mmol was added. The mixture was brought to room temperature and stirred overnight.
- N-t-Butyl-oxycarbonylglutamine (3.0 g, 12.18 mmol) was dissolved in 7 ml THF and brought to -15° C.
- CAIBE isobutylchloroformiate
- 4-methylmorpholine 1.3 ml, 12.18 mmol
- the mass spectra were recorded by means of electrospray ionisation (ESI) on an “API 165” or API 365” from the PE Sciex company.
- ESI electrospray ionisation
- API 165 API 365
- Pre-loaded Fmoc-Yaa-Wang resin (2.8 g/substitution level 0.57 mmol/g) was deprotected using 20% piperidine/N,N-dimethylformamide (DMF). After washing with DMF a solution of 2 eq (1.1 g) of Fmoc-Pro-OH were solved in DMF (12 ml solvent per gram resin). 2eq (1.04 g) of 2-(1H-Benzotriazole 1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 4 eq (1.11 ml) of N,N-diisopropylethylamine (DIEA) were added and placed in the reaction vessel.
- DIEA N,N-diisopropylethylamine
- Fmoc protecting group was removed as described above. After that 0.54 mmol of the Boc-amino acid, 0.54 mmol TBTU and 0.108 mmol DIEA in DMF were shaken for 20 min. The coupling cycle was repeated. Finally the peptide resin was washed and dried described above.
- TFA/H 2 O/triisipropylsilane (TIS) 9.5/0.25/0.25
- the yields of crude peptides were 80-90% on the average.
- the crude peptide was purified by HPLC on a Nucleosil C18 column (7 ⁇ m, 250*21.20 mm, 100 A) using a linear gradient of 0.1% TFA/H 2 O with increasing concentration of 0.1% TFA/acetonitrile (from 5% to 65% in 40 min) at 6 ml/min.
- t-butyl-Gly is defined as:
- Ser(Bzl) and Ser(P) are defined as benzylserine and phosphorylserine, respectively.
- Tyr(P) is defined as phosphoryltyrosine.
- Boc-Val-OH (3.00 g, 13.8 mmol) was dissolved in 10 ml of dry THF and cooled down to ⁇ 15° C.
- CAIBE (1.80 ml, 13.8 mmol) and NMM (1.52 ml, 13.8 mmol) where added and the solution was stirred until the formation of the mixed anhydride was complete. Then the mixture was brought to ⁇ 10° C. and NMM (1.52 ml, 13.8 mmol) was added followed by H-Pro-OMe*HCl (2.29 g, 13.8 mmol). The mixture was allowed to reach room temperature and left overnight. After removing the solvent and the usual workup the resulting ester 1 was taken without further characterisation.
- the ester 1 was dissolved in HCl/HOAc (5 ml, 6N) and left at 0° C. until the removal of the Boc-group was complete. The solvent was then removed and the resulting oil was treated with diethylether to give a white solid 2.
- Oxalylchloride (714 ⁇ l, 8.28 mmol) was dissolved in 10 ml of dry dichlormethane and brought to ⁇ 78° C. Then DMSO (817 ⁇ l, 8.28 mmol) was added dropwise. The solution was stirred for 20 min at ⁇ 78° C. Then 1 (1.00 g, 4.6 mmol) was added and the mixture was stirred for 20 min. After that TEA (2.58 ml, 18.4 mmol) was added and the mixture was allowed to reach room temperature. The mixture was diluted with hexane/ethylacetate (2/1 v/v) and 10 ml of HCl (10% in water) was added.
- the organic layer was separated and the aqueous phase was extracted with 20 ml of methylenechloride. All organic layers were collected and washed with brine, followed by water, then dried. The product was purified by column chromatography using silica gel and heptane/chloroform.
- Boc-Glu-Thia was modified at the ⁇ -carboxylic acid function by introducing radicals of varying size.
- the radicals were coupled by way of their amino group by forming an amide bond to the ⁇ -carboxylic acid function, with a variety of coupling methods being used depending on the radical.
- the following amino components were attached to Boc-Glu-Thia using the method stated: Coupling methods Amino component (see section 3.4) Yields Polyethylene glycol amine (M r ⁇ 8000) C 93% H-Gly-Gly-Gly-OH D + E 49% H-Gly-Gly-Gly-Gly-Gly-OH D + E 86%
- the starting materials for the synthesis are dissolved in a 500-fold excess of DMF. After the reaction is complete, the DMF is completely removed in vacuo and the residue is dissolved in a large amount of methanol. After ether is poured on, to form an upper layer, the product precipitates out together with the unreacted PEG. Fine purification was carried out by preparative HPLC separation on a gel filtration column (Pharmazia, Sephadex G-25, 90 ⁇ m, 260 mm-100 mm).
- N-terminal Boc protecting groups were cleaved off the compounds described in Table 6.2.2 using method F.
- the substances modified with Gly derivatives were purified by preparative HPLC separation and are present as trifluoroacetates.
- the H-Glu(PEG)-Thia was purified on a gel filtration column in the same manner as the Boc-protected precursor.
- Method A Peptide bond attachment by the mixed anhydride method using CFIBE as activation reagent
- reaction mixture is concentrated using a rotary evaporator, taken up in EA, washed with 5% KH 2 SO 4 solution, saturated NaHCO 3 solution and saturated NaCl solution and dried over NaSO 4 . After removal of the solvent in vacuo, the compound is recrystallized from EA/pentane.
- Method B Peptide bond attachment by the mixed anhydride method using pivalic acid chloride as activation reagent
- dipeptidyl peptidase IV from porcine kidney with a specific activity against glycylprolyl-4-nitroaniline of 37.5 U/mg and an enzyme concentration of 1.41 mg/ml in the stock solution was used.
- t-butyl-Gly is defined as:
- Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively.
- Tyr(P) is defined as phosphoryl-tyrosine.
- 100 ⁇ l inhibitor stock solution were mixed with 100 ⁇ l buffer (HEPES pH7.6) and 50 ⁇ l substrate (Gly-Pro-pNA, final concentration 0.4 mM) and preincubated at 30° C. Reaction was started by addition of 20 ⁇ l purified porcine DPIV. Formation of the product pNA was measured at 405 nm over 10 min using the HTS 7000Plus plate reader (Perkin Elmer) and slopes were calculated. The final inhibitor concentrations ranged between 1 mM and 30 nM. For calculation of IC50 GraFit 4.0.13 (Erithacus Software) was used.
- t-butyl-Gly is defined as:
- Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively.
- Tyr(P) is defined as phosphoryl-tyrosine.
- DP II (3.4.14.2) releases N-terminal dipeptides from oligopeptides if the N-terminus is not protonated (McDonald, J. K., Ellis, S. & Reilly, T. J., 1966, J. Biol. Chem., 241, 1494-1501). Pro and Ala in P 1 -position are preferred residues.
- the enzyme activity is described as DPIV-like activity, but DP II has an acidic pH-optimum. The enzyme used was purified from porcine kidney.
- Glutaminyl pyrrolidine and glutaminyl thiazolidine were tested for their cross reacting potency against dipeptidyl peptidase I, prolyl oligopeptidase and prolidase.
- DP I or cathepsin C is a lysosomal cysteine protease which cleaves off dipeptides from the N-terminus of their substrates (Gutman, H. R. & Fruton, J. S., 1948, J. Biol: Chem., 174, 851-858). It is classified as a cysteine protease.
- the enzyme used was purchased from Qiagen (Qiagen GmbH, Hilden, Germany).
- the enzyme was diluted 1000fold in MES buffer pH5,6 (40 mM MES, 4 mM DTT, 4 mM KCl, 2 mM EDTA, 0.015% Brij) and pre-incubated for 30 min at 30° C.
- Prolyl oligopeptidase (EC 3.4.21.26) is a serine type endoprotease which cleaves off peptides at the N-terminal part of the Xaa-Pro bond (Walter, R., Shlank, H., Glass, J. D., Schwartz, I. L. & Kerenyi, T. D., 1971, Science, 173, 827-829). Substrates are peptides with a molecular weight up to 3000 Da. The enzyme used was a recombinant human prolyl oligopeptidase. Recombinant expression was performed in E. coli under standard conditions as described elsewhere in the state of the art.
- Prolidase (EC 3.4.13.9) was first described by Bergmann & Fruton (Bergmann, M. & Fruton, J S, 1937, J. Biol Chem. 189-202). Prolidase releases the N-terminal amino acid from Xaa-Pro dipeptides and has a pH optimum between 6 and 9.
- Prolidase from porcine kidney was solved (1 mg/ml) in assay buffer (20 mM NH 4 (CH 3 COO) 2 , 3 mM MnCl 2 , pH 7.6). In order to get a fully active enzyme the solution was incubated for 60 min at room temperature.
- catheters were implanted into the carotid artery of Wistar rats under general anaesthesia (i.p. injection of 0.25 ml/kg b.w. Rompun® [2%], BayerVital, Germany and 0.5 ml/kg b.w. Ketamin 10, Atarost GmbH & Co., Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 IU/ml) three times per week. In case of catheter dysfunction, a second catheter was inserted into the contra-lateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 7 days after catheter implantation.
- general anaesthesia i.p. injection of 0.25 ml/kg b.w. Rompun® [2%], BayerVital,
- Rats with intact catheter function were administered placebo (1 ml saline, 0.154 mol/l) or test compound via the oral and the intra-vasal (intra-arterial) route. After overnight fasting, 100 ⁇ l samples of heparinised arterial blood were collected at ⁇ 30, ⁇ 5, and 0 min. The test substance was dissolved freshly in 1.0 ml saline (0.154 mol/l) and was administered at 0 min either orally via a feeding tube (75 mm; Fine Science Tools, Heidelberg, Germany) or via the intra-vasal route. In the case of oral administration, an additional volume of 1 ml saline was injected into the arterial catheter. In the case of intra-arterial administration, the catheter was immediately flushed with 30 ⁇ l saline and an additional 1 ml of saline was given orally via the feeding tube.
- the assay mixture for determination of plasma DPIV activity consisted of 80 ⁇ l reagent and 20 ⁇ l plasma sample. Kinetic measurement of the formation of the yellow product 4-nitroaniline from the substrate glycylprolyl-4-nitroaniline was performed at 390 nm for 1 min at 30° C. after 2 min pre-incubation at the same temperature. The DPIV activity was expressed in mU/ml.
- F344USA, F344JAP and F344GER substrains were obtained from a breeding colony at the Central Animal Laboratory at Hannover Medical School, Germany. All substrains were bred for one generation and maintained in a specific-pathogen-free facility at 25° C. under a 12h light-12h dark cycle (light on at 07.00 h), with ad libitum access to food and water. The exact number of animals used per experiment is indicated by the F values with at least four animals per condition and time point.
- CFSE-labeled MADB106 tumor cells were achieved using mAb characterizing the intracellular CFSE antigen (anti-CFSE; mAb DE1, Boehringer, Mannheim, Germany; mouse, 1:100).
- mAb characterizing the intracellular CFSE antigen anti-CFSE; mAb DE1, Boehringer, Mannheim, Germany; mouse, 1:100.
- APAAP stainings were performed as previously described (von Hörsten et al, 2000; Shingu et al., 2002). Control sections were included in which one or both primary antibodies were omitted.
- Each right upper lobe of the lungs was sectioned at 6 randomly chosen non-adjacent levels. From each level, three sections were evaluated. On average, 30 grid numbers per section were examined (i.e. 0.5625 mm 2 /grid ⁇ 30 grids ⁇ 3 sections ⁇ 6 levels) resulting in an area per animal of 3.04 cm 2 .
- FIG. 1 The number of lung surface tumor colonies after single isoleucyl thiazolidine fumarate administration in F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 1.
- Tumor cell adhesion and colonization is significantly modified by single injection of isoleucyl thiazolidine fumarate only in mutant F344 substrains suggesting an interaction of the ligand with mutant DPIV and tumor cells. Since the ligand did not significantly affect tumor adhesion in wild type F344USA rats, this may indicate that compound is not interacting with the binding site of MADB106 tumor cells.
- F344USA rats were obtained from a breeding colony at the Central Animal Laboratory at Hannover Medical School, Germany. All rats were bred at least for one generation and maintained in a specific-pathogen-free facility at 25° C. under a 12h light-12h dark cycle (light on at 07.00 h), with ad libitum access to food and water. The exact number of animals used per experiment is indicated by the F values with at least four animals per condition and time point.
- Osmotic minipumps (Alzet model 2ML4; flow rate, 2.5 ⁇ l/hr; Alza Corporation), administering a constant supply of the different compounds, aseptically prefilled with either saline or DPIV inhibitor were placed subcutaneously in the abdominal area.
- Minipums were attached to a cannula via polyethylene tubing. The cannula was implanted intragastrically with a heating-induced enlarged tip of the cannula in the lumen of the gaster.
- FIG. 7 The number of lung surface tumor colonies after chronic infusion of isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA, and valyl pyrrolidine fumarate in F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 7.
- DPIV Inhibitors isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA
- isoleucyl thiazolidine fumarate and isoleucyl cyanopyrrolidine TFA protect from metastasis either via interaction with cell adhesion processes or via a modification of the cellular host defense mechanisms.
- DPIV inhibitor treatment exhibits cytostatic effects.
Abstract
The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for treating conditions mediated by DPIV or DPIV-like enzymes, such as cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the treatment of metastasis and tumor colonization.
Description
- This application claims the priority of U.S. provisional application No. 60/301,158 entitled Peptide Structures Useful for Competitive modulation of Dipeptidyl Peptidase IV Catalysis filed on Jun. 27, 2001. Priority is also claimed from U.S. provisional application No. 60/360,909 entitled Glutaminyl-based DPIV Inhibitors filed on Feb. 28, 2002. This application also claims the priority of the following foreign applications EP 01 114 796.4 entitled Peptide Structures Useful for Competitive Modulation of Dipeptidyl Peptidase IV Catalysis having a priority date of Jun. 27, 2001, DE 101 50 203.6 entitled Peptidylketone als Inhibitoren der DPIV having a priority date of Oct. 12, 2001 and DE 101 54 689.0 entitled Substituierte Aminoketonverbindungen having a priority Date of Nov. 09, 2001. The above applications are incorporated in their entirety by reference.
- The present invention relates to inhibitors of dipeptidyl peptidase IV and dipeptidyl peptidase IV-like enzyme activity and, more particularly, pharmaceutical compositions containing said compounds, and the use of said compounds for the treatment of cancer and tumors. The present invention especially provides a method for the inhibition of metastasis and tumor colonization.
- Dipeptidyl peptidase IV (DPIV) is a serine protease which cleaves N-terminal dipeptides from a peptide chain containing, preferably, a proline residue in the penultimate position. Although the biological role of DPIV in mammalian systems has not been completely established, it is believed to play an important role in neuropeptide metabolism, T-cell activation, attachment of cancer cells to the endothelium and the entry of HIV into lymphoid cells.
- Likewise, it has been discovered that DPIV is responsible for inactivating glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide also known as gastric-inhibitory peptide (GIP). Since GLP-1 is a major stimulator of pancreatic insulin secretion and has direct beneficial effects on glucose disposal, in WO 97/40832 and U.S. Pat. No. 6,303,661 inhibition of DPIV and DPIV-like enzyme activity was shown to represent an attractive approach for treating non-insulin-dependent diabetes mellitus (NIDDM).
- The present invention provides a new use of DPIV-inhibitors for the treatment of conditions mediated by inhibition of DPIV and DPIV-like enzymes, in particular the treatment of cancer and tumors and the inhibition of metastasis and tumor colonization, and pharmaceutical compositions e.g. useful in inhibiting DPIV and DPIV-like enzymes and a method of inhibiting said enzyme activity.
- This invention relates to a method of treatment, in particular to a method for the treatment of cancer, tumors, metastasis and tumor colonization and to compositions for use in such method. Dipeptidyl peptidase IV (DPIV) is a post-proline (to a lesser extent post-alanine, post-serine or post-glycine) cleaving serine protease found in various tissues of the body including kidney, liver, and intestine.
- It is known that DPIV-Inhibitors may be useful for the treatment of impaired glucose tolerance and diabetes mellitus (International Patent Application, Publication Number WO 99/61431, Pederson R A et al, Diabetes. 1998 August; 47(8):1253-8 and Pauly RP et al, Metabolism 1999 March; 48(3):385-9). In particular WO 99/61431 discloses DPIV-Inhibitors comprising an amino acid residue and a thiazolidine or pyrrolidine group, and salts thereof, especially L-threo-isoleucyl thiazolidine, L-allo-isoleucyl thiazolidine, L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, L-allo-isoleucyl pyrrolidine, and salts thereof.
- Further examples of low molecular weight dipeptidyl peptidase IV inhibitors are agents such as tetrahydroisoquinolin-3-carboxamide derivatives, N-substituted 2-cyanopyroles and -pyrrolidines, N-(N′-substituted glycyl)2-cyanopyrrolidines, N-(substituted glycyl)-thiazolidines, N-(substituted glycyl)-4-cyanothiazolidines, amino-acyl-borono-prolyl-inhibitors, cyclopropyl-fused pyrrolidines and heterocyclic compounds. Inhibitors of dipeptidyl peptidase IV are described in U.S. Pat. Nos. 6,380,398, 6,011,155; 6,107,317; 6,110,949; 6,124,305; 6,172,081; WO 95/15309, WO 99/61431, WO 99/67278, WO 99/67279, DE 198 34 591, WO 97/40832, DE 196 16 486
C 2, WO 98/19998, WO 00/07617, WO 99/38501, WO 99/46272, WO 99/38501, WO 01/68603, WO 01/40180, WO 01/81337, WO 01/81304, WO 01/55105, WO 02/02560 and WO 02/14271, the teachings of which are herein incorporated by reference in their entirety. - The term DPIV-like enzymes relates to structurally and/or functionally DPIV/CD26-related enzyme proteins (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001, 36506: 1-10). In essence, this small group of enzymes has evolved during evolution to release H-Xaa-Pro-Dipeptides and H-Xaa-Ala-Dipeptides from N-terminus of oligo- or polypeptides. They show the common feature, that they accomotate in the Pro-position also Al, Ser, Thr and other amino acids with small hydrophobic side-chains as, Gly or Val. The hydrolytic efficacy is ranked Pro>AlaSer, Thr Gly, Val. Same proteins have been only available in such small quantities, that only the post-Pro or post-Ala cleavage could be established. While the proteins: DPIV, DP II, FAPα (Seprase),
DP 6,DP 8 andDP 9 are structurally related and show a high sequence homology, attractin is an extraordinary functional DPIV-like enzyme, characterized by a similar activity and inhibitory pattern. - Further DPIV-Like enzymes are disclosed in WO 01/19866, WO 02/04610, WO 02/34900 and WO02/31134. WO 01/19866 discloses novel human dipeptidyl aminopeptidase (DPP8) with structural and functional similarities to DPIV and fibroblast activation protein (FAP). WO 02/04610 provides reagents, which regulate human dipeptidyl peptidase IV-like enzyme and reagents which bind to human dipeptidyl peptidase IV-like enzyme gene product. These reagents can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, tumors and peripheral and central nervous system disorders including pain and neurodegenerative disorders. The dipeptidyl peptidase IV-like enzyme of WO 02/04610 is well known in the art. In the Gene Bank data base, this enzyme is registered as KIAA1492 (registration in February 2001, submitted on Apr. 04, 2000, AB040925). In the Merops data base, the dipeptidyl peptidase IV-like enzyme of WO 02/04610 is registered as non-protease homologue, because the active site serine motive is GKGYGG in contrast to DPIV, which has a active site serine motive consisting of GWSYGG. The Merops homologue of the dipeptidyl peptidase IV-like enzyme disclosed in WO 02/04610 and the active site motive thereof was confirmed by the human genome project. WO 02/34900 discloses a novel dipeptidyl peptidase 9 (DPP9) with significant homology with the amino acid sequences of DPIV and DPP8. WO 02/31134 discloses three DPIV-like enzymes, DPRP1, DPRP2 and DPRP3. Sequence analysis revealed, that DPRP1 is identical to DPP8, as disclosed in WO 01/19866, that DPRP2 is identical to DPP9 and that DPRP3 is identical to KIAA1492 as disclosed in WO 02/04610.
- DPIV and DPIV-like Enzymes in Immunophysiology and Cancer
- Dipeptidyl peptidase IV (DPIV; EC 3.4.14.5; CD26) CD26 is a M r 110,000 surface glycoprotein with an array of diverse functional properties that is expressed on a number of tissues, including epithelial cells and leukocyte subsets (Mentlein, 1999). Furthermore, it is a membrane-associated ectopeptidase that possesses DPIV-like activity in its extracellular domain and is able to cleave N-terminal dipeptides from polypeptides with either L-proline or L-alanine in the penultimate position. In general, DPIV is recognized as an ectopeptidase with a triple functional role. DPIV is involved in catalyzing the release of Xaa-Pro dipeptides from circulating hormones and chemokines (De Meester et al, 1999; Mentlein, 1999), in T cell dependent immune responses (Kähne et al, 1999; Korom et al, 1997), and in cell adhesion including metastasis (Mentlein, 1999).
- In addition DPIV has been identified as the ADA binding protein, thereby regulating ADA surface expression, with the DPIV/ADA complex perhaps playing a key role in the catalytic removal of local adenosine to regulate immune system function. Besides being a key immunoregulatory molecule, DPIV may have a potential role in the development of certain neoplasms (Mattern et al., 1993; Carbone et al., 1995). In eukaryotic cells, cell cycle progression is controlled at the G1-S checkpoint by a group of related enzymes known as the CDKs, which are positively regulated by their physical association with regulatory subunits called cyclins. It has been demonstrated that binding of soluble anti-CD26 antibodies inhibits the growth of anaplastic large cell T-cell lymphoma cell lines, both in in vitro and in vivo experiments (Ho et al., 2001).
- Cancer Pathomechanisms
- Cancer is a group of over 150 diseases characterized by the uncontrolled growth of abnormal cells in the body. Normal cells can become abnormal when they are exposed to carcinogens such as radiation or particular drugs or chemicals. They can also turn malignant (cancerous) when they are attacked by certain viruses or when some not-yet-fully-understood internal signal occurs. Once cells become malignant, they multiply more rapidly than usual. Then they often form masses called tumors that invade nearby tissue and interfere with normal bodily functions. Cancer cells also have a tendency to spread to other parts of the body, where they may form a secondary tumor.
- Mechanisms of Metastasis
- The outcome of cancer metastasis depends on multiple interactions within the target tissue and depends on the microenvironment including cellular adhesion molecules (Carlos, 2001), chemokines (Muller et al., 2001), or hydrodynamic effects (Haier and Nicholson, 2001) and many other factors (Fidler, 2001). In addition, a very rapid attraction of leukocytes and specific cellular responses at the tumor sites may play a critical role in the early host defense against cancer (Shingu et al.; 2002). These early changes may be of critical importance for the outcome of metastatic disease and may extend the present understanding of the host resistance against metastasis.
- DPIV and DPIV-like Enzymes and Tumor Adhesion and Colonization
- For cancer cell or metastatic cell adhesion, a prominent expression of DPIV on endothelia of lung capillaries accounts for arrest of blood borne breast cancer cells (Johnson et al, 1993). Fibronectin (FN) and probably also collagen collected on the breast cancer cell surface were identified as the principal ligands for DPIV (Abdel-Ghany et al, 1998; Cheng et al, 1998).
- Ho and colleagues (2001) show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD301 anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation.
- Protease Inhibitors, Antibodies and Proteases as Anti-tumor Agents
- WO 95/29691 discloses proline phosphonate derivatives as inhibitors of serine proteases with chymotrypsin-like, trypsin-like, elastase-like and dipeptidyl peptidase IV specificity and their roles as anti-inflammatory agents, anticoagulants, anti-tumor agents and anti-AIDS agents.
- WO 98/53812 and WO 97/48409 disclose novel methods of using phosphonate derivatives, hydroxyphosphinyl derivatives, and phosphoramidate derivatives to inhibit N-Acetylated α-Linked Acidic Dipeptidase (NAALADase) enzyme activity, and to treat prostate diseases, especially using these compounds for the inhibition of prostate cancer cell growth.
- WO 01/92273 discloses new benzenedicarboxylic acid derivative compounds, pharmaceutical compositions, diagnostic methods and diagnostic kits that include those compounds and methods of using those compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, affecting neuronal activity, affecting TGF-β activity, inhibiting angiogenesis and treating glutamate abnormalities, neuropathy, pain, compulsive disorders, prostate diseases, cancer and glaucoma.
- WO 01/34596 discloses pyrrolecarbonylimino derivatives, pharmaceutical compounds and methods of using those compounds to inhibit NAALADase enzyme activity, thereby affecting neuronal activities, inhibiting angiogenesis and treating glutamate abnormalities, compulsive disorders, prostate diseases and cancer.
- WO 00/71135 discloses a method for treating subjects with abnormal cell proliferation. The method involves administering to subjects in need of such treatment an effective amount of boro-proline compounds, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in an abnormal proliferative cell mass by the administration of a boro-proline derivative is also provided. The invention of WO 00/71135 is based, in part, on the observation, that the boro-proline derivatives are able to inhibit the enzymatic activity of fibroblast activation protein-alpha (FAP-α).
- WO 00/71571 relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein-alpha (FAP-α), said prodrug having a cleavage site which is recognised by FAP-α, and said drug being cytotoxic or cytostatic under physiological conditions. These prodrugs are converted into a drug at the site of the tumor.
- WO 00/10549 discloses compounds and a method for regulation of substrate activity in vivo useful for the treatment of medical disorders such as arteriosclerosis, allergies, inflammation, angiogenesis, cardiogenesis, neoplasm, tumor, cancer, a hepatic disease, an intestinal disease, organ vascularization, and microbial and viral infections. The compounds consist of a targeting moiety that binds to DPIV, and a reactive group, that reacts at a reactive center of DPIV. Said compounds are used to prevent chemokine alteration by inhibiting DPIV activity.
- WO 00/36420 discloses a method for identifying nucleotide sequences that are differentially expressed in tumor cells, preferably primary breast tumor cells, comprising exposing a tumor cell containing tissue sample to an agent specific for fibroblast activation protein (FAP) separating cells recognised by said agent from the remaining cells in the sample and harvesting said remaining cells. Nucleic acid molecules derived from the use of this technique are also described, together with compositions comprising the same and their uses in pharmaceutical compositions for treating a disease, preferably breast cancer.
- WO 99/47152 discloses a method of suppressing the malignant phenotype or inducing apoptosis of cancer cells in a subject, comprising introducing into the cancer cell an amount of a nucleic acid encoding a dipeptidyl peptidase IV protein or fibroblast activating protein-α, thereby suppressing the malignant phenotype of the cancer. WO 99/47152 also discloses a method of inducing expression of dipeptidyl peptidase IV or fibroblast activating protein-α in cancer cells of a subject, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an agent capable of activating transcription of the dipeptidyl peptidase IV gene or fibroblast activating protein-α gene and a pharmaceutical acceptable carrier or diluent.
- WO 01/74299 discloses antibodies that specifically bind to a membrane protease complex, the complex consisting of two homodimers of seprase and dipeptidyl peptidase IV (DPIV), obtained from mammalian, preferably human cell membranes. The antibodies specifically bind to the DPIV protease of the seprase-DPIV complex. This membrane protease complex resides on cell surface invadopodia at the leading edge of angiogenic endothelia, migratory fibroblasts, and invading cancer cells.
- WO 02/20825 relates to novel methods and compositions for detection and isolation of cancer cells with metastatic potential. WO 02/20825 further relates to assays for measuring the metastatic potential of such cancer cells and drug screening assays for the indentification of agents having anti-metastatic potential. Also disclosed are methods and compositions for inhibiting the metastatic potential of cancer cells by modulating the activity of serine integral membrane proteases [(SIMP) consisting of seprase and dipeptidyl peptidase IV (DPIV)] expressed on the surface of metastasizing cancer cells, by using antibodies against SIMP.
- Current Treatments of Cancer and Tumor Cell Adhesion
- Current cancer treatment regimens comprise surgery, chemotherapy, radiation therapy, and other treatment methods including immunotherapy. Immunotherapy is composed of the usage or the modification of intrinsic bodily mechanisms—in most cases immune mechanisms—to fight cancer. Chemotherapy kills cancer cells through the use of drugs or hormones. Taken either orally or through injection, chemotherapeutic agents are used to treat a wide variety of cancer. They may be given alone or in combination with surgery or radiation or both. Chemotherapy is an established way to destroy hard-to-detect cancer cells that have spread and are circulating in the body. Anemia (low number of red blood cells) is a frequent side effect of chemotherapy and may cause symptoms such as extreme tiredness, dizziness, or shortness of breath. Epoetin alfa (Procrit®, Epogen®)—recombinant erythropoietin that stimulates red blood cell production—is a prescription drug available for the treatment of chemotherapy-related anemia.
- Immunotherapy uses the body's own immune system or other parts of the organism to destroy cancer cells. This form of treatment is still being intensively studied in clinical trials; it is not yet widely available to most cancer patients. The various immunological agents used include substances produced by the body (such as the interferons, the interleukins and tumor necrosis factor) and laboratory-produced substances (such as monoclonal antibodies and vaccines). Immunological agents work in different ways and can be used independently or in combination with other forms of treatment.
- Angiogenesis Inhibitors as Anti-metastatic Drugs in Immunotherapy
- Angiogenesis inhibitors are drugs that block the development of new blood vessels. Solid tumors cannot grow without inducing the formation of new blood vessels. Blocking the development of new blood vessels cuts off the tumor's supply of oxygen and nutrients.
- Several angiogenesis inhibitors are currently being tested in human trials. In cancerous tissue, tumors cannot grow or spread (metastasize) without the development of new blood vessels. Blood vessels supply tissues with oxygen and nutrients necessary for survival and growth.
- The present invention provides new uses of DPIV-inhibitors of
formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms for treating cancer and tumors. In a more preferred embodiment, the compounds of the present invention are useful for the prevention and inhibition of metastasis and tumor colonization. - Reduced expression of the ectopeptidase DPIV and lack of DPIV-like activity in lungs of mutant F344 rats lacking DPIV enzymic activity and expression results in reduced adhesion of cancer cells and in reduced lung metastasis. In vivo cell adhesion and growth of the F344 rat syngeneic mammary adenocarcinoma MADB106 was studied in F344 rats after acutel and chronic treatment with DPIV-ligands in vivo. Mutant F344 substrains lacking DPIV enzymic activity and wild-type-like F344 were tested. Chronic intragastric infusion of isoleucyl cyano pyrrolidine TFA and isoleucyl thiazolidine fumarate via osmotic minipumps over two weeks dose-dependently reduced the cancer-induced weight loss and the number of tumor colonies on the lung surface. Thus, metastasis of MADB106 is reduced by chronic treatment using different DPIV Inhibitors (isoleucyl thiazolidine fumarate; isoleucyl cyano pyrrolidine TFA) suggesting protective-like class effects by the two different DPIV-inhibitior/ligands. Possibly, isoleucyl thiazolidine fumarate and isoleucyl cyano pyrrolidine TFA protect from metastasis either via interaction with cell adhesion processes, via a modification of the cellular host defense mechanisms, via modulation of angiogenesis, via direct effects on cancer cells, or via increased levels of DPIV substrates, which indirectly mediate protective-like effects.
- FIG. 1: Effect of single injection of isoleucyl thiazolidine fumarate on lung metastasis in F344 rats. Vital dye (Carboxyfluorescein; CFSE) labeled MADB106 tumor cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation. CFSE positive tumor cells in lungs were quantified by means of immunohistology and image analysis. Data represent means±SEM; no significant differences vs. saline treated controls were found.
- FIG. 2: Effect of single injection of isoleucyl thiazolidine fumarate on
tumor cell adhesion 30 min after injection in F344 substrains mutant for DPIV. CFSE labeled MADB106 tumor cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation. Note the promoting effect in mutant F344GER and F344JAP rats in contrast to the lack of effects in wild-type F344 rats. Data represent means±SEM; *p<0.05 reflecting significant differences vs. wild-type F344USA animals determined by ANOVA and Fisher PLSD. - FIG. 3: Effect of single injection of isoleucyl cyanopyrrolidine TFA on
tumor cell adhesion 30 min after injection in F344USA rats. CFSE labeled MADB106 cancer cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation. CFSE positive tumor cells in lungs were quantified by means of immunohistology and image analysis. Data represent means±SEM; significant differences vs. saline treated controls were not found. - FIG. 4: Effect of single injection of valyl pyrrolidine fumarate on
tumor cell adhesion 30 min after injection in F344USA rats. CFSE labeled of MADB106 adenocarcinoma cells were injected via the lateral tail vein and lungs were collected 30 min after inoculation. CFSE positive tumor cells in lungs were quantified by means of immunohistology and image analysis. Data represent means±SEM; significant differences vs. saline treated controls were not found. - FIG. 5: Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate on body weight change in grams in F344 rats with lung metastasis. A dose dependent reduction of the loss of body weight after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated. One factor ANOVA revealed a significant effect on body weight, which became significant in the post-hoc analysis at the 0.4 mg and 4 mg dosages. Data represent means±SEM; *p<0.05 reflecting significant differences vs. saline treated SHAM controls determined by Fisher PLSD. - FIG. 6: Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate on the number of lung tumor colonies in F344 rats. A dose dependent reduction of lung colony numbers after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated. One factor ANOVA revealed a significant effect, which became significant in the post-hoc analysis at the 4 mg dosage. Data represent means±SEM; *p<0.05 reflecting significant differences vs. saline treated SHAM controls determined by Fisher PLSD. - FIG. 7: Effect of chronic intragastric infusion of isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA, and valyl pyrrolidine fumarate on the number of lung tumor colonies in F344 rats. A significant reduction of lung colony numbers after chronic infusion of isoleucyl thiazolidine fumarate and isoleucyl cyanopyrrolidine TFA in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated. Data represent means±SEM; *p<0.05 reflecting significant differences vs. saline treated SHAM controls determined by ANOVA and Fisher PLSD. - The present invention relates to the area of dipeptidyl peptidase IV (DPIV) inhibition and, more particularly, to a new use of inhibitors of DPIV and DPIV-like enzyme activity for the treatment of cancer and tumors, in particular for the prevention and inhibition of metastasis and tumor colonization, and pharmaceutical compositions containing said compounds.
- In contrast to other proposed methods in the art, the present invention provides an orally available therapy with low molecular weight inhibitors of dipeptidyl peptidase IV. The instant invention represents a novel approach for the treatment of cancer and metastatic disease. It is user friendly, commercially useful and suitable for use in a therapeutic regime, especially concerning human diseases.
- Spontaneous mutations of the DPIV gene observed in substrains of F344 rats provide a model for studying the role of DPIV in tumor adhesion and colonization. The mutations in F344 rats result in a lack of DPIV enzymatic activity and are found in substrains from Germany (GER) and Japan (JAP) (Thompson et al, 1991; Tsuji et al, 1992), while rats from USA breeders show significant enzyme activity. In F344JAP rats, a G633R substitution in the DPIV protein causes markedly reduced expression of a mutant inactive enzyme (Cheng et al, 1999; Tsuji et al, 1992;), while the other DPIV negative F344GER substrain expresses a non-active mutant enzyme (Thompson et al, 1991). Studies by Pauli and co-workers (Abdel-Ghany et al, 1998; Cheng et al, 1998; Cheng et al, 1999; Johnson et al, 1993) have demonstrated an important role of DPIV/Fibronectin binding in lung metastasis and have discussed the F344JAP rat as a “protein knock-out” model, although this substrain expresses mutant, enzymatically inactive DPIV on endothelial cell surfaces, albeit at greatly reduced levels when compared to expression of wild type DPIV (Cheng et al, 1999).
- On the basis of these findings, the investigation of the role of DPIV expression and enzymic activity in cancer and cancer according to the present invention revealed the oral administration of DPIV inhibitors in results in a decrease of lung metastasis and colonization.
- The goal of the present invention is the development of dipeptidyl peptidase IV inhibitors and/or ligands, which display a high bioavailability. In another preferred embodiment, the present invention provides DPIV inhibitors, which have an exactly predictable activity time in the target tissue.
- Examples for target specific, orally available low molecular weight agents are prodrugs of stable and unstable dipeptidyl peptidase IV inhibitors which comprise general formula A-B-C, whereby A represents an amino acid, B represents the chemical bond between A and C or an amino acid, and C represents an unstable or a stable inhibitor of dipeptidyl peptidase IV respectively. They are described in WO 99/67278, WO 99/67279 the teachings of which are herein incorporated by reference in their entirety.
- The present invention relates to a novel method, in which the reduction of activity in the enzyme dipeptidyl peptidase (DPIV or CD 26), or of DPIV-Like enzyme activity, or where binding of a DPIV specific ligand exerts tumor suppressive or immunostimulating effects in the organisms of mammals induced by effectors of the enzyme leads as a causal consequence to a reduced growth or adhesion of cancer cells. Such treatment will result in a reduction or delay of cancer cell adhesion (metastasis) or the growth of tumor. As a consequence mammals bearing cancer will benefit from the treatment with inhibitors of DPIV a DPIV-like enzyme activity.
- The method of the present invention for treating cancer in an animal, including humans, in need thereof, comprises anti-cancer effects by binding or by inhibiting DPIV, or related enzyme activities, using an inhibitor or ligand of these enzymes. Oral administration of a DPIV inhibitor may be preferable in most circumstances.
- The present invention will now be illustrated with reference to the following examples focusing on the anti-cancer-like and anti-metastatic-like action of reduced DPIV-like activity and/or binding in an in vivo cancer cell adhesion assay (example 13), and in cancer colonization assays (example 14).
- In one illustrative embodiment, the present invention relates to dipeptide compounds and compounds analogous to dipeptide compounds that are formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof, referred to hereinafter as dipeptide compounds.
- The use of such compounds as inhibitors of DPIV or of DPIV-analogous enzyme activity is already known from DD 296 075, PCT/DE 97/00820 and PCT/EP 99/03712.
- Especially suitable for that purpose according to the invention are dipeptide compounds in which the amino acid is selected from a natural amino acid, such as, for example, leucine, valine, glutamine, glutamic acid, proline, isoleucine, asparagines and aspartic acid.
- The dipeptide compounds according to the invention exhibit at a concentration (of dipeptide compounds) of 10 μM, especially under the conditions indicated in Table 1, a reduction in the activity of dipeptidyl peptidase IV or DPIV-analogous enzyme activities of at least 10%, especially of at least 40%. Frequently a reduction in activity of at least 60% or at least 70% is also required. Preferred effectors may also exhibit a reduction in activity of a maximum of 20% or 30%.
-
- Further preferred compounds are given in Table 1.
- The salts of the dipeptide compounds can be present in a molar ration of dipeptide (-analogous) component to salt component of 1:1 or 2:1. Such a salt is, for example, (lle-Thia)2 fumaric acid.
TABLE 1 Structures of further preferred dipeptide compounds Effector H-Asn-pyrrolidine H-Asn-thiazolidine H-Asn-pyrrolidine H-Asn-thiazolidine H-Asp(NHOH)-pyrrolidine H-Asp(NHOH)-thiazolidine H-Glu-pyrrolidine H-Glu-thiazolidine H-Glu(NHOH)-pyrrolidine H-Glu(NHOH)-thiazolidine H-His-pyrrolidine H-His-thiazolidine H-Pro-pyrrolidine H-Pro-thiazolidine H-Ile-azididine H-Ile-pyrrolidine H-L-allo-Ile-thiazolidine H-Val-pyrrolidine H-Val-thiazolidine -
- wherein
- A, B, C, D and E are any amino acid residues including proteinogenic amino acids, non-proteinogenic amino acids, L-amino acids and D-amino acids and wherein E and/or D may be absent or B and/or A may be absent with additional conditions as hereinafter detailed:
- Further conditions regarding formula (3):
- A is any amino acid residue except D-amino acid residues;
- B is any proteinogenic amino acid residue, but
- If B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid and E may be unused to generate tetrapeptides of the formula A-B-C-D, or D and E may be unused to generate tripeptides of the formula A-B-C provided, but
- If B is not an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any α-amino acid except D-amino acids; D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid; E is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, but
- If D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any α-amino acid except D-amino acids and Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, and A may be unused to generate tetrapeptides of the formula B-C-D-E, or A and B may be unused to generate tripeptides of the formula C-D-E provided however,
- If D is not selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then E is any amino acid residue including D-amino acids.
- Amino acid residues used for the preparation of the compounds of formula (3) can be generally subclassified into four major subclasses as follows.
- Acidic: The residue has a negative charge due to loss of H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.
- Basic: The residue has a positive charge due to association with H ion at physiological pH and the residue is attracted by aqueous solution so as to seek the surface positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium at physiological pH.
- Neutral/nonpolar: The residues are not charged at physiological pH and the residue is repelled by aqueous solution so as to seek the inner positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium. These residues are also designated “hydrophobic” herein.
- Neutral/polar: The residues are not charged at physiological pH, but the residue is attracted by aqueous solution so as to seek the outer positions in the conformation of a peptide in which it is contained when the peptide is in aqueous medium.
- It is understood, of course, that in a statistical collection of individual residue molecules some molecules will be charged, and some not, and there will be an attraction for or repulsion from an aqueous medium to a greater or lesser extent. To fit the definition of “charged”, a significant percentage (at least approximately 25%) of the individual molecules are charged at physiological pH. The degree of attraction or repulsion required for classification as polar or nonpolar is arbitrary, and, therefore, amino acids specifically contemplated by the invention have been specifically classified as one or the other. Most amino acids not specifically named can be classified on the basis of known behavior.
- Amino acid residues can be further subclassified as cyclic or noncyclic, and aromatic or nonaromatic, self-explanatory classifications with respect to the side chain substituent groups of the residues, and as small or large. The residue is considered small if it contains a total of 4 carbon atoms or less, inclusive of the carboxyl carbon. Small residues are, of course, always nonaromatic.
- For the naturally occurring protein amino acids, subclassification according to the foregoing scheme is as follows.
- Acidic: Aspartic acid and Glutamic acid;
- Basic/noncyclic: Arginine, Lysine;
- Basic/cyclic: Histidine;
- Neutral/polar/small: Glycine, Serine and Cysteine;
- Neutral/polar/large/nonaromatic: Threonine, Asparagine, Glutamine;
- Neutral/polar/large/aromatic: Tyrosine;
- Neutral/nonpolar/small: Alanine;
- Neutral/nonpolar/large/nonaromatic: Valine, Isoleucine, Leucine, Methionine;
- Neutral/nonpolar/large/aromatic: Phenylalanine, and Tryptophan.
- The gene-encoded amino acid proline, although technically within the group neutral/nonpolar/large/cyclic and nonaromatic, is a special case due to its known effects on the secondary conformation of peptide chains, and is not, therefore, included in this specific defined group.
- Certain commonly encountered amino acids, which are not encoded by the genetic code, include, for example, beta-alanine (beta-ala), or other omega-amino acids, such as 3-amino propionic, 4-amino butyric and so forth, alpha-aminoisobutyric acid (Aib), sarcosine (Sar), ornithine (Orn), citrulline (Cit), homoarginine (Har), t-butylalanine (t-butyl-Ala), t-butylglycine (t-butyl-Gly), N-methylisoleucine (N-Melle), phenylglycine (Phg), cyclohexylalanine (Cha), norleucine (Nle), cysteic acid (Cya) and methionine sulfoxide (MSO). These also fall conveniently into particular categories.
- Based on the above definition,
- Sar and beta-Ala are neutral/nonpolar/small;
- t-butyl-Ala, t-butyl-Gly, N-Melle, Nle and Cha are neutral/nonpolar/large/nonaromatic;
- Har and Orn are basic/noncyclic;
- Cya is acidic;
- Cit, Acetyl-Lys, and MSO are neutral/polar/large/nonaromatic; and
- Phg is neutral/nonpolar/large/aromatic.
- The various omega-amino acids are classified according to size as neutral/nonpolar/small (beta-Ala, i.e., 3-aminopropionic, 4-aminobutyric) or large (all others).
- Other amino acid substitutions for those encoded in the genetic code can also be included in peptide compounds within the scope of the invention and can be classified within this general scheme.
- Proteinogenic amino acids are defined as natural protein-derived α-amino acids. Non-proteinogenic amino acids are defined as all other amino acids, which are not building blocks of common natural proteins.
- The resulting peptides may be synthesized as the free C-terminal acid or as the C-terminal amide form. The free acid peptides or the amides may be varied by side chain modifications. Such side chain modifications include for instance, but not restricted to, homoserine formation, pyroglutamic acid formation, disulphide bond formation, deamidation of asparagine or glutamine residues, methylation, t-butylation, t-butyloxycarbonylation, 4-methylbenzylation, thioanysilation, thiocresylation, bencyloxymethylation, 4-nitrophenylation, bencyloxycarbonylation, 2-nitrobencoylation, 2-nitrosulphenylation, 4-toluenesulphonylation, pentafluorophenylation, diphenylmethylation, 2-chlorobenzyloxycarbonylation, 2,4,5-trichlorophenylation, 2-bromobenzyloxycarbonylation, 9-fluorenylmethyloxycarbonylation, triphenylmethylation, 2,2,5,7,8,-pentamethylchroman-6-sulphonylation, hydroxylation, oxidation of methionine, formylation, acetylation, anisylation, bencylation, bencoylation, trifluoroacetylation, carboxylation of aspartic acid or glutamic acid, phosphorylation, sulphation, cysteinylation, glycolysation with pentoses, deoxyhexoses, hexosamines, hexoses or N-acetylhexosamines, farnesylation, myristolysation, biotinylation, palmitoylation, stearoylation, geranylgeranylation, glutathionylation, 5′-adenosylation, ADP-ribosylation, modification with N-glycolylneuraminic acid, N-acetylneuraminic acid, pyridoxal phosphate, lipoic acid, 4′-phosphopantetheine, or N-hydroxysuccinimide.
- In the compounds of formula (3), the amino acid residues comprising A, B, C, D, and E substituents are attached to the adjacent moiety according to standard nomenclature so that the amino-terminus (N-terminus) of the amino acids is drawn on the left and the carboxyl-terminus of the amino acid is drawn to the right.
- Until the present invention by Applicants, known peptide substrates of the proline-specific serine protease dipeptidyl peptidase IV in vitro are the tripeptides Diprotin A (lle-Pro-lle), Diprotin B (Val-Pro-Leu) and Diprotin C (Val-Pro-lle). Applicants have unexpectedly discovered that the compounds disclosed here act as substrates of dipeptidyl peptidase IV in vivo in a mammal and, in pharmacological doses, inhibit the physiological turnover of endogenous substrates by competitive catalysis.
- Particularly preferred compounds of the present invention that could be useful as modulators of dipeptidyl peptidase IV and DPIV—like enzymes include those compounds which show Ki-values for DPIV-binding, effectively in DPIV-inhibition in vivo after i.v. and/or p.o. administration to Wistar rats
-
- wherein
-
- X1 is H or a acyl or oxycarbonyl group incl. all amino acids and peptide residues,
- X2 is H, —(CH)n—NH—C5H3N—Y with n=2-4 or C5H3N—Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO2 or CN,
- X3 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue,
- X4 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue,
- X5 is H or an alkyl, alkoxy or phenyl residue,
- X6 is H or a alkyl residue.
- for n=1
- X is selected from: H, OR2, SR2, NR2R3, N+R2R3R4, wherein:
- R2 stands for acyl residues, which are substituted with alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are substituted with alkyl, cycloalkyl, aryl and heteroaryl residues,
- R3 stands for alkyl and acyl functions, wherein R2 and R3 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures,
- R4 stands for alkyl residues, wherein R2 and R4 or R3 and R4 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures.
- for n=0
-
- wherein
- B stands for: O, S, NR5, wherein R5 is H, a alkyl or acyl, C, D, E, F, G, H are independently selected from alkyl and substituted alkyl residues, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
- Z is selected from H, or a branched or single chain alkyl residue from C1-C9 or a branched or single chain alkenyl residue from C2-C9, a cycloalkyl residue from C3-C8, a cycloalkenyl residue from C5-C7, a aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
-
- wherein:
- R1 is H, a branched or linear C1-C9 alkyl residue, a branched or linear C2-C9 alkyl residue, a C3-C8 cycloalkyl-, C5-C7 cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof,
- R3 and R4 are selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen.
- A is H or an isoster of an carbonic acid, like a functional group selected from CN, SO3H, CONHOH, PO3R5R6, tetrazole, amide, ester, anhydride, thiazole and imidazole,
-
- wherein
- R5 is H, —(CH)n—NH—C5H3N—Y with n=2-4 and C5H3N—Y (a divalent pyridyl residue) with Y=H, Br, Cl, I, NO2 CN,
- R10 is H, a acyl, oxycarbonyl or a amino acid residue,
- W is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue,
- W1 is H, a alkyl, alkoxy or phenyl residue,
- Z is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue,
- Z1 is H or a alkyl residue,
- D is a cyclic C4-C7 alkyl, C4-C7 alkenyl residue or a alkyl substituted derivative thereof or a cyclic 4-7-membered heteroalkyl or 4-7-membered heteroalkenyl residue,
- X2 is O, NR6, N+(R7)2, or S,
- X3 to X12 are selected from CH2, CR8R9, NR6, N+(R7)2, O, S, SO and SO2, including all saturated and unsaturated structures,
- R6, R7, R8, R9 are selected from H, a branched or linear C1-C9 alkyl residue, a branched or lienar C2-C9 alkenyl residue, a C3-C8 cycloalkyl residue, a C5-C7 cycloalkenyl residue, an aryl or heteroaryl residue,
- with the following provisions:
- Formula 6: X6 is CH if A is not H,
- Formula 7: X10 is C if A is not H,
- Formula 8: X7 is CH if A is not H,
- Formula 9: X12 is C if A is not H.
- Because of the wide distribution of the protein in the body and the wide variety of mechanisms involving DPIV, DPIV-activity and DPIV-related proteins, systemic therapy (enteral or parenteral administration) with DPIV-inhibitors can result in a series of undesirable side-effects.
- It has been possible to show that side chain-modified substrates of the enzyme dipeptidyl peptidase IV can be recognised by the enzyme and cleaved in the same way as unmodified substrates (DEMUTH, H.-U., HEINS, J., 1995).
- For example, it has been possible to show that phosphorylated dipeptide-(B)-p-nitroanilides [KASPARI, A., et al., 1996] are substrates of DPIV. DPIV-inhibitors such as, for example, Glu(Gly)-Thia or Lys(Z-NO2)-Thia [REINHOLD, D., et al., 1998] are transported completely.
- The problem to be solved consisted in preparing compounds that can be used for targeted influencing of locally limited pathophysiological and physiological processes. The problem of the invention especially consists in obtaining locally limited inhibition of DPIV or DPIV-analogous activity for the purpose of targeted intervention in the regulation of the activity of locally active substrates.
-
- wherein
- A is an amino acid having at least one functional group in the side chain,
- B is a chemical compound covalently bound to at least one functional group of the side chain of A, namely
- oligopeptides having a chain length of up to 20 amino acids, except for homopolymers of glycine consisting of up to 6 glycine monomers, or
- polyethylene glycols having molar masses of up to 20 000 g/mol, and
- C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A.
-
- wherein
- A is an amino acid, preferably an α-amino acid, especially a natural α-amino acid having at least one functional group in the side chain, preferably threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine,
- B is a chemical compound covalently bound to at least one functional group in the side chain of A, namely oligopeptides having a chain length of up to 20 amino acids, polyethylene glycols having molar masses of up to 20 000 g/mol, optionally substituted organic amines, amides, alcohols, acids or aromatic compounds having from 8 to 50 C atoms,
- C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A,
- and at least one customary adjuvant appropriate for the site of action.
- Throughout the description and the claims for the compounds of formula (12), the expression “alkyl” can denote a C1-50 alkyl group, preferably a C6-30 alkyl group, especially a C8-12 alkyl group; for example, an alkyl group may be a methyl, ethyl, propyl, isopropyl or butyl group. The expression “alk”, for example in the expression “alkoxy”, and the expression “alkan”, for example in the expression “alkanoyl”, are defined as for “alkyl”; aromatic compounds are preferably substituted or optionally unsubstituted phenyl, benzyl, naphthyl, biphenyl or anthracene groups, which preferably have at least 8 C atoms; the expression “alkenyl” can denote a C2-10 alkenyl group, preferably a C2-6 alkenyl group, which has the double bond(s) at any desired location and may be substituted or unsubstituted; the expression “alkynyl” can denote a C2-10 alkynyl group, preferably a C2-6 alkynyl group, which has the triple bond(s) at any desired location and may be substituted or unsubstituted; the expression “substituted” or substituent can denote any desired substitution by one or more, preferably one or two, alkyl, alkenyl, alkynyl, mono- or multi-valent acyl, alkanoyl, alkoxyalkanoyl or alkoxyalkyl groups; the afore-mentioned substituents may in turn have one or more (but preferably zero) alkyl, alkenyl, alkynyl, mono- or multi-valent acyl, alkanoyl, alkoxyalkanoyl or alkoxyalkyl groups as side groups; organic amines, amides, alcohols or acids, each having from 8 to 50 C atoms, preferably from 10 to 20 C atoms, can have the formulae (alkyl)2N— or alkyl-NH—, —CO—N(alkyl)2 or —CO—NH(alkyl), -alkyl-OH or -alkyl-COOH.
- Despite an extended side chain function, the compounds of formula (12) can still bind to the active centre of the enzyme dipeptidyl peptidase IV and analogous enzymes but are no longer actively transported by the peptide transporter PepT1. The resulting reduced or greatly restricted transportability of the compounds according to the invention leads, in ideal manner, to local or site directed inhibition of DPIV and DPIV-like enzyme activity.
- The compounds of formula (12) or compounds used in accordance with the invention can be present or used, respectively, in the form of racemates or in the form of enantiomerically pure compounds, preferably in the L-threo or L-allo form with respect to part A of formula (12).
- By extending/expanding the side chain modifications, for example beyond a number of seven carbon atoms, it is accordingly possible to obtain a dramatic reduction in transportability (see Example 12). The Examples in Table 12.1 clearly show that, with increasing spatial size of the side chains, there is a reduction in the transportability of the substances. By spatially and sterically expanding the side chains, for example beyond the atom group size of a monosubstituted phenyl radical, hydroxylamine radical or amino acid residue, it is possible according to the invention to modify or suppress the transportability of the target substances.
- According to the present invention, the compounds of formula (12) inhibit DPIV or DPIV-like enzyme activity in the body of a mammal in a site specific manner. It is accordingly possible to influence local physiological and pathophysiological conditions (inflammation, psoriasis, arthritis, autoimmune diseases, allergies) effectively and with dramatically reduced side-effects.
- Preferred compounds of formula (12) are compounds, wherein the oligopeptides have chain lengths of from 3 to 15, especially from 4 to 10, amino acids, and/or the polyethylene glycols have molar masses of at least 250 g/mol, preferably of at least 1500 g/mol and up to 15 000 g/mol, and/or the optionally substituted organic amines, amides, alcohols, acids or aromatic compounds have at least 12 C atoms and preferably up to 30 C atoms.
- The compounds of the present invention can be converted into acid addition salts, especially pharmaceutically acceptable acid addition salts. The pharmaceutically acceptable salt generally takes a form in which an amino acids basic side chain is protonated with an inorganic or organic acid. Representative organic or inorganic acids include hydrochloric, hydrobromic, perchloric, sulfuric, nitric, phosphoric, acetic, propionic, glycolic, lactic, succinic, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroxyethanesulfonic, benzenesulfonic, oxalic, pamoic, 2-naphthalenesulfonic, p-toulenesulfonic, cyclohexanesulfamic, salicylic, saccharinic or trifluoroacetic acid. All pharmaceutically acceptable acid addition salt forms of the compounds of formulas (1) to (12) are intended to be embraced by the scope of this invention.
- In view of the close relationship between the free compounds and the compounds in the form of their salts, whenever a compound is referred to in this context, a corresponding salt is also intended, provided such is possible or appropriate under the circumstances.
- The present invention further includes within its scope prodrugs of the compounds of this invention. In general, such prodrugs will be functional derivatives of the compounds which are readily convertible in vivo into the desired therapeutically active compound. Thus, in these cases, the methods of treatment of the present invention, the term “administering” shall encompass the treatment of the various disorders described with prodrug versions of one or more of the claimed compounds, but which converts to the above specified compound in vivo after administration to the subject. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in “Design of Prodrugs”, ed. H. Bundgaard, Elsevier, 1985 and the patent applications DE 198 28 113 and DE 198 28 114, which are fully incorporated herein by reference.
- Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms of the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e. hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention.
- The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
- As indicated above, the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, are useful in inhibiting DPIV and DPIV-like enzyme activity. The ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV and DPIV-like enzyme activity may be demonstrated employing the DPIV activity assay for determination of the Ki-values and the IC50-values in vitro, as described in examples 7 and 8.
- The ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV in vivo may be demonstrated by oral or intravasal administration to Wistar rats, as described in example 11. The compounds of the present invention inhibit DPIV activity in vivo after both, oral and intravasal administration to Wistar rats.
- DPIV is present in a wide variety of mammalian organs and tissues e.g. the intestinal brush-border (Gutschmidt S. et al., “In situ” —measurements of protein contents in the brush border region along rat jejunal villi and their correlations with four enzyme activities. Histochemistry 1981, 72 (3), 467-79), exocrine epithelia, hepatocytes, renal tubuli, endothelia, myofibroblasts (Feller A. C. et al., A monoclonal antibody detecting dipeptidylpeptidase IV in human tissue. Virchows Arch. A. Pathol. Anat. Histopathol. 1986; 409 (2):263-73), nerve cells, lateral membranes of certain surface epithelia, e.g. Fallopian tube, uterus and vesicular gland, in the luminal cytoplasm of e.g., vesicular gland epithelium, and in mucous cells of Brunner's gland (Hartel S. et al., Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988; 89 (2): 151-61), reproductive organs, e.g. cauda epididymis and ampulla, seminal vesicles and their secretions (Agrawal & Vanha-Perttula, Dipeptidyl peptidases in bovine reproductive organs and secretions. Int. J. Androl. 1986, 9 (6): 435-52). In human serum, two molecular forms of dipeptidyl peptidase are present (Krepela E. et al., Demonstration of two molecular forms of dipeptidyl peptidase IV in normal human serum. Physiol. Bohemoslov. 1983, 32 (6): 486-96). The serum high molecular weight form of DPIV is expressed on the surface of activated T cells (Duke-Cohan J. S. et al., Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. J. Immunol. 1996,156 (5): 1714-21).
- The compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms are able to inhibit DPIV in vivo., In one embodiment of the present invention, all molecular forms, homologues and epitopes of DPIV from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
- Among the rare group of proline-specific proteases, DPIV was originally believed to be the only membrane-bound enzyme specific for proline as the penultimate residue at the amino-terminus of the polypeptide chain. However, other molecules, even structurally non-homologous with the DPIV but bearing corresponding enzyme activity, have been identified recently. DPIV-like enzymes, which are identified so far, are e.g. fibroblast activation protein α, dipeptidyl peptidase IV β, dipeptidyl aminopeptidase-like protein, N-acetylated α-linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin and dipeptidyl peptidase IV related protein (DPP 8), and are described in the review article by Sedo & Malik (Sedo & Malik, Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities? Biochimica et Biophysica Acta 2001, 36506: 1-10). Further DPIV like enzymes are disclosed in WO 01/19866, WO 02/04610 and WO 02/34900. WO 01/19866 discloses novel human dipeptidyl aminopeptidase (DPP8) with structural and functional similarities to DPIV and fibroblast activation protein (FAP). The dipeptidyl peptidase IV-like enzyme of WO 02/04610 is well known in the art. In the Gene Bank data base, this enzyme is registered as KIAA1492. In another preferred embodiment of the present invention, all molecular forms, homologues and epitopes of proteins comprising DPIV-like enzyme activity, from all mammalian tissues and organs, also of those, which are undiscovered yet, are intended to be embraced by the scope of this invention.
- The ability of the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms to inhibit DPIV-Like enzymes may be demonstrated employing an enzyme activity assay for determination of the Ki-values in vitro as described in example 9. The Ki-values of the compounds of the present invention against porcine dipeptidyl peptidase II were exemplary determined as Ki=8.52*10−5 M±6.33*10−6 M for glutaminyl pyrrolidine and Ki=1.07*10−5 M±3.81*10−7 M for glutaminyl thiazolidine.
- In another embodiment, the compounds of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms have only low, if no inhibitory activity against non-DPIV and non-DPIV-like proline specific enzymes. As described in example 10, with glutaminyl thiazolidine and glutaminyl pyrrolidine exemplarily, no inhibition of dipeptidyl peptidase I and prolyl oligopeptidase was found. Against prolidase, both compounds explained a marked lower efficacy compared to DPIV. The IC 50-values against prolidase were determined as
IC 50>3 mM for glutaminyl thiazolidine and asIC 50=3.4*10−4M±5.63*10−5 for glutaminyl pyrrolidine. - The present invention provides a method of treating a condition mediated by modulation of the DPIV or DPIV-like enzyme activity in a subject in need thereof which comprises administering any of the compounds of the present invention or pharmaceutical compositions thereof in a quantity and dosing regimen therapeutically effective to treat the condition. Additionally, the present invention includes the use of the compounds of this invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for the preparation of a medicament for the treatment of a condition mediated by modulation of the DPIV activity in a subject. The compound may be administered to a patient by any conventional route of administration, including, but not limited to, intravenous, oral, subcutaneous, intramuscular, intradermal and parenteral.
- In a further illustrative embodiment, the present invention provides formulations for the compounds of
formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms, in pharmaceutical compositions. - The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, who has been the object of treatment, observation or experiment.
- The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human, being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
- As used herein, the term “composition” is intended to encompass a product comprising the claimed compounds in the therapeutically effective amounts, as well as any product which results, directly or indirectly, from combinations of the claimed compounds.
- To prepare the pharmaceutical compositions of this invention, one or more compounds of
formulas 1 to 12, and their corresponding pharmaceutically acceptable acid addition salt forms, as the active ingredient, is intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending of the form of preparation desired for administration, e.g., oral or parenteral such as intramuscular. In preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed. Thus, for liquid oral preparations, such as for example, suspensions, elixirs and solutions, suitable carriers and additives may advantageously include water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like; for solid oral preparations such as, for example, powders, capsules, gelcaps and tablets, suitable carriers and additives include starches, sugars, diluents, granulating agents, lubricants, binders, disintegrating agents and the like. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desired, tablets may be sugar coated or enteric coated by standard techniques. For parenterals the carrier will usually comprise sterile water, through other ingredients, for example, for purposes such as aiding solubility or for preservation, may be included. - Injectable suspensions may also prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. The pharmaceutical compositions herein will contain, per dosage unit, e.g., tablet, capsule, powder, injection, teaspoonful and the like, an amount of the active ingredient necessary to deliver an effective dose as described above. The pharmaceutical compositions herein will contain, per unit a dosage unit, e.g., tablet, capsule, powder, injection, suppository, teaspoonful and the like, of from about 0.03 mg to 100 mg/kg (preferably 0.1-30 mg/kg) and may be given at a dosage of from about 0.1-300 mg/kg per day (preferably 1-50 mg/kg per day). The dosages, however, may be varied depending upon the requirement of the patients, the severity of the condition being treated and the compound being employed. The use of either daily administration or post-periodic dosing may be employed. Typically the dosage will be regulated by the physician based on the characteristics of the patient, his/her condition and the therapeutic effect desired.
- Preferably these compositions are in unit dosage forms from such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, autoinjector devices or suppositories; for oral parenteral, intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. Alternatively, the composition may be presented in a form suitable for once-weekly or once-monthly administration; for example, an insoluble salt of the active compound, such as the decanoate salt, may be adapted to provide a depot preparation for intramuscular injection. For preparing solid compositions such as tablets, the principal active ingredient is ideally mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is ideally dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective dosage forms such as tablets, pills and capsules. This solid preformulation composition may then be subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention.
- The tablets or pills of the novel composition can be advantageously coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
- This liquid forms in which the novel compositions of the present invention may be advantageously incorporated for administration orally or by injection include, aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
- Where the processes for the preparation of the compounds according to the invention give rise to mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. The compounds may, for example, be resolved into their components enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (−)-di-p-toluoyl-d-tartaric acid and/or (+)-di-p-toluoyl-l-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
- During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described inProtective Groups in Organic Chemistry, ed. J. F. W. McOmie, Plenum Press, 1973; and T. W. Greene & P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, fully incorporated herein by reference. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
- The method of treating conditions modulated by dipeptidyl peptidase IV and DPIV—like enzymes described in the present invention may also be carried out using a pharmaceutical composition comprising any of the compounds as defined herein and a pharmaceutically acceptable carrier. The pharmaceutical composition may contain between about 0.01 mg and 1000 mg, preferably about 5 to 500 mg, of the compound, and may be constituted into any form suitable for the mode of administration selected. Carriers include necessary and inert pharmaceutical excipients, including, but not limited to, binders, suspending agents, lubricants, flavorants, sweeteners, preservatives, dyes, and coatings. Compositions suitable for oral administration include solid forms, such as pills, tablets, caplets, capsules (each including immediate release, timed release and sustained release formulations), granules, and powders, and liquid forms, such as solutions, syrups, elixirs, emulsions, and suspensions. Forms useful for parenteral administration include sterile solutions, emulsions and suspensions.
- Advantageously, compounds of the present invention may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily. Furthermore, compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal skin patches well known to those of ordinary skill in that art. To be administered in the form of transdermal delivery system, the dosage administration will, of course, be continuous rather than intermittent throughout the dosage regimen and dosage strength will need to be accordingly modified to obtain the desired therapeutic effects.
- More preferably, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Moreover, when desired or necessary, suitable binders; lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include, without limitation, starch, gelatin, natural sugars such as glucose or betalactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and other compounds known within the art.
- The liquid forms are suitable in flavored suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methyl-cellulose and the like. For parenteral administration, sterile suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservatives are employed when intravenous administration is desired.
- The compound of the present invention can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles, and multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines using processes well described in the art.
- Compounds of the present invention may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamidephenol, polyhydroxyethylaspartamidephenol, or polyethyl eneoxidepolyllysine substituted with palmitoyl residue. Furthermore, compounds of the present invention may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polyactic acid, polyepsilon caprolactone, polyhydroxy butyeric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.
- Compounds of this invention may be administered in any of the foregoing compositions and according to dosage regimens established in the art whenever treatment of the addressed disorders is required.
- The daily dosage of the products may be varied over a wide range from 0.01 to 1.000 mg per adult human per day. For oral administration, the compositions are preferably provided in the form of tablets containing, 0.01, 0.05, 0.1, 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, 50.0, 100, 150, 200, 250 and 500 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.1 mg/kg to about 300 mg/kg of body weight per day. Preferably, the range is from about 1 to about 50 mg/kg of body weight per day. The compounds may be administered on a regimen of 1 to 4 times per day.
- Optimal dosages to be administered may be readily determined by those skilled in the art, and will vary with the particular compound used, the mode of administration, the strength of the preparation, bioavailability due to the mode of administration, and the advancement of disease condition. In addition, factors associated with the particular patient being treated, including patient age, weight, diet and time of administration, should generally be considered in adjusting dosages.
- Synthesis of dipeptide compounds
- 1.1 General synthesis of isoleucyl thiazolidine salt
- The Boc-protected amino acid BOC-lle-OH is placed in ethyl acetate and the batch is cooled to about −520 C. N-Methylmorpholine is added dropwise, pivalic acid chloride (on a laboratory scale) or neohexanoyl chloride (on a pilot-plant scale) is added dropwise at constant temperature. The reaction is stirred for a few minutes for activation. N-Methylmorpholine (laboratory scale) and thiazolidine hydrochloride (laboratory scale) are added dropwise in succession, thiazolidine (pilot-plant scale) is added. Working-up in the laboratory is effected in conventional manner using salt solutions, on a pilot-plant scale the batch is purified with NaOH and CH3COOH solutions.
- The removal of the BOC protecting group is carried out using HCl/dioxane (laboratory scale) or H2SO4 (pilot-plant scale). In the laboratory the hydrochloride is crystallised from EtOH/ether.
- On a pilot-plant scale the free amine is prepared by the addition of NaOH/NH3. Fumaric acid is dissolved in hot ethanol, the free amine is added dropwise, and (lle-Thia)2 furmarate (M=520.71 gmol−1) precipitates. The analysis of isomers and enantiomers is carried out by electrophoresis.
- 1.2 Synthesis of glutaminyl pyrrolidine free base
- Acylation:
- N-Benzyl-oxycarbonylglutamine (2.02 g, 7.21 mmol) was dissolved in 35 ml THF and brought to −15° C. Into that mixture CAIBE (isobutylchloroformiate) (0.937 ml, 7.21 mmol) and 4-methylmorpholine (0.795 ml, 7.21 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCl3/MeOH: 9/1). After warming to −10° C. pyrrolidine (0.596 ml, 7.21 mmol) was added. The mixture was brought to room temperature and stirred overnight.
- Workup:
- The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in ethylacetate (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCl3/MeOH: 9/1)
- Yield: 1.18 g, waxy solid
- Cleavage:
- 1.18 g of the resulting solid Z-protected compound was dissolved in 40 ml absolute ethanol. Into the solution ca. 20 mg Pd on charcoal (10%, FLUKA) was added and the suspension was shaken under a hydrogen atmosphere for 3h. The progress of the reaction was monitored by TLC (eluent: CHCl3/MeOH: 9/1). After completion of the reaction the was removed to provide the free base.
- Yield: 99%
- The purity was checked by means of TLC: n-butanole/AcOH/water/ethylacetate: 1/1/1/1, Rf=0.4. The identity of the reaction product was checked by NMR analysis.
- 1.3 Synthesis of glutaminyl thiazolidine hydrochloride
- Acylation:
- N-t-Butyl-oxycarbonylglutamine (2.0 g, 8.12 mmol) was dissolved in, 5 ml THF and brought to −15° C. Into that mixture CAIBE (isobutylchloroformiate) (1,06 ml, 8.12 mmol) and 4-methylmorpholine (0.895 ml, 8.12 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCl3/MeOH: 9/1). After warming to −10° C. another equivalent 4-methylmorpholine (0.895 ml, 8.12 mmol) and thiazolidinehydrochloride (1.02 g, 8.12 mmol was added. The mixture was brought to room temperature and stirred overnight.
- Workup:
- The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in chloroform (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCl3/MeOH: 9/1)
- Yield: 1.64 g, solid
- Cleavage:
- 640 mg of the resulting solid Boc-protected compound was dissolved in 3.1 ml ice cold HCl in dioxane (12.98 M, 20 equivalents) and left on ice. The progress of the reaction was monitored by TLC (eluent: CHCl3/MeOH: 9/1). After completion of the reaction the solvent was removed and the resulting oil was taken up in methanole and evaporated again. After that the resulting oil was dried over phosphorous-V-oxide and triturated two times with diethylether. The purity was checked by HPLC.
- Yield: 0.265 g
- The purity was checked by HPLC. The identity of the reaction product was checked by NMR analysis.
- 1.4 Synthesis of glutaminyl pyrrolidine hydrochloride
- Acylation:
- N-t-Butyl-oxycarbonylglutamine (3.0 g, 12.18 mmol) was dissolved in 7 ml THF and brought to -15° C. Into that mixture CAIBE (isobutylchloroformiate) (1,6 ml, 12.18 mmol) and 4-methylmorpholine (1.3 ml, 12.18 mmol) where added and the solution was stirred for 15 min. The formation of the mixed anhydride was checked by TLC (eluent: CHCl3/MeOH: 9/1). After warming to −10° C. 1 equivalent of pyrrolidine (1.0 ml, 12.18 mmol) was added. The mixture was brought to room temperature and stirred overnight.
- Workup:
- The sediment formed was filtered off and the solvent was evaporated. The resulting oil was taken up in chloroform (20 ml) and washed with a saturated solution of sodiumhydrogensulfate followed by a saturated solution of sodiumbicarbonate, water and brine. The organic layer was separated, dried and evaporated. The resulting product was checked for purity by TLC (eluent: CHCl3/MeOH: 9/1)
- Yield: 2.7 g solid
- Cleavage:
- 2.7g of the resulting solid was dissolved in 13.0 ml ice cold HCl in dioxane (12.98 M, 20 equivalents) and left on ice. The progress of the reaction was monitored by TLC (eluent: CHCl3/MeOH: 9/1). After completion of the reaction the solvent was removed and the resulting oil was taken up in methanole and evaporated again. After that the resulting oil was dried over phosphorous-V-oxide and triturated two times with diethylether.
- Yield: 980 mg
- The purity was checked by HPLC. The identity of the reaction product was, checked by NMR analysis.
- Chemical characterization of selected dipeptide compounds
- 2.1 Melting Point Determination
- Melting points were determined on a Kofler heating platform microscope from Leica Aktiengesellschaft, the values are not corrected, or on a DSC apparatus (Heumann-Pharma).
- 2.2 Optical Rotation
- The rotation values were recorded at different wavelengths on a “Polarimeter 341” or higher, from the Perkin-Elmer company.
- 2.3 Measurement Conditions for the Mass Spectroscopy
- The mass spectra were recorded by means of electrospray ionisation (ESI) on an “API 165” or API 365” from the PE Sciex company. The operation is carried out using an approximate concentration of c=10 μg/ml, the substance is taken up in MeOH/H2O 50:50, 0.1% HCO2H, the infusion is effected using a spray pump (20 μl/min). The measurement were made in positive mode [M+H]+, the ESI voltage is U=5600V.
-
- 2.4.1 Tests on isoleucyl thiazolidine fumarate (isomer)
Substance Mp (° C.) CE (min) MS [α]H2O L-threo-IT*F 150DSC 160 203 −10.7 (405 nm) D-threo-IT*F 147 158 203 not determined L-allo-IT*F 145-6 154 203 −4.58 (380 nm) D-allo-IT*F 144-6 150 203 4.5 (380 nm) - 2.4.2 Tests on other isoleucyl thiazolidine salts
IT*salt M (gmol−1) MP (° C.) succinate 522.73 116 tartrate 352.41 122 fumarate 520.71 156 hydrochloride 238.77 169 phosphate 300.32 105 - Synthesis of Xaa-Pro-Yaa tripeptides
- All syntheses were carried out on a peptide synthesizer SP 650 (Labortec AG) applying Fmoc/tBu-strategy. Protected amino acids were purchased from Novabiochem or Bachem. trifluoro acetic acid (TFA) was purchased from Merck, triisopropyl silane (TIS) was purchased from Fluka.
- Pre-loaded Fmoc-Yaa-Wang resin (2.8 g/substitution level 0.57 mmol/g) was deprotected using 20% piperidine/N,N-dimethylformamide (DMF). After washing with DMF a solution of 2 eq (1.1 g) of Fmoc-Pro-OH were solved in DMF (12 ml solvent per gram resin). 2eq (1.04 g) of 2-(1H-Benzotriazole 1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) and 4 eq (1.11 ml) of N,N-diisopropylethylamine (DIEA) were added and placed in the reaction vessel. The mixture was shaken at room temperature for 20 minutes. Then the coupling cycle was repeated. After subsequent washing with DMF, dichlormethane, isopropanol and diethyl ether the resulting Fmoc-Pro-lle-Wang resin was dried and then divided into 6 parts before coupling the last amino acid derivative.
- Fmoc protecting group was removed as described above. After that 0.54 mmol of the Boc-amino acid, 0.54 mmol TBTU and 0.108 mmol DIEA in DMF were shaken for 20 min. The coupling cycle was repeated. Finally the peptide resin was washed and dried described above.
- The peptide was cleaved from the resin using a mixture of trifluoroacetic acid (TFA) for 2.5 h, containing the following scavengers: TFA/H2O/triisipropylsilane (TIS)=9.5/0.25/0.25
- The yields of crude peptides were 80-90% on the average. The crude peptide was purified by HPLC on a Nucleosil C18 column (7 μm, 250*21.20 mm, 100 A) using a linear gradient of 0.1% TFA/H2O with increasing concentration of 0.1% TFA/acetonitrile (from 5% to 65% in 40 min) at 6 ml/min.
- The pure peptide was obtained by lyophilization, identified by Electrospray mass spectrometry and HPLC analysis. 3.1 Results—Identification of Xaa-Pro-Yaa tripeptides after chemical synthesis
Mass (exp.)1 Peptide Mass (calc.) [M + H+] HPLC k‘2 Abu-Pro-Ile 313.4 314.0 5.7 Cha-Pro-Ile 381.52 382.0 10.4 Nva-Pro-Ile 327.43 328.2 6.82 Phg-Pro-Ile 361.44 362.2 7.9 Nle-Pro-Ile 341.45 342.2 8.09 Pip-Pro-Ile 338.56 340.0 6.5 Thr-Pro-Ile 329.4 330.0 5.12 Trp-Pro-Ile 414.51 415.2 9.85 Phe-Pro-Ile 375.47 376.2 8.96 Ser-Pro-Ile 315.37 316.3 5.24 Ser(P)-Pro-Ile 395.37 396.0 3.35 Tyr(P)-Pro-Ile 471.47 472.3 5.14 Val-Pro-Val 313.4 314.0 5.07 Ile-Pro-Val 327.43 328.5 6.41 Ile-Pro-allo-Ile 341.4 342.0 7.72 Val-Pro-allo-Ile 327.4 328.5 6.51 Tyr-Pro-allo-Ile 391.5 392.0 7.02 2-Amino octanoic acid- 369.5 370.2 10.63 Pro-Ile Ser (Bzl)-Pro-Ile 405.49 406.0 9.87 Orn-Pro-Ile 342.42 343.1 3.73 Tic-Pro-Ile 387.46 388.0 8.57 Aze-Pro-Ile 311.4 312.4 5.29 Aib-Pro-Ile 313.4 314.0 5.25 t-butyl-Gly-Pro-Ile 341.47 342.1 7.16 Ile-Hyp-Ile 356.45 358.2 6.57 t-butyl-Gly-Pro-Val 327.4 328.4 6.32 t-butyl-Gly-Pro-Gly 285.4 286.3 3.74 t-butyl-Gly-Pro-Ile-amide 340.47 341.3 7.8 t-butyl Gly-Pro-D-Val 327.4 328.6 7.27 t-butyl-Gly-Pro-t-butyl-Gly 341.24 342.5 9.09 Ile-Pro-t-butyl-Gly 341.47 342.36 6.93 Val-Pro-t-butyl-Gly 327.4 328.15 5.98 - t0=1.16 min
-
- Ser(Bzl) and Ser(P) are defined as benzylserine and phosphorylserine, respectively. Tyr(P) is defined as phosphoryltyrosine.
-
- H-Val-Pro-OMe*
HCl 2 - Boc-Val-OH (3.00 g, 13.8 mmol) was dissolved in 10 ml of dry THF and cooled down to −15° C. To the mixture CAIBE (1.80 ml, 13.8 mmol) and NMM (1.52 ml, 13.8 mmol) where added and the solution was stirred until the formation of the mixed anhydride was complete. Then the mixture was brought to −10° C. and NMM (1.52 ml, 13.8 mmol) was added followed by H-Pro-OMe*HCl (2.29 g, 13.8 mmol). The mixture was allowed to reach room temperature and left overnight. After removing the solvent and the usual workup the resulting
ester 1 was taken without further characterisation. Theester 1 was dissolved in HCl/HOAc (5 ml, 6N) and left at 0° C. until the removal of the Boc-group was complete. The solvent was then removed and the resulting oil was treated with diethylether to give a white solid 2. - Yield: 2.5 g, 80%
- Z-Ala-Val-
Pro-OMe 3 - Z-Ala OH (3.5 g, 15.7 mmol) and 2 (4.18 g, 15.7 mmol) where treated in the same manner as above for 1, to give 3 as a white solid.
- Yield: 4.2 g, 64%
- Z-Ala-Val-
Pro-OH 4 -
- Yield: 3.5 g, 87%
- Z-Ala-Val-Pro-CH2-
Br 5 -
- Yield (crude): 1.8 g , 80%
- Z-protected acyloxymethylene ketones
- The acid (2eq) was dissolved in DMF and an equimolar amount of KF was added. The suspension was allowed to stir at room temperature for 1 hour. Then the brommethylene (1eq) component was added and the solution was allowed to stir overnight. After that the solvent was removed under vacuum and the resulting oil was dissolved in chloroform and washed with brine. Then the organic layer was separated dried (Na2SO4) and the solvent was removed. The product was purified by column chromatography using silica gel and heptane/chloroform.
- Z-Ala-Val-Pro-CH2O—C(O)—
CH 3 6 - Acetic acid (230 μl, 4.02 mmol), KF (0.234 g, 4.02 mmol), 5 (1.00 g, 2.01 mmol)
- Yield: 0.351 g, 36%
- Z-Ala-Val-Pro-CH2O—C(O)—
Ph 7 - Benzoic acid (0.275 g, 2.25 mmol), KF (0.131 mg, 2.25 mmol), 5 (0.56 g. 1.13 mmol)
- Yield: 0.34 g, 56%
- Deprotection
- The Z-protected compound was dissolved in HBr/AcOH and stirred. When the reaction was complete ether was added, the white precipitate formed was filtered off and dried.
- H-Ala-Val-Pro-CH2O—C(O)CH3*
HBr 8 - 6 (0.351 g, 0,73 mmol)
- Yield: 0.252 g, 98%
- H-Ala-Val-Pro-CH2O—C(O)Ph*
HBr 9 - 7 (0.34 g, 0.63 mmol)
- Yield: 0,251 g, 99%
-
- Boc-
isoleucinal 2 - Oxalylchloride (714 μl, 8.28 mmol) was dissolved in 10 ml of dry dichlormethane and brought to −78° C. Then DMSO (817 μl, 8.28 mmol) was added dropwise. The solution was stirred for 20 min at −78° C. Then 1 (1.00 g, 4.6 mmol) was added and the mixture was stirred for 20 min. After that TEA (2.58 ml, 18.4 mmol) was added and the mixture was allowed to reach room temperature. The mixture was diluted with hexane/ethylacetate (2/1 v/v) and 10 ml of HCl (10% in water) was added. The organic layer was separated and the aqueous phase was extracted with 20 ml of methylenechloride. All organic layers were collected and washed with brine, followed by water, then dried. The product was purified by column chromatography using silica gel and heptane/chloroform.
- Yield: 0.52 g, 52%
- tert-butyl N-1-[cyclopentyl(hydroxy)methyl]-2-
methylbutylcarbamate 3 - 2 (0.52 g, 2.42 mmol) was dissolved in 10 ml of dry THF and cooled down to 0° C. Then cyclopentylmagnesiumbromide (1.45 ml of a 2 M solution) was added. After completion of the reaction (2 ml) of water was added and solution was neutralized by adding aqueous HCl. Then methylenechloride was added and the organic layer was separated and dried (Na2SO4). After evaporation the resulting oil was used without further characterisation.
- tert-butyl N-[1-(cyclopentylcarbonyl)-2-methylbutyl]
carbamate 4 - 3 (0.61 g, 2.15 mmol) was treated like 1. Oxalylchloride (333 μl, 3.87 mmol), DMSO (382 μl, 5.37 mmol), TEA (1.2 ml, 8.59 mmol)
- Yield: 0.180 g, 30%
- 1-cyclopentyl-3-methyl-1-oxo-2-
pentanaminium chloride 5 - 4 (0.18 g, 0.63 mmol) was dissolved in 2 ml HCl (7 N in dioxane). After completion of the reaction the solvent was removed and the resulting oil was purified by column chromatography on silical gel using a chloroform/methanol/water gradient. The resulting oil was triturated with ether.
- Yield: 0.060 g, 54%
- Synthesis of Side Chain Modified DPIV-inhibitors
- 6.1 Synthesis of Boc-glutamyl-thiazolidine (Boc-Glu-Thia)
- Reaction of Boc-Glu(OMe)-OH with Thia*HCl according to Method B (see section 6.4 for methods), hydrolysis of Boc-Glu(OMe)-Thia according to Method G
- 6.1.1 Analytical Data for Boc-Glu-Thia
Empirical formula Mr MS [M + H]+ [α]20D Elemental Synthesis TLC: Concen- analysis HPLC method Rf/system tration (calc./ Rt Compound Yield m.p. Solvent found) % [min]/system Boc-Glu- C13H22N2O5S 319.5 −3.1 C:49.04/48.89 13.93/ Thia 318.38 0.52/A1 c = 1 H:6.96/6.82 A2 B + G 0.42/B1 methanol N:8.80/8.59 62% 115-118° C. - 6.2 Side chain-modified Boc-glutamyl thiazolidines
- Boc-Glu-Thia was modified at the γ-carboxylic acid function by introducing radicals of varying size. The radicals were coupled by way of their amino group by forming an amide bond to the γ-carboxylic acid function, with a variety of coupling methods being used depending on the radical. The following amino components were attached to Boc-Glu-Thia using the method stated:
Coupling methods Amino component (see section 3.4) Yields Polyethylene glycol amine (Mr ≈ 8000) C 93% H-Gly-Gly-Gly-OH D + E 49% H-Gly-Gly-Gly-Gly-Gly-OH D + E 86% - In 2 cases, purification of the reaction products differs from the general description of synthesis.
- Boc-Glu(Gly5)-Thia
- The product already precipitates out from the mixture on stirring overnight; it is subsequently filtered off and washed with 0.1N HCl and copious amounts of water and then dried over P4O10 in vacuo.
- Boc-Glu(PEG)-Thia
- In contrast to the general procedure, the starting materials for the synthesis are dissolved in a 500-fold excess of DMF. After the reaction is complete, the DMF is completely removed in vacuo and the residue is dissolved in a large amount of methanol. After ether is poured on, to form an upper layer, the product precipitates out together with the unreacted PEG. Fine purification was carried out by preparative HPLC separation on a gel filtration column (Pharmazia, Sephadex G-25, 90 μm, 260 mm-100 mm).
- Separating conditions: eluant: water; flow rate: 5 ml/min; λ=220 nm
- 6.2.2 Synthesis data for side chain-modified Boc-glutamyl thiazolidines
Empirical MS [M + H]+ Elemental formula TLC/Rf/ [α]20D analysis HPLC Mr system Concentration (calc./ Rt Compound Yield m.p. Solvent found) % [min]/system Boc- C19H31N5O8S 490.5 C:46.62 Glu(Gly3)- 489.54 H:6.38 Thia 49% N:14.31 Boc- C23H37N7O10S 604.5 n.dm. C:45.76/45.60 11.93/A2 Glu(Gly5)- 603.64 0.09/C H:6.18/6.11 Thia 86% decomp. N:16.24/16.56 from 202° C. Boc- 93% ≈8000 n.dm. n.dm. n.dm. Glu(PEG)- (mass Thia emphasis) 52-53° C. - 6.3 Side chain-modified glutamyl thiazolidines
- The N-terminal Boc protecting groups were cleaved off the compounds described in Table 6.2.2 using method F. The substances modified with Gly derivatives were purified by preparative HPLC separation and are present as trifluoroacetates. The H-Glu(PEG)-Thia was purified on a gel filtration column in the same manner as the Boc-protected precursor.
-
Empirical MS [M + H]+ Elemental formula TLC/Rf/ [α]20D analysis HPLC Mr system Concentration (calc./ Rt[min]/ Compound Yield m.p. Solvent found) % system H- C16H24N5O8SF3 503.45 +4.1 C:38.17/37.56 7.84/C3 Glu(Gly3)- 503.45 0.32/C c = 1 H:4.80/4.78 Thia *TFA 94% 91-94° C. methanol N:13.91/13.43 H- C20H30N7O10SF3 617.55 n.dm. C:38.90/38.82 8.22/C3 Glu(Gly5)- 0.25/C H:4.90/4.79 Thia *TFA 617.55 105-107° C. N:15.88/15.39 98% H- 92% ≈8000 n.dm. n.dm. n.dm. Glu(PEG)- (mass Thia *HCl emphasis) - 6.4 General Synthesis Procedures
- Method A: Peptide bond attachment by the mixed anhydride method using CFIBE as activation reagent
- 10 mmol of N-terminally protected amino acid or peptide are dissolved in 20 ml of absolute THF. The solution is cooled to −15° C.±20° C. With stirring in each case, 10 mmol of N-MM and 10 mmol of chloroformic acid isobutyl ester are added in succession, the stated temperature range being strictly adhered to. After approximately 6 min, 10 mmol of the amino component is added. When the amino component is a salt, a further 10 mmol of N-MM is then added to the reaction mixture. The reaction mixture is then stirred for 2 h in the cold state and overnight at room temperature. The reaction mixture is concentrated using a rotary evaporator, taken up in EA, washed with 5% KH2SO4 solution, saturated NaHCO3 solution and saturated NaCl solution and dried over NaSO4. After removal of the solvent in vacuo, the compound is recrystallized from EA/pentane.
- Method B: Peptide bond attachment by the mixed anhydride method using pivalic acid chloride as activation reagent
- 10 mmol of N-terminally protected amino acid or peptide are dissolved in 20 ml of absolute THF. The solution is cooled to 0° C. With stirring in each case, 10 mmol of N-MM and 10 mmol of pivalic acid chloride are added in succession, the stated temperature range being strictly adhered to. After approximately 6 min, the mixture is cooled to −15° C. and, once the lower temperature has been reached, 10 mmol of the amino component is added. When the amino component is a salt, a further 10 mmol of N-MM is then added to the reaction mixture. The reaction mixture is then stirred for 2 h in the cold state and overnight at room temperature.
- Further working up is carried out as in Method A.
- Method C: Peptide bond attachment using TBTU as activation reagent
- 10 mmol of the N-terminally protected amino acid or peptide and 10 mmol of the C-terminally protected amino component are dissolved in 20 ml of absolute DMF. The solution is cooled to 0° C. With stirring in each case, 10 mmol of DIPEA and 10 mmol of TBTU are added in succession. The reaction mixture is stirred for one hour at 0° C. and then overnight at room temperature. The DMF is completely removed in vacuo and the product is worked up as described in Method A.
- Method D: Synthesis of an active ester (N-hydroxysuccinimide ester)
- 10 mmol of N-terminally protected amino acid or peptide and 10 mmol of N-hydroxysuccinimide are dissolved in 20 ml of absolute THF. The solution is cooled to 0° C. and 10 mmol of dicyclohexylcarbodiimide are added, with stirring. The reaction mixture is stirred for a further 2 h at 0° C. and then overnight at room temperature. The resulting N,N′-dicyclohexylurea is filtered off and the solvent is removed in vacuo and the remaining product is recrystallized from EA/pentane.
- Method E: Amide bond attachment using N-hydroxysuccinimide esters
- 10 mmol of the C-terminally unprotected amino component is introduced into an NaHCO3 solution (20 mmol in 20 ml of water). At room temperature and with stirring, 10 mmol of the N-terminally protected N-hydroxysuccinimide ester dissolved in 10 ml of dioxane are slowly added dropwise. Stirring of the reaction mixture is continued overnight and the solvent is then removed in vacuo.
- Further working up is carried out as in Method A.
- Method F: Cleavage of the Boc Protecting Group
- 3 ml of 1.1N HCl/glacial acetic acid (Method F1) or 3 ml of 1.1N HCl/dioxane (Method F2) or 3 ml of 50% TFA in DCM (Method F3) are added to 1 mmol of Boc-protected amino acid pyrrolidide, thiazolidide or peptide. The cleavage at RT is monitored by means of TLC. After the reaction is complete (approximately 2 h), the compound is precipitated in the form of the hydrochloride using absolute diethyl ether and is isolated with suction and dried over P4O10 in vacuo. Using methanol/ether, the product is recrystallized or reprecipitated.
- Method G: Hydrolysis
- 1 mmol of peptide methyl ester is dissolved in 10 ml of acetone and 11 ml of 0.1M NaOH solution and stirred at room temperature. The course of the hydrolysis is monitored by means of TLC. After the reaction is complete, the acetone is removed in vacuo. The remaining aqueous solution is acidified, using concentrated KH2SO4 solution, until a pH of 2-3 is reached. The product is then extracted several times using EA; the combined ethyl acetate fractions are washed with saturated NaCl solution and dried over NaSO4, and the solvent is removed in vacuo. Crystallization from EA/pentane is carried out.
- Ki-determination
- For Ki determination, dipeptidyl peptidase IV from porcine kidney with a specific activity against glycylprolyl-4-nitroaniline of 37.5 U/mg and an enzyme concentration of 1.41 mg/ml in the stock solution was used.
- Assay Mixture:
- 100 μl test compound in a concentration range of 1*10−5M-1*10−8M respectively were admixed with 50 μl glycylprolyl-4-nitroaniline in different concentrations (0.4 mM, 0.2 mM, 0.1 mM, 0,05 mM) and 100 μl HEPES (40 mM, pH7.6; ion strength=0.125). The assay mixture was pre-incubated at 30° C. for 30 min. After pre-incubation, 20 μl DPIV (1:600 diluted) was added and measurement of yellow color development due to 4-nitroaniline release was performed at 30° C. and λ=405 nm for 10 min. using a plate reader (HTS7000 plus, Applied Biosystems, Weiterstadt, Germany).
- The Ki-values were calculated using Graphit version 4.0.13, 4.0.13 and 4.0.15 (Erithacus Software, Ltd, UK). 7.1 Results—Ki Values of DPIV Inhibition
Compound Ki [M] H-Asn-pyrrolidine 1.20 * 10−5 H-Asn-thiazolidine 3.5 * 10−6 H-Asp-pyrrolidine 1.4 * 10−8 H-Asp-thiazolidine 2.9 * 10−6 H-Asp(NHOH)-pyrrolidine 1.3 * 10−5 H-Asp(NHOH)-thiazolidine 8.8 * 10−6 H-Glu-pyrrolidine 2.2 * 10−6 H-Glu-thiazolidine 6.1 * 10−7 H-Glu(NHOH)-pyrrolidine 2.8 * 10−6 H-Glu(NHOH)-thiazolidine 1.7 * 10−6 H-His-pyrrolidine 3.5 * 10−6 H-His-thiazolidine 1.8 * 10−6 H-Pro-pyrrolidine 4.1 * 10−6 H-Pro-thiazolidine 1.2 * 10−6 H-Ile-azididine 3.1 * 10−6 H-Ile-pyrrolidine 2.1 * 10−7 H-L-threo-Ile-thiazolidine 8.0 * 10−8 H-L-allo-Ile-thiazolidine 1.9 * 10−7 D-threo-isoleucyl-thiazolidine-fumarate no inhibition D-allo-isoleucyl-thiazolidine-fumarate no inhibition H-L-threo-Ile-thiazolidine-succinate 5.1 * 10−8 H-L-threo-Ile-thiazolidine-tartrate 8.3 * 10−8 H-L-threo-Ile-thiazolidine-fumarate 8.3 * 10−8 H-L-threo-Ile-thiazolidine-hydrochloride 7.2 * 10−8 H-L-threo-Ile-thiazolidine-phosphate 1.3 * 10−7 H-Val-pyrrolidine 4.8 * 10−7 H-Val-thiazolidine 2.7 * 10−7 Diprotin A 3.45 * 10−6 Diprotin B 2.24 * 10−5 Nva-Pro-Ile 6.17 * 10−6 Cha-Pro-Ile 5.99 * 10−6 Nle-Pro-Ile 9.60 * 10−6 Phe-Pro-Ile 1.47 * 10−5 Val-Pro-Val 4.45 * 10−6 Ile-Pro-Val 5.25 * 10−6 Abu-Pro-Ile 8.75 * 10−6 Ile-Pro-allo-Ile 5.22 * 10−6 Val-Pro-allo-Ile 9.54 * 10−6 Tyr-Pro-allo-Ile 1.82 * 10−5 AOA-Pro-Ile 1.26 * 10−5 t-butyl-Gly-Pro-Ile 3.10 * 10−6 Ser(Bzl)-Pro-Ile 2.16 * 10−5 Aze-Pro-Ile 2.05 * 10−5 t-butyl-Gly-Pro-Val 3.08 * 10−6 Gln-Pyrr 2.26 * 10−6 Gln-Thia 1.21 * 10−6 Val-Pro-t-butyl-Gly 1.96 * 10−5 t-butyl-Gly-Pro-Gly 1.51 * 10−5 Ile-Pro-t-butyl-Gly 1.89 * 10−5 t-butyl-Gly-Pro-IleNH2 5.60 * 10−6 t-butyl-Gly-Pro-D-Val 2.65 * 10−5 t-butyl-Gly-Pro-t-butyl-Gly 1.41 * 10−5 Ile-cyclopentyl ketone 6.29 * 10−6 t-butyl-Gly-cyclohexyl ketone 2.73 * 10−4 Ile-cyclohexyl ketone 5.68 * 10−5 Val-cyclopentyl ketone 1.31 * 10−5 Val-Pro- methyl ketone 4.76 * 10−8 Val-Pro- acyloxy methyl ketone 1.05 * 10−9 Val-Pro- benzoyl methyl ketone 5.36 * 10−10 Val-Pro-benzothiazol methyl ketone 3.73 * 10−8 H-Glu-Thia 6.2 * 10−7 H-Gly(NHOH)-Thia 1.7 * 10−6 H-Glu(Gly3)-Thia 1.92 * 10−8 H-Glu(Gly5)-Thia 9.93 * 10−8 H-Glu(PEG)-Thia 3.11 * 10−6 -
- Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively. Tyr(P) is defined as phosphoryl-tyrosine.
- Determination of IC50-Values
- 100 μl inhibitor stock solution were mixed with 100 μl buffer (HEPES pH7.6) and 50 μl substrate (Gly-Pro-pNA, final concentration 0.4 mM) and preincubated at 30° C. Reaction was started by addition of 20 μl purified porcine DPIV. Formation of the product pNA was measured at 405 nm over 10 min using the HTS 7000Plus plate reader (Perkin Elmer) and slopes were calculated. The final inhibitor concentrations ranged between 1 mM and 30 nM. For calculation of IC50 GraFit 4.0.13 (Erithacus Software) was used.
- 8.1 Results—Determination of IC50 Values
Compound IC50 [M] Ile-thiazolidine fumarate 1.28 * 10−7 Diprotin A 4.69 * 10−6 Diprotin B 5.54 * 10−5 Phg-Pro-Ile 1.54 * 10−4 Nva-Pro-Ile 2.49 * 10−5 Cha-Pro-Ile 2.03 * 10−5 Nle-Pro-Ile 2.19 * 10−5 Ser(P)-Pro-Ile 0.012 Tyr(P)-Pro-Ile 0.002 Phe-Pro-Ile 6.20 * 10−5 Trp-Pro-IIe 3.17 * 10−4 Ser-Pro-Ile 2.81 * 10−4 Thr-Pro-Ile 1.00 * 10−4 Val-Pro-Val 1.64 * 10−5 Ile-Pro-Val 1.52 * 10−5 Abu-Pro-Ile 3.43 * 10−5 Pip-Pro-Ile 0.100 Ile-Pro-allo-Ile 1.54 * 10−5 Val-Pro-allo-Ile 1.80 * 10−5 Tyr-Pro-allo-Ile 6.41 * 10−5 AOA-Pro-Ile 4.21 * 10−5 t-butyl-Gly-Pro-Ile 9.34 * 10−6 Ser(Bz)-Pro-Ile 6.78 * 10−5 Tic-Pro-Ile 0.001 Orn-Pro-Ile 2.16 * 10−4 Gln-Thia 5.27 * 10−6 Aze-Pro-Ile 7.28 * 10−5 Ile-Hyp-Ile 0.006 t-butyl-Gly-Pro-Val 1.38 * 10−5 Gln-Pyrr 1.50 * 10−5 Val-Pro-t-butyl-Gly 6.75 * 10−5 t-butyl-Gly-Pro-Gly 5.63 * 10−5 Ile-Pro-t-butyl-Gly 8.23 * 10−5 t-butyl-Gly-Pro-IleNH2 2.29 * 10−5 t-butyl-Gly-Pro-D-Val 1.12 * 10−4 t-butyl-Gly-Pro-t-butyl-Gly 2.45 * 10−5 Aib-Pro-Ile no inhibition Ile-cyclopentyl ketone 3.82 * 10−5 t-butyl-Gly-cyclohexyl ketone 2.73 * 10−4 Ile-cyclohexyl ketone 2.93 * 10−4 Val-cyclopentyl ketone 4.90 * 10−5 Val-cyclohexyl ketone 0.001 Val-Pro- methyl ketone 5.79 * 10−7 Val-Pro- acyloxy methyl ketone 1.02 * 10−8 Val-Pro- benzoyl methyl ketone 1.79 * 10−8 Val-Pro-benzothiazol methyl ketone 1.38 * 10−7 -
- Ser(Bzl) and Ser(P) are defined as benzyl-serine and phosphoryl-serine, respectively. Tyr(P) is defined as phosphoryl-tyrosine.
- Inhibition of DPIV-like enzymes—dipeptidyl peptidase II
- DP II (3.4.14.2) releases N-terminal dipeptides from oligopeptides if the N-terminus is not protonated (McDonald, J. K., Ellis, S. & Reilly, T. J., 1966,J. Biol. Chem., 241, 1494-1501). Pro and Ala in P1-position are preferred residues. The enzyme activity is described as DPIV-like activity, but DP II has an acidic pH-optimum. The enzyme used was purified from porcine kidney.
- Assay:
- 100 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 1*10−4M-5*10−8M were admixed with 100 μl μl buffer solution (40 mM HEPES, pH7.6, 0.015% Brij, 1 mM DTT), 50 μl lysylalanylaminomethylcoumarine solution (5 mM) and 20 μl porcine DP II (250fold diluted in buffer solution). Fluorescence measurement was performed at 30° C. and λexiatation=380 nm, λemission=465 nm for 25 min using a plate reader (HTS7000plus, Applied Biosystems, Weiterstadt, Germany). The Ki-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK) and were determined as Ki=8.52*10−5 M±6.33*10−6 M for glutaminyl pyrrolidine and Ki=1.07*10−5 M±3.81*10−7 M for glutaminyl thiazolidine.
- Cross Reacting Enzymes
- Glutaminyl pyrrolidine and glutaminyl thiazolidine were tested for their cross reacting potency against dipeptidyl peptidase I, prolyl oligopeptidase and prolidase.
- Dipeptidyl peptidase I (DP I, cathepsin C):
- DP I or cathepsin C is a lysosomal cysteine protease which cleaves off dipeptides from the N-terminus of their substrates (Gutman, H. R. & Fruton, J. S., 1948,J. Biol: Chem., 174, 851-858). It is classified as a cysteine protease. The enzyme used was purchased from Qiagen (Qiagen GmbH, Hilden, Germany). In order to get a fully active enzyme, the enzyme was diluted 1000fold in MES buffer pH5,6 (40 mM MES, 4 mM DTT, 4 mM KCl, 2 mM EDTA, 0.015% Brij) and pre-incubated for 30 min at 30° C.
- Assay:
- 50 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in a concentration range of 1*10−5M-1*10−7M were admixed with 110 μl buffer-enzyme-mixture. The assay mixture was pre-incubated at 30° C. for 15 min. After pre-incubation, 100 μl histidylseryl-β-nitroaniline (2*10−5M) was added and measurement of yellow color development due to β-nitroaniline release was performed at 30° C. and λexcitation=380 nm, λemission=465 nm for 10 min., using a plate reader (HTS7000 plus, Applied Biosystems, Weiterstadt, Germany).
- The IC50-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). No inhibition of the DP I enzyme activity by glutaminyl pyrrolidine or glutaminyl thiazolidine was found.
- Prolyl oligopeptidase (POP)
- Prolyl oligopeptidase (EC 3.4.21.26) is a serine type endoprotease which cleaves off peptides at the N-terminal part of the Xaa-Pro bond (Walter, R., Shlank, H., Glass, J. D., Schwartz, I. L. & Kerenyi, T. D., 1971,Science, 173, 827-829). Substrates are peptides with a molecular weight up to 3000 Da. The enzyme used was a recombinant human prolyl oligopeptidase. Recombinant expression was performed in E. coli under standard conditions as described elsewhere in the state of the art.
- Assay:
- 100 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 1*10−4M-5*10−8M were admixed with 100 μl μl buffer solution (40 mM HEPES, pH7.6, 0.015% Brij, 1 mM DTT) and 20 μl POP solution. The assay mixture was pre-incubated at 30° C. for 15 min. After pre-incubation, 50 μl glycylprolylprolyl-4-nitroaniline solution (0.29 mM) was added and measurement of yellow color development due to 4-nitroaniline release was performed at 30° C. and λ=405 nm for 10 min using a plate reader (sunrise, Tecan, Crailsheim, Germany). The IC50-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). No inhibition of POP activity by glutaminyl pyrrolidine or glutaminyl thiazolidine was found.
- Prolidase (X-Pro dipeptidase)
- Prolidase (EC 3.4.13.9) was first described by Bergmann & Fruton (Bergmann, M. & Fruton, J S, 1937,J. Biol Chem. 189-202). Prolidase releases the N-terminal amino acid from Xaa-Pro dipeptides and has a pH optimum between 6 and 9.
- Prolidase from porcine kidney (ICN Biomedicals, Eschwege, Germany) was solved (1 mg/ml) in assay buffer (20 mM NH4(CH3COO)2, 3 mM MnCl2, pH 7.6). In order to get a fully active enzyme the solution was incubated for 60 min at room temperature.
- Assay:
- 450 μl glutaminyl pyrrolidine or glutaminyl thiazolidine in an concentration range of 5*10−3 M-5*10−7 M were admixed with 500 μl buffer solution (20 mM NH4(CH3COO)2, pH 7.6) and 250 μl lle-Pro-OH (0.5 mM in the assay mixture). The assay mixture was pre-incubated at 30° C. for 5 min. After pre-incubation, 75 μl Prolidase (1:10 diluted in assay buffer) were added and measurement was performed at 30° C. and λ=220 nm for 20 min using a UV/Vis photometer, UV1 (Thermo Spectronic, Cambridge, UK).
- The IC 50-values were calculated using Graphit 4.0.15 (Erithacus Software, Ltd., UK). They were determined as IC50>3 mM for glutaminyl thiazolidine and as IC50=3.4*10−4M±5.63*10−5 for glutaminyl pyrrolidine.
- Determination of DPIV Inhibiting Activity after Intravasal and Oral Administration to Wistar Rats
- Animals
- Male Wistar rats (Shoe: Wist(Sho)) with a body weight ranging between 250 and 350 g were purchased from Tierzucht Schönwalde (Schönwalde, Germany).
- Housing Conditions
- Animals were single-caged under conventional conditions with controlled temperature (22±2° C.) on a 12/12 hours light/dark cycle (light on at 06:00 AM). Standard pelleted chow (ssniff® Soest, Germany) and tap water acidified with HCl were allowed ad libitum.
- Catheter Insertion into Carotid Artery
- After ≧one week of adaptation at the housing conditions, catheters were implanted into the carotid artery of Wistar rats under general anaesthesia (i.p. injection of 0.25 ml/kg b.w. Rompun® [2%], BayerVital, Germany and 0.5 ml/kg b.w.
Ketamin 10, Atarost GmbH & Co., Twistringen, Germany). The animals were allowed to recover for one week. The catheters were flushed with heparin-saline (100 IU/ml) three times per week. In case of catheter dysfunction, a second catheter was inserted into the contra-lateral carotid artery of the respective rat. After one week of recovery from surgery, this animal was reintegrated into the study. In case of dysfunction of the second catheter, the animal was withdrawn from the study. A new animal was recruited and the experiments were continued in the planned sequence, beginning at least 7 days after catheter implantation. - Experimental Design
- Rats with intact catheter function were administered placebo (1 ml saline, 0.154 mol/l) or test compound via the oral and the intra-vasal (intra-arterial) route. After overnight fasting, 100 μl samples of heparinised arterial blood were collected at −30, −5, and 0 min. The test substance was dissolved freshly in 1.0 ml saline (0.154 mol/l) and was administered at 0 min either orally via a feeding tube (75 mm; Fine Science Tools, Heidelberg, Germany) or via the intra-vasal route. In the case of oral administration, an additional volume of 1 ml saline was injected into the arterial catheter. In the case of intra-arterial administration, the catheter was immediately flushed with 30 μl saline and an additional 1 ml of saline was given orally via the feeding tube.
- After application of placebo or the test substances, arterial blood samples were taken at 2.5, 5, 7.5, 10, 15, 20, 40, 60 and 120 min from the carotid catheter of the conscious unrestrained rats. All blood samples were collected into ice cooled Eppendorf tubes (Eppendorf-Netheler-Hinz, Hamburg, Germany) filled with 10 μl 1 M sodium citrate buffer (pH 3.0) for plasma DPIV activity measurement. Eppendorf tubes were centrifuged immediately (12000 rpm for 2 min,
Hettich Zentrifuge EBA 12, Tuttlingen; Germany): The plasma fractions were stored on ice until analysis or were frozen at −20° C. until analysis. All plasma samples were labelled with the following data: - Code number
- Animal Number
- Date of sampling
- Time of sampling
- Analytical Methods
- The assay mixture for determination of plasma DPIV activity consisted of 80 μl reagent and 20 μl plasma sample. Kinetic measurement of the formation of the yellow product 4-nitroaniline from the substrate glycylprolyl-4-nitroaniline was performed at 390 nm for 1 min at 30° C. after 2 min pre-incubation at the same temperature. The DPIV activity was expressed in mU/ml.
- Statistical Methods
- Statistical evaluations and graphics were performed with PRISM® 3.02 (GraphPad Software, Inc.). All parameters were analysed in a descriptive manner including mean and SD.
- 11.1 Results—in vivo DPIV-inhibition at tmax
Dose STRUCTURE (mg/kg) i.v. (%) p.o. (%) Gln-Pyrr 100 80 67 Gln-Thia 100 88 71 Diprotin A 100 73 no inhibition Diprotin B 100 50 no inhibition Tyr(P)-Pro-Ile 100 37 no inhibition tBuGly-Pro-Ile 100 71 28 tButGly-Pro-Val 100 72 25 Ala-Val-Pro- 100 89 86 Acyloxymethylketone Ala-Val-Pro-Benzoyl- 100 97 76 methylketone Ile-cyclopentyl-ketone 100 34 15 - Action of side chain-modified glutamyl thiazolidines as non-readily-transportable DPIV-inhibitors
- Side chain-modified glutamyl thiazolidines having a structure H-Glu(X)-Thia were synthesised, with polyethylene glycol or glycine oligomers of various chain lengths being used as X (see Method A of example for description of synthesis). The binding characteristics of those derivatives and their transportability by the peptide transporter PepT1 were investigated.
- Surprisingly, it was found that the side chain modifications alter the binding characteristics of the compounds to DPIV only to a slight extent. In contrast, the ability of the inhibitors to be transported by the peptide transporter is dramatically diminished by the side chain modification.
- Side chain modified inhibitors of DPIV or DPIV-like enzymes are therefore well suited to achieving site directed inhibition of DPIV in the body.
- 12.1 Results: Transportability of Selected DPIV-inhibitors.
Compound EC50 (mM)1 Imax (nA)2 amino acid thiazolidides H-Ile-Thia 0.98 25 ± 8 H-Glu-Thia 1.1 35 ± 13 side chain-modified glutamylthiazolidines H-Gly(NHOH)-Thia 3.18 42 ± 11 H-Glu(Gly3)-Thia 8.54 n.d.3 H-Glu(Gly5)-Thia >10 n.d.3 H-Glu(PEG)-Thia >10 n.d.3 -
- In vivo Cancer Cell Adhesion Assay
- Using a novel in vivo adhesion assay which takes advantage of vital dye labeled tumor cells and their detection in the target tissue in situ (von Hörsten et al, 2000; Shingu et al., 2002), the current example investigates whether the in vivo adhesion of MADB106 tumor cells differs in DPIV in treated wild type F344 rats and F344 substrains with a mutation of the DPIV gene.
- Animals, Injection of Tumor Cells and Processing of Lungs
- F344USA, F344JAP and F344GER substrains were obtained from a breeding colony at the Central Animal Laboratory at Hannover Medical School, Germany. All substrains were bred for one generation and maintained in a specific-pathogen-free facility at 25° C. under a 12h light-12h dark cycle (light on at 07.00 h), with ad libitum access to food and water. The exact number of animals used per experiment is indicated by the F values with at least four animals per condition and time point.
- Cell culture, injection of tumor cells, dissection of the animals and immunohistochemistry were conducted as previously described (von Hörsten et al., 2000). In brief, 1×106 MADB106 tumor cells derived from log phase of tumor growth were injected via the lateral tail vein and lungs removed at different time points thereafter. For in situ quantification of tumor cells at early time points after injection (30 min), cells were vital dye stained using the fluorescein derivate 5-(and -6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) before injection. For quantification of lung surface colonies at later time points (2 weeks after tumor cell inoculation), en-bloc dissected lungs and the heart were injected with 8 ml Bouin's solution (72% saturated picric acid solution, 23% formaldehyde, and 5% glacial acetic acid) and fixed in the same solution until lung surface nodules were counted (see below).
- Experiments
- Four experiments were conducted:
- Effect of a single injection of isoleucyl thiazolidine fumarate (2 mg i.v.+isoleucyl thiazolidine fumarate 2 mg i.p.) on lung tumor colonization in F344USA wild-type rats;
- Effect of single injection of isoleucyl thiazolidine fumarate 2 mg i.v.+isoleucyl thiazolidine fumarate 2 mg i.p. on tumor cell adhesion to lungs of F344JAP, F344GER and F344USA rats;
- Effect of single injection of isoleucyl cyanopyrrolidine (0.1 mg i.v.+0.1 mg i.p.) on tumor cell adhesion to lungs of F344USA wild-type rats;
- Effect of single injection of valyl-pyrrolidine fumarate (0.1 mg i.v.+0.1 mg i.p.) on tumor cell adhesion to lungs of F344USA wild-type rats;
- Immunohistochemistry of CFSE-labeled tumor Cells in Lungs
- Immunostaining of CFSE-labeled MADB106 tumor cells was achieved using mAb characterizing the intracellular CFSE antigen (anti-CFSE; mAb DE1, Boehringer, Mannheim, Germany; mouse, 1:100). For immunohistochemistry, one or two consecutive APAAP stainings were performed as previously described (von Hörsten et al, 2000; Shingu et al., 2002). Control sections were included in which one or both primary antibodies were omitted.
- Quantification of Tumor Targets: In vivo/in situ Cell Adhesion Assay
- Vital dye (Carboxyfluorescein; CFSE) labeling of MADB106 tumor cells allows the quantification of tumor cells and NK cells in thick sections of lung tissue by stereology in situ (von Hörsten et al, 2000). In the present study we produced thin sections (8 μm) of the same lungs (n=10) and performed additional microscopic counting by image analysis of DE1 positive cells. This was done to further simplify the previously validated stereological quantification technique. Therefore, in the present study, the assessment of DE1 positive tumor cells in lung tissue from
different substrains 30 min after tumor inoculation was carried out using image analysis approach. All CFSE-labeled MADB106 tumor cells and leukocyte subsets within a grid on the ocular lens were counted (Zeiss Kpl-W 12.5×; grid 0.75×0.75 mm=0.5625 mm2/grid, using a Zeiss Neofluar objective, ×10, NA=0.3). Each right upper lobe of the lungs was sectioned at 6 randomly chosen non-adjacent levels. From each level, three sections were evaluated. On average, 30 grid numbers per section were examined (i.e. 0.5625 mm2/grid×30 grids×3 sections×6 levels) resulting in an area per animal of 3.04 cm2. - Quantification of Macrometastasis on Lungs
- For quantification of lung surface colonies at later time points (2 weeks after tumor cell inoculation), en-bloc dissected lungs and the heart were injected with 8 ml Bouin's solution (72% saturated picric acid solution, 23% formaldehyde, and 5% glacial acetic acid) and fixed in the same solution until lung surface nodules were counted. Three areas per lungs were examined using a gauge (1 cm2) and lung surface colony numbers were expressed as mean/cm2 according to the method of Wexler (Wexler, 1966).
- Statistical Analysis
- Data from in vivo adhesion assay were analyzed by one-way ANOVAs and Fisher's PLSD post hoc tests, if appropriate. An asterisk indicates significant post hoc effects vs. saline (SHAM) treated controls obtained by Fisher's PLSD. All data are presented as means±S.E.M.
- Results
- Effect of a single injection of isoleucyl thiazolidine fumarate on lung tumor colonization in F344USA rats
- The number of lung surface tumor colonies after single isoleucyl thiazolidine fumarate administration in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 1. One factor ANOVA revealed no significant effect (F(1,12)=3.2; p=0.1 n.s.) on colony numbers. A trend toward decreased colony numbers in experimental rats was evident. - Effect of single injection of isoleucyl thiazolidine fumarate on tumor adhesion in F344JAP, F344GER and F344USA rats
- The mean number of CFSE positive cells in lung tissue at 30 min after inoculation of MADB106 tumor cells in the three substrains is illustrated in FIG. 2. Two-way ANOVA showed a significant effect of “substrain” (F(2,43)=3.5; p<0.04) and “treatment” (F(1,43)=44.1; p<0.0001), as well as a significant interaction factors but no significant interaction (F(2,43)=26.2; p<0.0001). Separate one factor ANOVAs split for these substrains revealed that these effects are significant.
- Effect of single injection of isoleucyl cyanopyrrolidine TFA on tumor adhesion of F344USA rats
- The mean number of CFSE positive cells in lung tissue at 30 min after inoculation of MADB106 tumor cells after isoleucyl cyanopyrrolidine TFA treatment is illustrated in FIG. 3. ANOVA showed no significant effect of “treatment” (F(1,18)=0.1; p=0.8n.s.).
- Effect of single injection of valyl pyrrolidine fumarate on tumor adhesion of F344USA rats
- The mean number of CFSE positive cells in lung tissue at 30 min after inoculation of MADB106 tumor cells after valyl pyrrolidine fumarate treatment is illustrated in FIG. 4. ANOVA showed no significant effect of “treatment” (F(1,18)=0.6; p=0.5n.s.).
- Discussion
- Tumor cell adhesion and colonization is significantly modified by single injection of isoleucyl thiazolidine fumarate only in mutant F344 substrains suggesting an interaction of the ligand with mutant DPIV and tumor cells. Since the ligand did not significantly affect tumor adhesion in wild type F344USA rats, this may indicate that compound is not interacting with the binding site of MADB106 tumor cells.
- Cancer Colonization Assays
- In the previous example it was demonstrated that MADB106 tumor cell adhesion is significantly modified by a single administration of isoleucyl thiazolidine fumarate only in mutant F344 substrains but not in wild type DPIV expressing F344USA rats. DPIV inhibitors/ligands may interact with the growth of tumor metastases exhibiting properties similar to chemotherapeutic compounds and/or immunotherapeutical compounds. In contrats to that, the current example investigates whether the tumor colonization of MADB106 tumor cells differs in chronically DPIV-inhibitor treated wild type F344 rats.
- Animals, Injection of Tumor Cells and Processing of Lungs
- F344USA rats were obtained from a breeding colony at the Central Animal Laboratory at Hannover Medical School, Germany. All rats were bred at least for one generation and maintained in a specific-pathogen-free facility at 25° C. under a 12h light-12h dark cycle (light on at 07.00 h), with ad libitum access to food and water. The exact number of animals used per experiment is indicated by the F values with at least four animals per condition and time point.
- Cell culture, injection of tumor cells, dissection of the animals and immunohistochemistry were conducted as previously described (von Hörsten et al., 2000; Shingu et al., 2002). In brief, 1×106 MADB106 tumor cells derived from log phase of tumor growth were injected via the lateral tail vein and lungs removed at different time points thereafter. For in situ quantification of tumor cells at early time points after injection (30 min), cells were vital dye stained using the fluorescein derivate 5-(and -6)-carboxyfluorescein diacetate succinimidyl ester (CFSE) before injection. For quantification of lung surface colonies at later time points (2 weeks after tumor cell inoculation), en-bloc dissected lungs and the heart were injected with 8 ml Bouin's solution (72% saturated picric acid solution, 23% formaldehyde, and 5% glacial acetic acid) and fixed in the same solution until lung surface nodules were counted (see below).
- Experiments
- Two experiments were conducted:
- Effect of chronic infusion of different dosages of isoleucyl thiazolidine fumarate (0 mg, 0.04 mg, 0.4 mg, 4 mg/24h intragastral via implanted osmotic minipumps) on body weight change and lung tumor colonization in F344USA wild-type rats
- Effect of chronic infusion of isoleucyl thiazolidine fumarate (4 mg/24h intragastral via implanted osmotic minipumps), lisoleucyl cyanopyrrolidine TFA (0.1 mg/24 h intragastral via implanted osmotic minipumps) and valyl pyrrolidine fumarate (0.1 mg/24 h intragastral via implanted osmotic minipumps) on lung tumor colonization in F344USA wild-type rats.
- Implantation of Osmotic Minipumps for Chronic Intragastric Infusion of Compounds
- Osmotic minipumps (Alzet model 2ML4; flow rate, 2.5 μl/hr; Alza Corporation), administering a constant supply of the different compounds, aseptically prefilled with either saline or DPIV inhibitor were placed subcutaneously in the abdominal area. Minipums were attached to a cannula via polyethylene tubing. The cannula was implanted intragastrically with a heating-induced enlarged tip of the cannula in the lumen of the gaster.
- Quantification of Macrometastasis on Lungs
- For quantification of lung surface colonies at later time points (2 weeks after tumor cell inoculation), en-bloc dissected lungs and the heart were injected with 8 ml Bouin's solution (72% saturated picric acid solution, 23% formaldehyde, and 5% glacial acetic acid) and fixed in the same solution until lung surface nodules were counted. Three areas per lungs were examined using a gauge (1 cm2) and lung surface colony numbers were expressed as mean/cm2 according to the method of Wexler (Wexler, 1966).
- Statistical Analysis
- Data from in vivo body weight gain and number of lung surface tumor colonies were analyzed by one-way ANOVAs and Fisher's PLSD post hoc tests, if appropriate. An asterisk indicates significant post hoc effects vs. saline (SHAM) treated controls obtained by Fisher's PLSD. All data are presented as means±S.E.M.
- Results
- Effect of chronic infusion of isoleucyl thiazolidine fumarate (0 mg, 0.04 mg, 0.4 mg, 4 mg/24 h) on lung tumor colonization
- The change of body weight after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 5. One factor ANOVA revealed a significant effect (F(3,22)=3.5; p=0.03) on body weight, which became significant in the post-hoc analysis at the 0.4 mg and 4 mg dosages. - The number of lung surface tumor colonies after chronic infusion of different dosages of isoleucyl thiazolidine fumarate in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 6. One factor ANOVA revealed a significant effect (F(3,22)=3.8; p=0.03) on colony numbers, which became significant in the post-hoc analysis at the 4 mg dosage. - Effect of chronic infusion of isoleucyl thiazolidine fumarate, isoleucyl cyanopyrrolidine TFA, and valyl pyrrolidine fumarate on lung tumor colonization
- The number of lung surface tumor colonies after chronic infusion of isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA, and valyl pyrrolidine fumarate in
F344 rats 2 weeks after injection of MADB106 tumor cells is illustrated in FIG. 7. One factor ANOVA revealed a significant effect (F(3,20)=3.8; p=0.03) on colony numbers, which became significant in the post-hoc analysis for isoleucyl cyanopyrrolidine TFA and isoleucyl thiazolidine fumarate compounds. - Discussion
- Metastasis of MADB106 is reduced by chronic treatment using different DPIV Inhibitors (isoleucyl thiazolidine fumarate; isoleucyl cyanopyrrolidine TFA) suggesting protective-like class effects. Possibly, isoleucyl thiazolidine fumarate and isoleucyl cyanopyrrolidine TFA protect from metastasis either via interaction with cell adhesion processes or via a modification of the cellular host defense mechanisms. It is also possible that DPIV inhibitor treatment exhibits cytostatic effects. These antimetastic effects substantiate the biological properties of DPIV Inhibitors for the treatment of cancer and metastatic disease.
- References
- Abdel-Ghany M, Cheng H, Levine R, Pauli B U (1998) Truncated dipeptidyl peptidase IV is a potent antiadhesion and anti-metastasis peptide for rat breast cancer calls. Invasion Metastasis 18: 35-43
- Aguirre K M, McCormik R J, Schwarzbauer J E (1994) Fibronectin self-association is mediated by complementary sites within the amino-terminal one-third of the molecule. J Biol Chem 269: 27863-27868
- Barlozzari T, Leonhardt J, Wiltrout R H, Herberman R B, Reynolds C W (1985) Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J Immunol 134: 2783-2789
- Bühling F, Kunz D, Reinhold D, Ulmer, A J, Ernst M, Flad H D, Ansorge S (1994) Expression and functional role of dipeptidyl peptidase IV (CD26) on human natural killer cells. Nat Immun 13: 270-279
- Cheng H C, Abdel-Ghany M, Elble R C, Pauli B U (1998) Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin. J Biol Chem 273: 24207-24215
- Cheng H C, Abdel-Ghany M, Zhang S, Pauli B U (1999) Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?. Clin Exp Metastasis 17: 609-615
- Chernousov M A, Fogerty F J, Koteliansky V E, Mosher D F (1991) Role of the I-9 and III-1 modules of fibronectin in formation of an extracellular fibronectin matrix. J Biol Chem 266: 10851-10858
- De Meester I, Korom S, Van Damme J, Scharpé S (1999) CD26, let it cut or cut it down. Immun today 20: 367-375
- Held-Feindt J, Krisch B, Mentlein R (1999) Molecular analysis of the
somatostatin receptor subtype 2 in human glioma cells. Mol Brain Res 64: 101-107 - Hocking D C, Smith R K, McKeown-Longo P J (1996) A novel role for the integrin-binding 111-10 module in fibronectin matrix assembly. J Cell Biol 133: 431-444
- Hoshimoto K, Ohta N, Ohkura T, Inaba N (2000) Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1/Th2 balance? Gynecol Obstet Inves 50: 260-263
- Ingham K C, Brew S A, Huff S, Litvinovich S V (1997) Cryptic self-association sites in type III modules of fibronectin. J Biol Chem 272: 1718-1724
- Iwata S, Yamaguchi N, Munakata Y, Ikushima H, Lee J F, Hosono O, Schlossman S F, Morimoto C (1999) CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int immunol 11: 417-426
- Jacobs R, Stoll M, Stratmann G, Leo R, Link H, Schmidt R E (1992) CD16− CD56+ natural killer cells after bone marrow transplantation. Blood 79: 3239-3244
- Kähne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D (1999) Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med 4: 3-15
- Korom S, De Meester I, Stadibauer T H, Chandraker A, Schaub M, Sayegh M H, Belyaev A, Haemers A, Scharpe S, Kupiec-Weglinski J W (1997) Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardic allograft survival in rat recipients. Transplntation 63: 1495-1500
- Mentlein R and Struckhoff G (1989) Purification of two dipeptidylaminopeptidases II from rat brain and their action on proline-containing neuropeptides. J Neurochem 52:1284-1293
- Mentlein R (1999) Dipeptidyl-peptidase IV (CD26)—role in the inactivation of regulatory peptides. Regul Pept 85: 9-24
- Morla A and Ruoslahti E (1992) A fibronectin self-assembly site involved in fibronectin matrix assembly: reconstruction in a synthetic peptide. J Cell Biol 118: 421-429
- Struyf S, Proost P, Schols D, De Clercq E, Opdenakker G, Lenaerts J P, Detheux M, Parmentier M, De Meester I, Scharpe S, Van Damme J (1999) CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with
CC chemokine receptor 3. J Immunol 162: 4903-4909 - Tayebati S K, Bronzetti E, Morra di Cella S, Mulatero P, Ricci A, Rossodivita I, Schena M, Schiavone D, Veglio F, Amenta F (2000) In situ hybridization and immunohistochemistry of α1-adrenoceptors in human periperal blood lymphocytes. J Auton Pharmacol 20: 305-312
- Thompson N L, Hixson D C, Callanan H, Panzica M, Flanagan D, Faris R A, Hong W J, Hartel-Schenk S, Doyle D (1991) A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein. Use as a liver-cell transplantation model. Biochem J 273: 497-502
- Tsuji E, Misumi Y, Fujiwara T, Takami N, Ogata S, Ikehara Y (1992) An active-site mutation (Gly633→Arg) of dipeptidyl peptidase IV causes its retention and rapid degradation in the endoplasmic reticulum. Biochemistry 31: 11921-11927
- von Hörsten S, Ballof J, Helfritz F, Nave H, Meyer D, Schmidt R E, Stalp M, Klemm A, Tschernig T, Pabst R (1998) Modulation of innate immune functions by intracerebroventricularly applied neuropeptide Y: dose and time dependent effects. Life Sci 63: 909-922
- Wexler H (1966) Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst 36: 641-645.
Claims (20)
1. A method for reducing cancer or a related disorder comprising the step of administering a therapeutically effective amount of at least one inhibitor of dipeptidyl peptidase IV (DPIV) or DPIV-like enzyme activity, wherein said inhibitor is selected from the group consisting of dipeptide compounds, peptide compounds comprising tri-, tetra- and pentapeptides, peptidylketones, aminoketone derivatives and side chain modified DP IV inhibitors.
2. The method according to claim 1 , wherein the related disorder is metastasis.
3. The method according to claim 1 , wherein the related disorder is tumor colonization.
4. The method according to claim 1 , wherein the dideptidyl peptidase IV-like enzyme is selected from the group consisting of fibroblast activation protein α, dipeptidyl peptidase IV β, dipeptidyl aminopeptidase-like protein, N-acetylated α-linked acidic dipeptidase, quiescent cell proline dipeptidase, dipeptidyl peptidase II, attractin and dipeptidyl peptidase IV related protein (DPP 8), dipeptidyl peptidase 9 (DPP9) or KIAA1492.
5. The method according to claim 1 , wherein the structure of the dideptidyl peptidase IV-like enzyme is undiscovered.
6. The method according to claim 1 , wherein the inhibitor is a dipeptide compound formed from an amino acid and a thiazolidine or pyrrolidine group, and salts thereof.
7. The method according to claim 6 wherein the dipeptide compound is selected from the group consisting of L-threo-isoleucyl pyrrolidine, L-allo-isoleucyl thiazolidine, 1-allo-isoleucyl pyrrolydine, L-glutaminyl thiazolidine, L-glutaminyl pyrrolidine, L-glutamic acid thiazolidine, L-glutamic acid pyrrolidine and salts thereof.
8. The method according to claim 1 wherein the inhibitor is a peptide compound useful for competetive modulation of dipeptidyl peptidase IV catalysis represented by the general formula
wherein
A, B, C, D and E are any amino acid residues including proteinogenic amino acids, non-proteinogenic amino acids, L-amino acids and D-amino acids and wherein E and/or D may be absent or B and/or A may be absent provided that:
A is any amino acid residue except D-amino acid residues;
B is any proteinogenic amino acid residue, but
If B is an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid and E may be unused to generate tetrapeptides of the formula A-B-C-D, or D and E may be unused to generate tripeptides of the formula A-B-C provided, but
If B is not an amino acid selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any α-amino acid except D-amino acids; D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid; E is any amino acid residue including D-amino acids, except Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, but
If D is Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then C is any α-amino acid except D-amino acids and Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, and A may be unused to generate tetrapeptides of the formula B-C-D-E, or A and B may be unused to generate tripeptides of the formula C-D-E provided however,
If D is not selected from Pro, Ala, Ser, Gly, Hyp, acetidine-(2)-carboxylic acid or pipecolic acid, then E is any amino acid residue including D-amino acids.
9. The method according to claim 1 , wherein the inhibitor is peptidylketone represented by the general formula
including all stereoisomers and pharmaceutical acceptable salts thereof, wherein
A is selected from:
and
X1 is H or a acyl or oxycarbonyl group including all amino acids and peptide residues;
X2 is H, —(CH)n—NH—C5H3N—Y with n=2-4 or C5H3N—Y (a divalent pyridyl residue) and Y is selected from H, Br, Cl, I, NO2 or CN;
X3 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue;
X4 is H or selected from an alkyl, alkoxy, halogen, nitro, cyano or carboxy substituted phenyl or pyridyl residue;
X5 is H or an alkyl, alkoxy or phenyl residue; and
X6 is H or a alkyl residue; provided that
for n=1, X
is selected from: H, OR2, SR2, NR2 R3, N+R2 R3R4, wherein:
R2 stands for acyl residues, which are substituted with alkyl, cycloalkyl, aryl or heteroaryl residues, or for all amino acids and peptidic residues, or alkyl residues, which are substituted with alkyl, cycloalkyl, aryl and heteroaryl residues;
R3 stands for alkyl and acyl functions, wherein R2 and R3 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures;
R4 stands for alkyl residues, wherein R2 and R4 or R3 and R4 may be embedded in ring structures of saturated and unsaturated carbocyclic or heterocyclic structures; and
for n=0, X
is selected from:
wherein
B stands for: O, S, NR5, wherein R5 is H, a alkyl or acyl, C, D, E, F, G, H are independently selected from alkyl and substituted alkyl residues, oxyalkyl, thioalkyl, aminoalkyl, carbonylalkyl, acyl, carbamoyl, aryl and heteroaryl residues; and
Z is selected from H, or a branched or single chain alkyl residue from C1-C9 or a branched or single chain alkenyl residue from C2-C9, a cycloalkyl residue from C3-C8, a cycloalkenyl residue from C5-C7, a aryl- or heteroaryl residue, or a side chain selected from all side chains of all natural amino acids or derivatives thereof.
10. The method according to claim 1 wherein the inhibitor is a aminoketone derivative represented by the general formulas 5, 6, 7, 8, 9, 10 and 11, including all stereoisomers and pharmaceutical acceptable salts thereof,
wherein:
R1 is H, a branched or linear C1-C9 alkyl residue, a branched or linear C2-C9 alkenyl residue, a C3-C8 cycloalkyl-, C5-C7 cycloalkenyl-, aryl- or heteroaryl residue or a side chain of a natural amino acid or a derivative thereof;
R3 and R4 are selected from H, hydroxy, alkyl, alkoxy, aryloxy, nitro, cyano or halogen,
A is H or an isoster of an carbonic acid, like a functional group selected from CN, SO3H, CONHOH, PO3R5R6, tetrazole, amide, ester, anhydride, thiazole and imidazole;
B is selected from:
wherein:
R5 is H, —(CH)n—NH—C5H3N—Y with n=2-4 and C5H3N—Y (a divalent pyridyl residue) with Y=H, Br, Cl, I, NO2 CN;
R10 is H, a acyl, oxycarbonyl or a amino acid residue;
W is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue;
W1 is H, a alkyl, alkoxy or phenyl residue;
Z is H or a phenyl or pyridyl residue, substituted with alkyl, alkoxy, halogen, nitro, cyano or carboxy residue;
Z1 is H or a alkyl residue;
D is a cyclic C4-C7 alkyl, C4-C7 alkenyl residue or a alkyl substituted derivative thereof or a cyclic 4-7-membered heteroalkyl or 4-7-membered heteroalkenyl residue;
X2 is O, NR6, N+(R7)2, or S;
X3 to X12 are selected from CH2, CR8R9, NR6, N+(R7)2, O, S, SO and SO2, including all saturated and unsaturated structures;
R6, R7, R8, R9 are selected from H, a branched or linear C1-C9 alkyl residue, a branched or lienar C2-C9 alkenyl residue, a C3-C8 cycloalkyl residue, a C5-C7 cycloalkenyl residue, an aryl or heteroaryl residue;
with the following provisos:
Formula 6: X6 is CH if A is not H;
Formula 7: X10 is C if A is not H;
Formula 8: X7 is CH if A is not H; and
Formula 9: X12 is C if A is not H.
11. The method according to claim 1 , wherein the inhibitor is a side chain modified inhibitor of DPIV or DPIV-like enzyme activity represented by the general formula,
including all stereoisomers and pharmaceutical acceptable salts thereof, wherein
A is an amino acid having at least one functional group in the side chain;
B is a chemical compound covalently bound to at least one functional group of the side chain of A, namely
oligopeptides having a chain length of up to 20 amino acids, except for homopolymers of glycine consisting of up to 6 glycine monomers; or
polyethylene glycols having molar masses of up to 20,000 g/mol; or
optionally substituted organic amines, amides, alcohols, acids or aromatic compounds having from 8 to 50 C atoms; and
C is a thiazolidine, pyrrolidine, cyanopyrrolidine, hydroxyproline, dehydroproline or piperidine group amide-bonded to A.
12. The method according to claim 11 , wherein A is an amino acid, preferably an α-amino acid, especially a natural α-amino acid having at least one functional group in the side chain selected from the group consisting of threonine, tyrosine, serine, arginine, lysine, aspartic acid, glutamic acid or cysteine.
13. The method according to claim 8 wherein said inhibitor is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a said inhibitor or a pharmaceutically acceptable acid addition salt thereof.
14. A pharmaceutical composition comprising: an inhibitor of DPIV or DPIV-like enzyme activity or a pharmaceutically acceptable acid addition salt thereof for the manufacture of a medicament for inhibiting dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzyme activity for the prevention or treatment of diseases or conditions related to dipeptidyl peptidase IV or dipeptidyl peptidase IV-like enzymes.
15. The pharmaceutical composition according to claim 14 for the manufacture of a medicament for the treatment of cancer and related disorders.
16. The pharmaceutical composition according to claim 14 for the manufacture of a medicament for the treatment of metastasis.
17. The pharmaceutical composition according to claim 14 for the manufacture of a medicament for the treatment of tumor colonization.
18. The method according to claim 9 wherein said inhibitor is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a said inhibitor or a pharmaceutically acceptable acid addition salt thereof.
19. The method according to claim 10 wherein said inhibitor is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a said inhibitor or a pharmaceutically acceptable acid addition salt thereof.
20. The method according to claim 11 wherein said inhibitor is a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of a said inhibitor or a pharmaceutically acceptable acid addition salt thereof.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/172,809 US20030130199A1 (en) | 2001-06-27 | 2002-06-13 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US11/093,991 US7109347B2 (en) | 2001-06-27 | 2005-03-30 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US11/481,349 US7368576B2 (en) | 2001-06-27 | 2006-07-05 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30115801P | 2001-06-27 | 2001-06-27 | |
EP01114796.4 | 2001-06-27 | ||
EP01114796 | 2001-06-27 | ||
DE10150203.6 | 2001-10-12 | ||
DE10150203A DE10150203A1 (en) | 2001-10-12 | 2001-10-12 | Use of dipeptidyl peptidase IV inhibitor in treatment of cancer |
DE10154689A DE10154689A1 (en) | 2001-11-09 | 2001-11-09 | Substituted amino ketone compounds |
DE10154689.0 | 2001-11-09 | ||
US36090902P | 2002-02-28 | 2002-02-28 | |
US10/172,809 US20030130199A1 (en) | 2001-06-27 | 2002-06-13 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/093,991 Continuation US7109347B2 (en) | 2001-06-27 | 2005-03-30 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030130199A1 true US20030130199A1 (en) | 2003-07-10 |
Family
ID=43706178
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/172,809 Abandoned US20030130199A1 (en) | 2001-06-27 | 2002-06-13 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US11/093,991 Expired - Fee Related US7109347B2 (en) | 2001-06-27 | 2005-03-30 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US11/481,349 Expired - Fee Related US7368576B2 (en) | 2001-06-27 | 2006-07-05 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/093,991 Expired - Fee Related US7109347B2 (en) | 2001-06-27 | 2005-03-30 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US11/481,349 Expired - Fee Related US7368576B2 (en) | 2001-06-27 | 2006-07-05 | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
Country Status (1)
Country | Link |
---|---|
US (3) | US20030130199A1 (en) |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040077601A1 (en) * | 2002-07-09 | 2004-04-22 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
US20040152192A1 (en) * | 1997-09-29 | 2004-08-05 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US20060052310A1 (en) * | 1998-08-21 | 2006-03-09 | Point Therapeutics, Inc. | Regulation of substrate activity |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
US20060154866A1 (en) * | 2005-01-10 | 2006-07-13 | Zhi-Liang Chu | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2007127204A2 (en) * | 2006-04-24 | 2007-11-08 | Dara Biosciences, Inc. | Methods and compositions relating to immunostimulation |
US20080234292A1 (en) * | 2004-07-23 | 2008-09-25 | Susan Marie Royalty | Peptidase Inhibitors |
US20080287476A1 (en) * | 2007-03-13 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US20090246217A1 (en) * | 2005-10-04 | 2009-10-01 | Inimex Pharmaceuticals Inc. | Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20100190750A1 (en) * | 2006-04-11 | 2010-07-29 | Arena Pharmaceuticals, Inc. | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto |
US20100203038A1 (en) * | 2006-04-11 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
US20100203556A1 (en) * | 2008-04-07 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US8076330B2 (en) | 2005-04-22 | 2011-12-13 | Amgen Inc. | Dipeptidyl peptidase-IV inhibitors |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US20150232510A1 (en) * | 2012-03-09 | 2015-08-20 | Morinaga Milk Industry Co., Ltd | Dipeptidyl peptidase-iv inhibitor |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
DE10315569A1 (en) * | 2003-04-05 | 2004-10-14 | Merck Patent Gmbh | Substituted pyrazole compounds |
EP1620091B1 (en) * | 2003-05-05 | 2010-03-31 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
NZ572274A (en) * | 2003-05-05 | 2009-06-26 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
US7732162B2 (en) * | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
US20050171112A1 (en) * | 2003-11-03 | 2005-08-04 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
US20100099721A1 (en) * | 2003-11-03 | 2010-04-22 | Probiodrug Ag | Novel compounds for the treatment of neurological disorders |
US7304086B2 (en) | 2004-02-05 | 2007-12-04 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
WO2007117419A2 (en) * | 2006-03-31 | 2007-10-18 | Dara Biosciences, Inc. | Methods and compositions relating to post-prolyl cleaving enzyme inhibitors |
US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
JP5148941B2 (en) * | 2007-07-11 | 2013-02-20 | 公益財団法人微生物化学研究会 | Antitumor agent comprising sulfostine and sulfostine-related compounds as active ingredients |
WO2009037719A1 (en) * | 2007-09-21 | 2009-03-26 | Lupin Limited | Novel compounds as dipeptidyl peptidase iv (dpp iv) inhibitors |
US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
US20100173827A1 (en) * | 2008-12-16 | 2010-07-08 | Jerzy Alexander Georgiades | Role of proline rich peptides in cellular communication mechanisms and treatment of diseases |
US8748457B2 (en) | 2009-06-18 | 2014-06-10 | Lupin Limited | 2-amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent DPP-IV inhibitors |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US4028402A (en) * | 1974-10-11 | 1977-06-07 | Hoffmann-La Roche Inc. | Biguanide salts |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US5624894A (en) * | 1992-09-17 | 1997-04-29 | University Of Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US5939560A (en) * | 1993-12-03 | 1999-08-17 | Ferring B.V. | Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US20030119750A1 (en) * | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE296075C (en) | ||||
DE2009743A1 (en) | 1970-03-03 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Substituted biguanides with antihyperglycemic effects |
DD296075A5 (en) | 1989-08-07 | 1991-11-21 | Martin-Luther-Universitaet Halle-Wittenberg,De | PROCESS FOR THE PREPARATION OF NEW INHIBITORS OF DIPEPTIDYL PEPTIDASE IV |
ATE164852T1 (en) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | GLP-1 ANALOGUE USABLE IN DIABETES TREATMENT |
WO1991016339A1 (en) | 1990-04-14 | 1991-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type iv |
US6517824B1 (en) * | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
WO1991017767A1 (en) | 1990-05-21 | 1991-11-28 | New England Medical Center Hospitals, Inc. | Method of treating inhibition of dipeptidyl aminopeptidase type iv |
JPH0819154B2 (en) | 1991-03-14 | 1996-02-28 | 江崎グリコ株式会社 | Peptides that inhibit dipeptidyl carboxypeptidase |
JPH04334357A (en) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | Acyl derivative having enzyme-inhibiting action |
GB9115740D0 (en) | 1991-07-20 | 1991-09-04 | Smithkline Beecham Plc | Medicaments |
DK0610317T3 (en) | 1991-10-22 | 2001-02-19 | New England Medical Center Inc | Inhibitors of dipeptidyl aminopeptidase type IV |
JPH07509219A (en) | 1992-04-01 | 1995-10-12 | ザ ユニバーシティー オブ トレド | 4-[4'-piperidinyl or 3'-pyrrolidinyl]-substituted imidazoles as H↓3 receptor antagonists and methods of therapeutic use thereof |
FR2696740B1 (en) | 1992-10-13 | 1994-12-30 | Dospharma Sa | Produced derivatives of dimethylbiguanide and applications as medicaments. |
WO1995011689A1 (en) | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
CA2137206A1 (en) | 1993-12-09 | 1995-06-10 | John A. Galloway | Glucagon-like insulinotropic peptides, compositions and methods |
US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
AU1891295A (en) | 1994-02-22 | 1995-09-04 | Knoll Aktiengesellschaft | Use of 1-(arylalkylaminoalkyl) imidazoles for treating neurological damage |
DE69504637T2 (en) * | 1994-02-22 | 1999-05-06 | Merrell Pharma Inc | INDOLDER DERIVATIVES FOR THE TREATMENT OF ESTROGEN-DEPENDENT NEOPLASMS AND DISEASES |
US5552426A (en) * | 1994-04-29 | 1996-09-03 | Eli Lilly And Company | Methods for treating a physiological disorder associated with β-amyloid peptide |
US6448282B1 (en) * | 1995-05-30 | 2002-09-10 | Gliatech, Inc. | 1H-4(5)-substituted imidazole derivatives |
DE19616486C5 (en) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Method for lowering the blood glucose level in mammals |
WO1997045117A1 (en) | 1996-05-29 | 1997-12-04 | Prototek, Inc. | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
US5827898A (en) * | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
AR016751A1 (en) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | METHOD FOR INHIBITING THE RELEASE OF THE BETA-AMYLOID PEPTIDE IN A CELL, PHARMACEUTICAL COMPOSITION AND USEFUL COMPOUNDS IN THIS METHOD |
CA2320091A1 (en) | 1998-02-13 | 1999-08-19 | Dr. Willmar Schwabe Gmbh & Co. | Stable hyperforin salts, methods of manufacturing them, and their use for the treatment of alzheimer's disease |
US5994379A (en) | 1998-02-13 | 1999-11-30 | Merck Frosst Canada, Inc. | Bisaryl COX-2 inhibiting compounds, compositions and methods of use |
JP2002506075A (en) | 1998-03-09 | 2002-02-26 | フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ | Serine peptidase modulator |
DE19823831A1 (en) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | New pharmaceutical use of isoleucyl thiazolidide and its salts |
IL139885A (en) | 1998-06-05 | 2004-05-12 | Point Therapeutics Inc | Cyclic boroproline compounds |
DE19826972A1 (en) | 1998-06-18 | 1999-12-23 | Univ Magdeburg Tech | Inhibiting keratinocyte activation and proliferation, for treatment of dermatological disorders such as psoriasis or actinic precancerous states |
WO2000001849A1 (en) | 1998-07-02 | 2000-01-13 | Invitro Diagnostics, Inc. | Methods, compositions and apparatus for making nucleic acid molecules having a selected affinity to a target molecule |
DE19834610A1 (en) | 1998-07-31 | 2000-02-24 | Probiodrug Ges Fuer Arzneim | New N-dipeptidyl O-acyl hydroxylamine derivatives useful as dipeptidyl peptidase I inhibitors, e.g. for treating cancer or immunological or metabolic disorders |
DE19834591A1 (en) | 1998-07-31 | 2000-02-03 | Probiodrug Ges Fuer Arzneim | Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia |
KR20010079669A (en) | 1998-08-21 | 2001-08-22 | 바바라 피. 월너 | Regulation of Substrate Activity |
AU3960400A (en) | 1999-03-05 | 2000-09-28 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
US6211182B1 (en) | 1999-03-08 | 2001-04-03 | Schering Corporation | Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms |
US6921748B1 (en) | 1999-03-29 | 2005-07-26 | Uutech Limited | Analogs of gastric inhibitory polypeptide and their use for treatment of diabetes |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6172081B1 (en) * | 1999-06-24 | 2001-01-09 | Novartis Ag | Tetrahydroisoquinoline 3-carboxamide derivatives |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
GB9917909D0 (en) | 1999-07-31 | 1999-09-29 | Synphar Lab Inc | Cysteine protease inhibitors |
NZ519146A (en) | 1999-11-03 | 2004-02-27 | Albany Molecular Res Inc | 4-phenyl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
AU1916401A (en) | 1999-11-12 | 2001-06-06 | Guilford Pharmaceuticals Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
US7064145B2 (en) * | 2000-02-25 | 2006-06-20 | Novo Nordisk A/S | Inhibition of beta cell degeneration |
AU2001233622A1 (en) | 2000-02-25 | 2001-09-03 | Novo-Nordisk A/S | Inhibition of beta cell degeneration |
DE60042585D1 (en) | 2000-02-29 | 2009-09-03 | Univ Firenze | 3-aza-6,8-dioxabicycloÄ3.2.1Üoctane and analogs and combinatorial libraries containing them |
US6605589B1 (en) * | 2000-03-31 | 2003-08-12 | Parker Hughes Institute | Cathepsin inhibitors in cancer treatment |
ES2320630T5 (en) * | 2000-03-31 | 2013-03-12 | Royalty Pharma Collection Trust | Method for the improvement of islet signaling in diabetes mellitus and for its prevention |
US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
DE10025464A1 (en) | 2000-05-23 | 2001-12-06 | Inst Medizintechnologie Magdeb | Combined use of enzyme inhibitors for the therapy of autoimmune diseases, in transplants and tumor diseases, as well as combinations of pharmaceutical preparations comprising enzyme inhibitors |
AU2001269769A1 (en) | 2000-06-07 | 2001-12-17 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Methods for making bis-heterocyclic alkaloids |
GB0014969D0 (en) | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
WO2002013821A1 (en) | 2000-08-17 | 2002-02-21 | Gliatech, Inc. | Novel alicyclic imidazoles as h3 agents |
CA2422162C (en) | 2000-09-09 | 2012-10-23 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
US20030130199A1 (en) * | 2001-06-27 | 2003-07-10 | Von Hoersten Stephan | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents |
US7279550B2 (en) | 2001-08-13 | 2007-10-09 | Probiodrug Ag | Irreversible cysteine protease inhibitors of legumain |
CA2476681A1 (en) | 2002-02-19 | 2003-08-28 | Bruce N. Rogers | Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease |
BRPI0409241A (en) | 2003-04-10 | 2006-03-28 | Pfizer | bicyclic compounds as nr2b receptor antagonists, pharmaceutical compositions comprising them and their use |
-
2002
- 2002-06-13 US US10/172,809 patent/US20030130199A1/en not_active Abandoned
-
2005
- 2005-03-30 US US11/093,991 patent/US7109347B2/en not_active Expired - Fee Related
-
2006
- 2006-07-05 US US11/481,349 patent/US7368576B2/en not_active Expired - Fee Related
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2961377A (en) * | 1957-08-05 | 1960-11-22 | Us Vitamin Pharm Corp | Oral anti-diabetic compositions and methods |
US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
US3879541A (en) * | 1970-03-03 | 1975-04-22 | Bayer Ag | Antihyperglycemic methods and compositions |
US3960949A (en) * | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
US4028402A (en) * | 1974-10-11 | 1977-06-07 | Hoffmann-La Roche Inc. | Biguanide salts |
US4935493A (en) * | 1987-10-06 | 1990-06-19 | E. I. Du Pont De Nemours And Company | Protease inhibitors |
US5433955A (en) * | 1989-01-23 | 1995-07-18 | Akzo N.V. | Site specific in vivo activation of therapeutic drugs |
US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
US5624894A (en) * | 1992-09-17 | 1997-04-29 | University Of Florida | Brain-enhanced delivery of neuroactive peptides by sequential metabolism |
US5939560A (en) * | 1993-12-03 | 1999-08-17 | Ferring B.V. | Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof |
US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5614379A (en) * | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
US6006753A (en) * | 1996-08-30 | 1999-12-28 | Eli Lilly And Company | Use of GLP-1 or analogs to abolish catabolic changes after surgery |
US20030119750A1 (en) * | 2001-06-27 | 2003-06-26 | Hans-Ulrich Demuth | Use of dipeptidyl peptidase IV inhibitors |
Cited By (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040152192A1 (en) * | 1997-09-29 | 2004-08-05 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
US7276371B2 (en) | 1997-09-29 | 2007-10-02 | Point Therapeutics, Inc. | Stimulation of hematopoietic cells in vitro |
US20060052310A1 (en) * | 1998-08-21 | 2006-03-09 | Point Therapeutics, Inc. | Regulation of substrate activity |
US7265118B2 (en) | 1998-08-21 | 2007-09-04 | Point Therapeutics, Inc. | Regulation of substrate activity |
US7259138B2 (en) | 1999-05-25 | 2007-08-21 | Point Therapeutics, Inc. | Anti-tumor agents |
US6949514B2 (en) | 1999-05-25 | 2005-09-27 | Point Therapeutics, Inc. | Anti-tumor agents |
US20050272703A1 (en) * | 1999-05-25 | 2005-12-08 | Point Therapeutics, Inc. | Anti-tumor agents |
US20060287245A1 (en) * | 1999-05-25 | 2006-12-21 | Point Therapeutics, Inc. | Anti-tumor agents |
US6890904B1 (en) | 1999-05-25 | 2005-05-10 | Point Therapeutics, Inc. | Anti-tumor agents |
US7282484B2 (en) | 1999-05-25 | 2007-10-16 | Point Therapeutics, Inc. | Anti-tumor agents |
US20040077601A1 (en) * | 2002-07-09 | 2004-04-22 | Point Therapeutics, Inc. | Methods and compositions relating to isoleucine boroproline compounds |
US7687625B2 (en) | 2003-03-25 | 2010-03-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US20040242566A1 (en) * | 2003-03-25 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
US7790736B2 (en) | 2003-08-13 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7723344B2 (en) | 2003-08-13 | 2010-05-25 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7790734B2 (en) | 2003-09-08 | 2010-09-07 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8329900B2 (en) | 2004-03-15 | 2012-12-11 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8188275B2 (en) | 2004-03-15 | 2012-05-29 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8173663B2 (en) | 2004-03-15 | 2012-05-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8288539B2 (en) | 2004-03-15 | 2012-10-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7906523B2 (en) | 2004-03-15 | 2011-03-15 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7781584B2 (en) | 2004-03-15 | 2010-08-24 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7807689B2 (en) | 2004-03-15 | 2010-10-05 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
US7825242B2 (en) | 2004-07-16 | 2010-11-02 | Takeda Pharmaceutical Company Limted | Dipeptidyl peptidase inhibitors |
US20080234292A1 (en) * | 2004-07-23 | 2008-09-25 | Susan Marie Royalty | Peptidase Inhibitors |
US7842707B2 (en) | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
US20070072830A1 (en) * | 2004-09-21 | 2007-03-29 | Point Therapeutics, Inc. | Methods for treating diabetes |
US20060063719A1 (en) * | 2004-09-21 | 2006-03-23 | Point Therapeutics, Inc. | Methods for treating diabetes |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8198232B2 (en) | 2005-01-10 | 2012-06-12 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8022034B2 (en) | 2005-01-10 | 2011-09-20 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US20100137293A1 (en) * | 2005-01-10 | 2010-06-03 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US7803754B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US7803753B2 (en) | 2005-01-10 | 2010-09-28 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8003597B2 (en) | 2005-01-10 | 2011-08-23 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US20100298333A1 (en) * | 2005-01-10 | 2010-11-25 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US8030270B2 (en) | 2005-01-10 | 2011-10-04 | Arena Pharmaceuticals, Inc. | Methods for identifying GLP-1 secretagogues |
US20100285494A1 (en) * | 2005-01-10 | 2010-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US20100286153A1 (en) * | 2005-01-10 | 2010-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US20100286172A1 (en) * | 2005-01-10 | 2010-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US20100285495A1 (en) * | 2005-01-10 | 2010-11-11 | Arena Pharmaceuticals, Inc. | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level |
US20060154866A1 (en) * | 2005-01-10 | 2006-07-13 | Zhi-Liang Chu | Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
US8076330B2 (en) | 2005-04-22 | 2011-12-13 | Amgen Inc. | Dipeptidyl peptidase-IV inhibitors |
US8906901B2 (en) | 2005-09-14 | 2014-12-09 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US9416157B2 (en) | 2005-10-04 | 2016-08-16 | Soligenix, Inc. | Peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunity |
US20090246217A1 (en) * | 2005-10-04 | 2009-10-01 | Inimex Pharmaceuticals Inc. | Novel Peptides for Treating and Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity |
US8124721B2 (en) | 2005-10-04 | 2012-02-28 | Inimex Pharmaceuticals Inc. | Peptides for modulating innate immunity |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US8580526B2 (en) | 2006-04-11 | 2013-11-12 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 receptor to identify compounds which stimulate glucose-dependent insulinotropic peptide secretion |
US7833730B2 (en) | 2006-04-11 | 2010-11-16 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US8017574B2 (en) | 2006-04-11 | 2011-09-13 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretagogues |
US20100203038A1 (en) * | 2006-04-11 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
US8026074B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify compounds useful for increasing bone mass in an individual |
US8026212B2 (en) | 2006-04-11 | 2011-09-27 | Arena Pharmaceuticals, Inc. | Methods of preparing pharmaceutical compositions comprising GPR119 agonists having the effect of glucose-dependent insulinotropic peptide secretatgogues |
EP2253311A2 (en) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, as well as combination therapy relating thereto |
US20100190750A1 (en) * | 2006-04-11 | 2010-07-29 | Arena Pharmaceuticals, Inc. | GPR119 Receptor Agonists in Methods of Increasing Bone Mass and of Treating Osteoporosis and Other Conditions Characterized by Low Bone Mass, and Combination Therapy Relating Thereto |
US7816364B2 (en) | 2006-04-11 | 2010-10-19 | Arena Pharmaceuticals, Inc. | GRP119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
US20100203037A1 (en) * | 2006-04-11 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
US20100203577A1 (en) * | 2006-04-11 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
US8101626B2 (en) | 2006-04-11 | 2012-01-24 | Arena Pharmaceuticals, Inc. | GPR119 receptor agonists in methods of increasing bone mass and of treating osteoporosis and other conditions characterized by low bone mass, and combination therapy relating thereto |
WO2007127204A2 (en) * | 2006-04-24 | 2007-11-08 | Dara Biosciences, Inc. | Methods and compositions relating to immunostimulation |
WO2007127204A3 (en) * | 2006-04-24 | 2008-11-20 | Dara Biosciences Inc | Methods and compositions relating to immunostimulation |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US20080287476A1 (en) * | 2007-03-13 | 2008-11-20 | Takeda Pharmaceutical Company Limited | Administration of dipeptidyl peptidase inhibitors |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
US20100203556A1 (en) * | 2008-04-07 | 2010-08-12 | Arena Pharmaceuticals, Inc. | Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy |
US20100210666A1 (en) * | 2008-04-07 | 2010-08-19 | Arena Pharmaceuticals, Inc. | Methods of using a g protein-coupled receptor to identify peptide yy (pyy) secretagogues and compounds useful in the treatment of conditions modulated by pyy |
US7838254B2 (en) | 2008-04-07 | 2010-11-23 | Arena Pharmaceuticals, Inc. | Methods of using GPR119 to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
US8883714B2 (en) | 2008-04-07 | 2014-11-11 | Arena Pharmaceuticals, Inc. | Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues |
US8486646B2 (en) | 2008-04-07 | 2013-07-16 | Arena Pharmaceuticals, Inc. | Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues |
WO2011005929A1 (en) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Piperidine derivative and its use for the treatment of diabets and obesity |
WO2011127051A1 (en) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012040279A1 (en) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145603A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US9617300B2 (en) * | 2012-03-09 | 2017-04-11 | Morinaga Milk Industry Co., Ltd. | Dipeptidyl peptidase-IV inhibitor |
US20150232510A1 (en) * | 2012-03-09 | 2015-08-20 | Morinaga Milk Industry Co., Ltd | Dipeptidyl peptidase-iv inhibitor |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
Also Published As
Publication number | Publication date |
---|---|
US7368576B2 (en) | 2008-05-06 |
US7109347B2 (en) | 2006-09-19 |
US20050171025A1 (en) | 2005-08-04 |
US20060293248A1 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7368576B2 (en) | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents | |
AU2002321135B2 (en) | Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents | |
US7368421B2 (en) | Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis | |
AU2002321135A1 (en) | Dipepitdyl peptidase IV inhibitors and their uses as anti-cancer agents | |
ZA200300833B (en) | Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents. | |
US20070207946A1 (en) | Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels | |
US6946480B2 (en) | Glutaminyl based DPIV inhibitors | |
RU2305553C2 (en) | New dipeptidyl peptidase iv inhibitors and uses thereof as hypotensive agent | |
AU2002331224B2 (en) | Peptidyl ketones as inhibitors of DPIV | |
AU2002328306A1 (en) | Use of dipeptidyl peptidase IV inhibitors as therapeutics for neurological disorders | |
US7374898B2 (en) | Peptide inhibitors against seprase | |
CENTER | Pospisilik et al.(43) Pub. Date: Sep. 18, 2003 | |
US20060194852A1 (en) | Glutaminyl based DPIV inhibitors | |
NZ545366A (en) | Glutaminyl based DPIV inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: PROBIODRUG, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:VON HOERSTEN, STEPHAN;DEMUTH, HANS-ULRICH;HOFFMANN, TORSTEN;REEL/FRAME:013230/0252;SIGNING DATES FROM 20020703 TO 20020729 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |